UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

      

FORM 10-Q

      

(Mark One)

 

x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2013

or

 

¨

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 001-35560

      

ImmunoCellular Therapeutics, Ltd.

(Exact name of registrant as specified in its charter)

      

   

 

Delaware

   

93-1301885

(State or other jurisdiction of

incorporation or organization)

   

(IRS Employer

Identification No.)

   

   

23622 Calabasas Road, Suite 300

Calabasas, California

   

91302

(Address of principal executive offices)

   

(Zip code)

(818) 264-2300

(Registrant’s telephone number, including area code)

      

   

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  x   No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  x   No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

   

 

Large accelerated filer

¨

      

Accelerated Filer

x

   

   

   

   

   

Non-accelerated filer

¨

      

Smaller reporting company

¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  ¨   No  x

The Issuer had 54,595,104 shares of its common stock outstanding as of August 2, 2013.

      

   

   

   

   

       

 

   

   


ImmunoCellular Therapeutics, Ltd.

FORM 10-Q

Table of Contents

   

 

   

Page

PART 1

   

FINANCIAL INFORMATION  

 

  3

   

   

Item 1: Financial Statements  

 

  3

   

   

Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations  

 

 

  19 

   

   

Item 3: Quantitative and Qualitative Disclosures About Market Risk  

 

  23

   

   

Item 4: Controls and Procedures  

 

  24

   

   

PART II

   

OTHER INFORMATION  

 

  25

   

   

Item 1: Legal Proceedings  

 

  25

   

   

Item 1A: Risk Factors  

 

  25

   

   

Item 2: Unregistered Sales of Equity Securities and Use of Proceeds  

 

  25

   

   

Item 3: Defaults Upon Senior Securities  

 

  25

   

   

Item 4: Mine Safety Disclosures  

 

  25

   

   

Item 5: Other Information  

 

  25

   

   

Item 6: Exhibits  

 

  26

   

   

SIGNATURES  

 

  27

   

   

EXHIBIT INDEX  

 

  28

   

   

   

   

 

 2 


PART 1

FINANCIAL INFORMATION

Item 1. Financial Statements

ImmunoCellular Therapeutics, Ltd.

(A Development Stage Company)

Condensed Balance Sheets

   

 

   

June 30,
2013

   

      

December 31,
2012

   

   

(unaudited)

   

      

   

   

Assets

   

   

   

      

   

   

   

Current assets:

   

   

   

      

   

   

   

Cash and cash equivalents

$

25,452,382

   

      

$

26,216,668

   

Other assets

   

402,075

   

      

   

714,508

   

Total current assets

   

25,854,457

   

      

   

26,931,176

   

Property and equipment, net

   

85,229

   

      

   

76,289

   

Other assets

   

241,575

   

      

   

11,736

   

Total assets

$

26,181,261

   

      

$

27,019,201

   

Liabilities and Shareholders’ Equity

   

   

   

      

   

   

   

Current liabilities:

   

   

   

      

   

   

   

Accounts payable

$

329,263

   

      

$

732,851

   

Accrued compensation and benefits

   

291,134

   

      

   

309,345

   

Accrued expenses

   

202,869

   

      

   

56,111

   

Total current liabilities

   

823,266

   

      

   

1,098,307

   

Warrant Liability

   

2,311,391

   

      

   

2,852,880

   

Commitments and contingencies (Note 5)

   

   

   

      

   

   

   

Shareholders’ equity:

   

   

   

      

   

   

   

Common stock, $0.0001 par value; 99,000,000 shares authorized; 53,964,696 shares and 51,500,996 shares issued and outstanding as of June 30, 2013 and December 31, 2012,  respectively

   

5,396

   

      

   

5,150

   

Additional paid in capital

   

71,334,158

   

      

   

66,231,694

   

Deficit accumulated during the development stage

   

(48,292,950

)

      

   

(43,168,830

)

Total shareholders’ equity

   

23,046,604

   

      

   

23,068,014

   

Total liabilities and shareholders’ equity

$

26,181,261

   

      

$

27,019,201

   

   

   

   

   

   

   

   

   

   

   

The accompanying notes are an integral part of these unaudited condensed financial statements.

   

   

 

 3 


ImmunoCellular Therapeutics, Ltd.

(A Development Stage Company)

Condensed Statements of Operations

(unaudited)

   

 

   

For the Three Months Ended June 30, 2013

   

   

For the
Three Months Ended
June 30,
2012

   

   

For the Six
Months Ended June 30,
2013

   

   

For the Six
Months Ended June 30,
2012

   

   

February 25, 2004 (Inception) to June 30
2013

   

Revenues

$

0

   

   

$

0

   

   

$

0

   

   

$

0

   

   

$

300,000

   

Expenses:

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Research and development

   

1,213,570

   

   

   

2,189,633

   

   

   

2,628,831

   

   

   

4,188,169

   

   

   

20,888,944

   

Stock based compensation

   

179,946

   

   

   

103,617

   

   

   

344,074

   

   

   

348,724

   

   

   

9,060,086

   

General and administrative

   

788,420

   

   

   

837,322

   

   

   

1,557,687

   

   

   

1,643,120

   

   

   

14,242,433

   

Total expenses

   

2,181,936

   

   

   

3,130,572

   

   

   

4,530,592

   

   

   

6,180,013

   

   

   

44,191,463

   

Loss before other income (expense) and income  taxes

   

(2,181,936

)

   

   

(3,130,572

)

   

   

(4,530,592

)

   

   

(6,180,013

)

   

   

(43,891,463

)

Interest income

   

4,094

   

   

   

1,975

   

   

   

10,643

   

   

   

3,009

   

   

   

358,385

   

Financing expense

   

0

   

   

   

0

   

   

   

0

   

   

   

(368,524

)

   

   

(397,294

)

Change in fair value of warrant liability

   

2,027,513

   

   

   

(3,323,220

)

   

   

(604,171

)

   

   

(7,795,724

)

   

   

(2,270,078

)

Loss before income taxes

   

(150,329

)

   

   

(6,451,817

)

   

   

(5,124,120

)

   

   

(14,341,252

)

   

   

(46,200,450

)

Income taxes

   

0

   

   

   

0

   

   

   

0

   

   

   

0

   

   

   

0

   

Net loss

   

(150,329

)

   

   

(6,451,817

)

   

   

(5,124,120

)

   

   

(14,341,252

)

   

   

(46,200,450

)

Deemed dividend on redemption of preferred  stock

   

0

   

   

   

0

   

   

   

0

   

   

   

0

   

   

   

(2,092,500

)

Net loss attributable to common stock

$

(150,329

)

   

$

(6,451,817

)

   

$

(5,124,120

)

   

$

(14,341,252

)

   

$

(48,292,950

)

Net loss per share, basic and diluted

$

(0.00

)

   

$

(0.16

)

   

$

(0.10

)

   

$

(0.37

)

   

$

(2.61

)

Weighted average number of shares basic and  diluted

   

52,972,702

   

   

   

39,892,802

   

   

   

52,264,104

   

   

   

38,497,810

   

   

   

18,472,012

   

   

   

   

   

   

   

   

   

   

   

   

   

The accompanying notes are an integral part of these unaudited condensed financial statements.

   

   

 

 4 


ImmunoCellular Therapeutics, Ltd.

(A Development Stage Company)

Condensed Statements of Shareholders’ Equity (Deficit)

(unaudited)

   

 

   

Preferred Stock

   

      

Common Stock

   

   

Additional
Paid-in
Capital

   

   

Promissory
Note

   

      

Deficit
Accumulated
During the
Development
Stage

   

   

Total

   

   

Shares

      

Amount

   

      

Shares

   

   

Amount

   

   

   

      

   

Initial capitalization at $0.00002 per share

0

   

      

$

0

      

      

6,256,500

      

   

$

10

   

   

$

87

   

   

$

0

      

      

$

0

   

   

$

97

   

Common stock issued for cash during 2004 at $ 0.00078 per share

0

   

      

   

0

      

      

193,500

      

   

   

15

   

   

   

135

   

   

   

0

      

      

   

0

   

   

   

150

   

Net loss

0

   

      

   

0

      

      

0

      

   

   

0

   

   

   

0

   

   

   

0

      

      

   

(11,741

)

   

   

(11,741

)

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Balance at December 31, 2004

0

   

      

   

0

      

      

6,450,000

      

   

   

25

   

   

   

222

   

   

   

0

      

      

   

(11,741

)

   

   

(11,494

)

Common stock issued for cash during 2005 at $ 0.19 per share

0

   

      

   

0

      

      

387,000

      

   

   

659

   

   

   

74,341

   

   

   

0

      

      

   

0

   

   

   

75,000

   

Common stock issued for cash during 2005 at $ 0.32 per share

0

   

      

   

0

      

      

154,800

      

   

   

16

   

   

   

49,984

   

   

   

0

      

      

   

0

   

   

   

50,000

   

Common stock issued for research and development during 2005 at $ 0.99 per share

0

   

      

   

0

      

      

154,800

      

   

   

15

   

   

   

152,745

   

   

   

0

      

      

   

0

   

   

   

152,760

   

Net loss

0

   

      

   

0

      

      

0

      

   

   

0

   

   

   

0

   

   

   

0

      

      

   

(246,004

)

   

   

(246,004

)

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Balance at December 31, 2005

0

   

      

   

0

      

      

7,146,600

      

   

   

715

   

   

   

277,292

   

   

   

0

      

      

   

(257,745

)

   

   

20,262

   

Common stock issued for services during 2006 at $ 0.50 per share

0

   

      

   

0

      

      

73,093

      

   

   

7

   

   

   

36,539

   

   

   

0

      

      

   

0

   

   

   

36,546

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Common stock issued for cash during 2006 in private placements at $ 1.00 per share, net of redemptions

0

   

      

   

0

      

      

1,510,000

      

   

   

151

   

   

   

549,249

   

   

   

0

      

      

   

0

   

   

   

549,400

   

Common stock issued for research and development during 2006  at $ 1.00 per share

0

   

      

   

0

      

      

694,000

      

   

   

69

   

   

   

693,931

   

   

   

0

      

      

   

0

   

   

   

694,000

   

Shares issued in connection with reverse merger

0

   

      

   

0

      

      

825,124

      

   

   

83

   

   

   

(83

)

   

   

0

      

      

   

0

   

   

   

0

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Shares cancelled in connection with the sale of Optical Molecular Imaging, Inc.

0

   

      

   

0

      

      

(2,059,100

)

   

   

(206

)

   

   

(64,794

)

   

   

0

      

      

   

0

   

   

   

(65,000

)

Exercise of stock options

0

   

      

   

0

      

      

10,062

   

   

   

1

   

   

   

3,521

   

   

   

0

      

      

   

0

   

   

   

3,522

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Stock based compensation (options)

0

   

      

   

0

      

      

0

      

   

   

0

   

   

   

4,103,645

   

   

   

0

      

      

   

0

   

   

   

4,103,645

   

Net loss

0

   

      

   

0

      

      

0

      

   

   

0

   

   

   

0

   

   

   

0

      

      

   

(5,152,713

)

   

   

(5,152,713

)

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Balance at December 31, 2006

0

   

      

   

0

      

      

8,199,779

      

   

   

820

   

   

   

5,599,300

   

   

   

0

      

      

   

(5,410,458

)

   

   

189,662

   

Common stock issued for cash during 2007 in private placements at $ 1.50  per share

0

   

      

   

0

      

      

3,531,603

      

   

   

353

   

   

   

4,892,133

   

   

   

0

      

      

   

0

   

   

   

4,892,486

   

Exercise of stock options

0

   

      

   

0

      

      

51,111

      

   

   

5

   

   

   

(5

)

   

   

0

      

      

   

0

   

   

   

0

   

Reclassification of warrant derivative liability

0

   

      

   

0

      

      

0

      

   

   

0

   

   

   

2,233,600

   

   

   

0

      

      

   

0

   

   

   

2,233,600

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Stock based compensation (options)

0

   

      

   

0

      

      

0

      

   

   

0

   

   

   

1,296,714

   

   

   

0

      

      

   

0

   

   

   

1,296,714

   

Net loss

0

   

      

   

0

      

      

0

      

   

   

0

   

   

   

0

   

   

   

0

      

      

   

(3,614,753

)

   

   

(3,614,753

)

   

 

 5 

   

   


   

 

   

Preferred Stock

   

      

Common Stock

   

      

Additional
Paid-in
Capital

   

   

Promissory
Note

   

   

Deficit
Accumulated
During the
Development
Stage

   

   

Total

   

   

Shares

   

   

Amount

   

      

Shares

   

      

Amount

   

      

   

   

   

Balance at December 31, 2007

0

   

   

  $

0

      

      

11,782,493

      

      

$

1,178

      

      

   

14,021,742

   

   

   

0

   

   

   

(9,025,211

)

   

   

4,997,709

   

Common stock issued for research and development during 2008 at $0.53 per share

0

   

   

   

0

      

      

800,000

      

      

   

80

      

      

   

423,920

   

   

   

0

   

   

   

0

   

   

   

424,000

   

Common stock issued for research and development during 2008 at $ 0.65 per share

0

   

   

   

0

      

      

100,000

      

      

   

10

      

      

   

64,990

   

   

   

0

   

   

   

0

   

   

   

65,000

   

Stock based compensation (options)

0

   

   

   

0

      

      

0

      

      

   

0

      

      

   

513,357

   

   

   

0

   

   

   

0

   

   

   

513,357

   

Net loss

0

   

   

   

0

      

      

0

      

      

   

0

      

      

   

0

   

   

   

0

   

   

   

(3,059,730

)

   

   

(3,059,730

)

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Balance at December 31, 2008

0

   

   

   

0

      

      

12,682,493

      

      

   

1,268

      

      

   

15,024,009

   

   

   

0

   

   

   

(12,084,941

)

   

   

2,940,336

   

Exercise of warrants

0

   

   

   

0

      

      

1,970,992

      

      

   

197

      

      

   

462,551

   

   

   

0

   

   

   

0

   

   

   

462,748

   

Exercise of stock options

0

   

   

   

0

      

      

214,357

      

      

   

22

      

      

   

64,460

   

   

   

(52,668

)

   

   

0

   

   

   

11,814

   

Stock based compensation (options)

0

   

   

   

0

      

      

0

      

      

   

0

      

      

   

308,302

   

   

   

0

   

   

   

0

   

   

   

308,302

   

Net loss

0

   

   

   

0

      

      

0

      

      

   

0

      

      

   

0

   

   

   

0

   

   

   

(2,626,205

)

   

   

(2,626,205

)

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Balance at December 31, 2009

0

   

   

   

0

      

      

14,867,842

      

      

   

1,487

      

      

   

15,859,322

   

   

   

(52,668

)

   

   

(14,711,146

)

   

   

1,096,995

   

Common stock and warrants issued for cash during 2010 at $ 1.00 per share, net of offering costs

0

   

   

   

0

      

      

4,230,910

      

      

   

423

      

      

   

3,248,315

   

   

   

0

   

   

   

0

   

   

   

3,248,738

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Preferred stock and warrants issued for cash during 2010 at $ 10,000 per share, net of offering costs

400

   

   

   

0

      

      

0

      

      

   

0

      

      

   

0

   

   

   

0

   

   

   

0

   

   

   

0

   

Exercise of warrants in exchange for promissory note

0

   

   

   

0

      

      

2,700,000

      

      

   

270

      

      

   

5,399,730

   

   

   

(5,400,000

)

   

   

0

   

   

   

0

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Redemption of preferred stock for repayment of promissory note

(400

)

   

   

0

      

      

0

      

      

   

0

      

      

   

0

   

   

   

5,400,000

   

   

   

(2,092,500

)

   

   

3,307,500

   

Exercise of stock options

0

   

   

   

0

      

      

50,000

      

      

   

5

      

      

   

26,495

   

   

   

0

   

   

   

0

   

   

   

26,500

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Cashless exercise of stock options

0

   

   

   

0

      

      

297,156

      

      

   

30

      

      

   

(30

)

   

   

0

   

   

   

0

   

   

   

0

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Common stock issued for services during 2010 at $ 0.90 per share

0

   

   

   

0

      

      

60,000

      

      

   

6

      

      

   

53,994

   

   

   

0

   

   

   

0

   

   

   

54,000

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Common stock issued for services during 2010 at $ 1.06 per share

0

   

   

   

0

      

      

7,694

      

      

   

0

      

      

   

8,156

   

   

   

0

   

   

   

0

   

   

   

8,156

   

Stock based compensation

0

   

   

   

0

      

      

0

      

      

   

0

      

      

   

745,697

   

   

   

0

   

   

   

0

   

   

   

745,697

   

Interest on promissory note

0

   

   

   

0

      

      

0

      

      

   

0

      

      

   

0

   

   

   

(1,614

)

   

   

0

   

   

   

(1,614

)

Net loss

0

   

   

   

0

      

      

0

      

      

   

0

      

      

   

0

   

   

   

0

   

   

   

(6,150,142

)

   

   

(6,150,142

)

Balance at December 31, 2010

0

   

   

   

0

      

      

22,213,602

      

      

   

2,221

      

      

   

25,341,679

   

   

   

(54,282

)

   

   

(22,953,788

)

   

   

2,335,830

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Common stock and warrants issued for cash during 2011 at $ 1.55 per share, net of offering costs

0

      

   

   

0

      

      

5,219,768

      

      

   

522

      

      

   

4,982,817

   

   

   

0

   

   

   

0

   

   

   

4,983,339

   

Exercise of stock options

0

      

   

   

0

      

      

382,000

      

      

   

38

      

      

   

388,341

   

   

   

0

   

   

   

0

   

   

   

388,379

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Cashless exercise of stock options

0

   

   

   

0

      

      

667,077

      

      

   

67

      

      

   

(67

)

   

   

0

   

   

   

0

   

   

   

0

   

Stock based compensation

0

   

   

   

0

      

      

131,537

      

      

   

13

      

      

   

1,190,120

   

   

   

0

   

   

   

0

   

   

   

1,190,133

   

Interest on promissory note

0

   

   

   

0

      

      

0

      

      

   

0

      

      

   

0

   

   

   

(352

)

   

   

0

   

   

   

(352

)

Redemption of promissory note

0

   

      

   

0

      

      

0

      

      

   

0

      

      

   

0

      

   

   

54,634

      

      

   

0

   

   

   

54,634

   

Net loss

0

   

      

   

0

      

      

0

      

      

   

0

      

      

   

0

      

   

   

0

      

      

   

(5,719,903

)

   

   

(5,719,903

)

   

   

 

   

Preferred Stock

   

      

Common Stock

   

      

Additional
Paid-in
Capital

   

   

Promissory
Note

   

      

Deficit
Accumulated
During the
Development
Stage

   

   

Total

   

   

Shares

   

      

Amount

   

      

Shares

   

      

Amount

   

      

   

      

   

 

 6 


   

 

   

Shares

   

      

Amount

   

      

Shares

   

      

Amount

   

      

   

      

   

Balance at December 31, 2011

0

      

      

$

0

      

      

28,613,984

      

      

$

2,861

      

      

   

31,902,890

   

   

   

0

   

      

   

(28,673,691

)

   

   

3,232,060

   

Common stock and warrants issued for cash during 2012 at $1.10 per share,  net of offering costs in January 2012

0

      

      

   

0

      

      

9,489,436

      

      

   

949

      

      

   

9,270,421

   

   

   

0

      

      

   

0

   

   

   

9,271,370

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Common stock and warrants issued for cash during 2012 at $ 2.10 per share,  net of offering costs in October 2012

0

      

      

   

0

      

      

10,000,000

      

      

   

1,000

      

      

   

19,358,553

   

   

   

0

      

      

   

0

   

   

   

19,359,553

   

Exercise of warrants

0

      

      

   

0

      

      

2,295,334

      

      

   

230

      

      

   

3,201,690

   

   

   

0

      

      

   

0

   

   

   

3,201,920

   

Reclassification of warrant liability upon exercise

0

      

      

   

0

      

      

0

      

      

   

0

      

      

   

1,981,743

   

   

   

0

      

      

   

0

   

   

   

1,981,743

   

Cashless exercise of warrants

0

      

      

   

0

      

      

288,973

      

      

   

29

      

      

   

(29

)

   

   

0

      

      

   

0

   

   

   

0

   

Cashless exercise of stock options

0

      

      

   

0

      

      

792,018

      

      

   

79

      

      

   

(79

)

   

   

0

      

      

   

0

   

   

   

0

   

Restricted stock vested

0

      

      

   

0

      

      

1,251

      

      

   

0

      

      

   

0

   

   

   

0

      

      

   

0

   

   

   

0

   

Stock based compensation

0

      

      

   

0

      

      

0

      

      

   

0

      

      

   

496,007

   

   

   

0

      

      

   

0

   

   

   

496,007

   

Exercise of stock options

0

      

      

   

0

      

      

20,000

      

      

   

2

      

      

   

20,498

   

   

   

0

      

      

   

0

   

   

   

20,500

   

Net loss

0

      

      

   

0

      

      

0

      

      

   

0

      

      

   

0

   

   

   

0

      

      

   

(14,495,139

)

   

   

(14,495,139

)

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Balance at December 31, 2012

0

      

      

   

0

      

      

51,500,996

      

      

   

5,150

      

      

   

66,231,694

   

   

   

0

      

      

   

(43,168,830

)

   

   

23,068,014

   

Exercise of warrants

0

      

      

   

0

      

      

2,079,805

      

      

   

208

      

      

   

4,195,089

   

   

   

0

      

      

   

0

   

   

   

4,195,297

   

Cashless exercise of warrants

0

   

   

   

0

   

   

25,792

   

   

   

3

   

   

   

(3

)

   

   

0

   

   

   

0

   

   

   

0

   

Exercise of stock options

0

      

      

   

0

      

      

95,401

      

      

   

9

      

      

   

84,122

   

   

   

0

      

      

   

0

   

   

   

84,131

   

Cashless exercise of stock options

0

      

      

   

0

      

      

58,559

      

      

   

6

      

      

   

(6

)

   

   

0

      

      

   

0

   

   

   

0

   

Stock based compensation

0

      

      

   

0

      

      

0

      

      

   

0

      

      

   

344,074

   

   

   

0

      

      

   

0

   

   

   

344,074

   

Common stock issued for license rights in January 2013 at $ 2.41 per  share

0

      

      

   

0

      

      

31,155

      

      

   

3

      

      

   

74,997

   

   

   

0

      

      

   

0

   

   

   

75,000

   

Common stock issued through controlled equity offering during May 2013  at an average of $ 2.55 per share

0

   

   

   

0

   

   

172,988

   

   

   

17

   

   

   

404,191

   

   

   

0

   

   

   

0

   

   

   

404,208

   

Net loss

0

      

      

   

0

      

      

0

      

      

   

0

      

      

   

0

   

   

   

0

      

      

   

(5,124,120

)

   

   

(5,124,120

)

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

Balance at June 30, 2013

0

      

      

$

0

      

      

53,964,696

      

      

$

5,396

      

      

$

71,334,158

   

   

$

0

      

      

$

(48,292,950

)

   

$

23,046,604

   

   

   

   

The accompanying notes are an integral part of these unaudited condensed financial statements.

   

   

 

 7 


ImmunoCellular Therapeutics, Ltd.

(A Development Stage Company)

Condensed Statements of Cash Flows

(unaudited)

   

 

   

For the
Six Months Ended
June 30,
2013

   

      

For the
Six Months Ended
June 30,
2012

   

   

February 25, 2004 (Inception)
June 30,
2013

   

Cash flows from operating activities:

   

   

   

      

   

   

   

   

   

   

   

Net loss

$

(5,124,120

)

      

$

(14,341,252

)

   

$

(46,200,450

)

Adjustments to reconcile net loss to net cash used in operating activities:

   

   

   

      

   

   

   

   

   

   

   

Depreciation and amortization

   

21,684

   

      

   

22,888

   

   

   

96,969

   

Loss on disposal of assets

   

3,817

   

      

   

0

   

   

   

3,817

   

Interest accrued on promissory note

   

0

   

      

   

0

   

   

   

0

   

Change in fair value of warrant liability

   

604,171

   

      

   

7,795,724

   

   

   

2,270,079

   

Financing expense

   

0

   

      

   

368,524

   

   

   

397,294

   

Stock-based compensation

   

344,074

   

      

   

348,724

   

   

   

8,997,930

   

Common stock issued for services

   

0

   

      

   

0

   

   

   

98,703

   

Common stock issued for research and development

   

0

   

      

   

0

   

   

   

1,335,760

   

Changes in assets and liabilities:

   

   

   

      

   

   

   

   

   

   

   

Other assets

   

307,594

   

      

   

(526,800

)

   

   

(484,813

)

Accounts payable

   

(403,588

)

      

   

(560,266

)

   

   

328,913

   

Accrued liabilities

   

128,546

   

      

   

3,238

   

   

   

494,002

   

Net cash used in operating activities

   

(4,117,822

)

      

   

(6,889,220

)

   

   

(32,661,796

)

Cash flows from investing activities:

   

   

   

      

   

   

   

   

   

   

   

Purchase of property and equipment

   

(34,441

)

      

   

(5,668

)

   

   

(190,133

)

Cash paid for sale of Optical Molecular Imaging, Inc.

   

0

   

      

   

0

   

   

   

(25,000

)

Net cash used in investing activities

   

(34,441

)

      

   

(5,668

)

   

   

(215,133

)

Cash flows from financing activities:

   

   

   

      

   

   

   

   

   

   

   

Proceeds from exercise of stock options

   

84,131

   

      

   

11,000

   

   

   

534,844

   

Proceeds from exercise of warrants

   

3,049,638

   

      

   

2,199,193

   

   

   

6,714,304

   

Payments on promissory note receivable

   

0

   

      

   

0

   

   

   

53,018

   

Proceeds from issuance of common stock and warrants, net of offering costs

   

404,208

   

      

   

9,371,370

   

   

   

47,397,987

   

Proceeds from issuance of preferred stock and warrants, net of offering costs

   

0

   

      

   

0

   

   

   

3,779,158

   

Other assets

   

(150,000

)

   

   

0

   

   

   

(150,000

)

Net cash provided by financing activities

   

3,387,977

   

      

   

11,581,563

   

   

   

58,329,311

   

Increase (decrease) in cash and cash equivalents

   

(764,286

)

      

   

4,686,675

   

   

   

25,452,382

   

Cash and cash equivalents, beginning of period

   

26,216,668

   

      

   

6,653,168

   

   

   

0

   

Cash and cash equivalents, end of period

$

25,452,382

   

      

$

11,339,843

   

   

$

25,452,382

   

Supplemental cash flows disclosures:

   

   

   

      

   

   

   

   

   

   

   

Interest expense paid

$

0

   

      

$

0

   

   

$

0

   

Income taxes paid

$

0

   

      

$

0

   

   

$

0

   

Supplemental non-cash financing disclosures:

   

   

   

      

   

   

   

   

   

   

   

Exercise of warrants in exchange for promissory note

$

0

   

      

$

0

   

   

$

3,350,000

   

Redemption of preferred stock for repayment of promissory note

$

0

   

      

$

0

   

   

$

3,350,000

   

Deemed dividend on redemption of preferred stock

$

0

   

      

$

0

   

   

$

2,092,500

   

Warrant liability converted to additional paid in capital upon exercise

$

1,145,659

   

      

$

1,622,648

   

   

$

3,127,404

   

Deposits used to acquire property and equipment

$

0

   

      

$

35,882

   

   

$

35,882

   

Deferred offering costs

$

0

   

      

$

0

   

   

$

182,599

   

Common stock issued for license rights

$

75,000

   

      

$

0

   

   

$

75,000

   

   

The accompanying notes are an integral part of these unaudited condensed financial statements.

   

   

   

 

 8 


ImmunoCellular Therapeutics, Ltd.

(A Development Stage Company)

Notes to Unaudited Condensed Financial Statements

   

1. Nature of Organization and Development Stage Operations

ImmunoCellular Therapeutics, Ltd. (the Company) is a development stage company that is seeking to develop and commercialize new therapeutics to fight cancer using the immune system.

Since the Company’s inception on February 25, 2004, the Company has been primarily engaged in the acquisition of certain intellectual property, together with development of its product candidates and the recent clinical testing activities for one of its vaccine product candidates, and has not generated any recurring revenues. The Company’s lead product candidate, ICT-107, is in Phase II clinical development. The Company has two other candidates, ICT-140 and ICT-121, that each have investigational new drug (IND) applications for initiation of clinical development. The Company has sustained operating losses and, as of June 30, 2013, the Company had an accumulated deficit of $48,292,950. The Company expects to incur significant research, development and administrative expenses before any of its products can be launched and recurring revenues generated.

Interim Results

The accompanying condensed financial statements as of June 30, 2013 and for the three and six months periods ended June 30, 2013 and 2012 and for the period from February 25, 2004 (inception) to June 30, 2013 are unaudited, but include all adjustments, consisting of normal recurring entries, which the Company’s management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2012 have been derived from the Company’s audited financial statements included in its Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission (SEC) on March 11, 2013.

The financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the U.S. (GAAP) have been condensed or omitted pursuant to such rules and regulations. The financial statements should be read in conjunction with the Company’s audited financial statements in its Form 10-K for the year ended December 31, 2012. The Company’s operating results will fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.

   

2. Summary of Significant Accounting Policies

Development Stage Enterprise – The Company is a development stage enterprise and is devoting substantially all of its present efforts to research and development. All losses accumulated since inception are considered part of the Company’s development stage activities.

Liquidity – As of June 30, 2013, the Company had working capital of $25,031,191, compared to working capital of $25,832,869 as of December 31, 2012. The estimated cost of completing the development of either of our current vaccine product candidates and of obtaining all required regulatory approvals to market either of those product candidates is substantially greater than the amount of funds we currently have available. However, we believe that our existing cash balances will be sufficient to fund our operations for at least the next twelve months, although there is no assurance that such proceeds will be sufficient.

Cash and cash equivalents – The Company considers all highly liquid instruments with an original maturity of 90 days or less at acquisition to be cash equivalents. As of June 30, 2013 and December 31, 2012, the Company had $22,907,190 and $23,646,922, respectively, of certificates of deposit. The Company places its cash and cash equivalents with various banks in order to maintain FDIC insurance on all of its investments.

Property and Equipment – Property and equipment are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally three to five years) of the related assets. Computer and computer equipment are depreciated over 3 years. Management continuously monitors and evaluates the realizability of recorded long-lived assets to determine whether their carrying values have been impaired. The Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the nondiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Any impairment loss is measured by comparing the fair value of the asset to its carrying amount. Repairs and maintenance costs are expensed as incurred.

Research and Development Costs – Research and development expenses consist of costs incurred for direct research and development and are expensed as incurred.

 

 9 


Stock Based Compensation – The Company records the cost for all share-based payment transactions in the Company’s financial statements.

Stock option grants issued prior to March 31, 2011 to employees and officers and directors were valued using the Black-Scholes pricing model. Stock option grants made subsequent to March 31, 2011 were valued using the binomial lattice simulation model.

Fair value was estimated at the date of grant using the following weighted average assumptions:

   

 

   

Six months
Ended
June 30,
2013

   

   

Six months
Ended
June 30,
2012

   

Risk-free interest rate

   

0.74

%

   

   

0.84

%

Expected dividend yield

   

None

   

   

   

None

   

Expected life

   

4.54 Years

   

   

   

5.17 Years

   

Expected volatility

   

90.5

%

   

   

66.32

%

Expected forfeitures

   

0

%

   

   

0

%

The risk-free interest rate used is based on the implied yield currently available in U.S. Treasury securities at maturity with an equivalent term. The Company has not declared or paid any dividends and does not currently expect to do so in the future. The expected term of options represents the period that our stock-based awards are expected to be outstanding and was determined based on projected holding periods for the remaining unexercised shares. Consideration was given to the contractual terms of our stock-based awards, vesting schedules and expectations of future employee behavior. For the six months ended June 30, 2013, the expected volatility is based upon the historical volatility of the Company’s common stock. For the six months ended June 30, 2012, the expected volatility is based on market prices of traded options for comparable entities within our industry. Forfeitures have been estimated to be nil.

The Company’s stock price volatility and option lives involve management’s best estimates, both of which impact the fair value of the option calculated and, ultimately, the expense that will be recognized over the life of the option.

When options are exercised, our policy is to issue previously unissued shares of common stock to satisfy share option exercises. As of June 30, 2013, the Company had approximately 10,612,215 million shares of authorized but unissued common stock.

No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets.

Income Taxes – The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. As of June 30, 2013 and December 31, 2012, the Company fully reserved its deferred tax assets. The Company recognizes in its financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. The Company is not currently under examination by any taxing authority nor has it been notified of an impending examination. The Company’s tax returns for the years ended December 31, 2012, 2011 and 2010 remain open for possible review.

Fair Value of Financial Instruments – The carrying amounts reported in the balance sheets for cash, cash equivalents, and accounts payable approximate their fair values due to their quick turnover. The fair value of warrant derivative liability is estimated using the Binomial Lattice option valuation model.

Fair value for financial reporting is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1—quoted prices in active markets for identical assets or liabilities

Level 2—quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3—inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

 

 10 


Warrant liabilities represent the only financial assets or liabilities recorded at fair value by the Company. The fair value of warrant liabilities are determined based on Level 3 inputs.

Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these financial statements.

Basic and Diluted Loss per Common Share – Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents (which consist of options and warrants) are excluded from the computation if the effect would be antidilutive. Common share equivalents which could potentially dilute earnings per share, and which were excluded from the computation of diluted loss per share, totaled 21,992,841 shares and 20,013,824 shares at June 30, 2013 and 2012 respectively.

Recently Issued Accounting Standards – In June 2011, the Financial Accounting Standards Board (FASB) issued ASU No. 2011-5, which amends the Comprehensive Income Topic of the ASC. The ASU eliminates the option to present the components of other comprehensive income as part of the statement of changes in shareholders’ equity, and instead requires consecutive presentation of the statement of net income and other comprehensive income either in a continuous statement of comprehensive income or in two separate but consecutive statements. ASU No. 2011-5 became effective for interim and annual periods beginning after December 15, 2011. In February 2013, the FASB issued ASU No. 2013-02, which further amends the Comprehensive Income Topic of the ASC. This amendment requires entities to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount is being reclassified in its entirety to net income. This standard became effective for periods beginning after December 15, 2012. The adoption of these ASU’s did not have a material impact on the Company’s results of operations, financial condition or liquidity.

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities Exchange Commission (the “SEC”) did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

   

3. Property and Equipment

Property and equipment consist of the following:

   

 

   

June 30,
2013

   

      

December 31,
2012

   

Computers

$

55,418

   

      

$

23,192

   

Research equipment

   

120,025

   

      

   

128,381

   

   

   

175,443

   

      

   

151,573

   

Accumulated depreciation

   

(90,214

)

      

   

(75,284

)

   

$

85,229

   

      

$

76,289

   

Depreciation expense was $10,842 and $11,444 for the three months ended June 30, 2013 and 2012, respectively. Depreciation expense was $21,684 and $22,888 for the six months ended June 30, 2013 and 2012, respectively. Depreciation expense was $96,969 for the period from February 25, 2004 (date of inception) to June 30, 2013.

   

4. Related-Party Transactions

Cedars-Sinai Medical Center License Agreement

Dr. John Yu, our Chief Scientific Officer and former interim Chief Executive Officer, is a neurosurgeon at Cedars-Sinai Medical Center (Cedars-Sinai). In November 2006, the Company entered into a license agreement with Cedars-Sinai under which the Company acquired an exclusive, worldwide license to its technology for use as cellular therapies, including cancer stem cell and dendritic cell-based vaccines for neurological disorders that include brain tumors and neurodegenerative disorders and other cancers. This technology is covered by a number of pending U.S. and foreign patent applications, and the term of the license will be until the last to expire of any patents that are issued covering this technology.

As an upfront licensing fee, the Company issued Cedars-Sinai 694,000 shares of its common stock and paid Cedars-Sinai $62,000. Additional specified milestone payments will be required to be paid to Cedars-Sinai when the Company initiates patient enrollment in its first Phase III clinical trial and when it receives FDA marketing approval for its first product.

 

 11 


The Company has agreed to pay Cedars-Sinai specified percentages of all of its sublicensing income and gross revenues from sales of products based on the licensed technology. To maintain its rights to the licensed technology, the Company must meet certain development and funding milestones. These milestones include, among others, commencing a Phase I clinical trial for a product candidate by March 31, 2007 and raising at least $5,000,000 in funding from equity or other sources by December 31, 2008. The Company satisfied the foregoing funding requirement in 2007 and commenced a Phase I clinical trial in May 2007, which was within the applicable cure period for the milestone requirement. Through December 31, 2009, the Company has paid Cedars-Sinai a total of $166,660 in connection with the Phase I clinical trial. The Company also was required to commence a Phase II clinical trial for a product candidate by December 31, 2008 and a waiver of this requirement was obtained from Cedars-Sinai (see Second Amendment below).

On June 16, 2008, the Company entered into a First Amendment to Exclusive License Agreement (the Amendment) with Cedars-Sinai. The Amendment amended the License Agreement to include in the Company’s exclusive license from Cedars-Sinai under that agreement an epitope to CD133 and certain related intellectual property. Management believes this technology will be covered by a U.S. patent application that will be filed by the parties. Pursuant to the Amendment, the Company issued Cedars-Sinai 100,000 shares of the Company’s common stock as an additional license fee for the licensed CD133 epitope technology, which will be subject to the royalty and other terms of the License Agreement.

On July 22, 2009, the Company entered into a Second Amendment to Exclusive License Agreement (the Second Amendment) with Cedars-Sinai to become effective August 1, 2009. The Second Amendment amended the License Agreement to revise the milestones set forth in the License Agreement that the Company must achieve in order to maintain its license rights under that agreement. The revised milestones include the replacement of a milestone that required commencement of a Phase II clinical trial for the Company’s first product candidate by no later than December 31, 2008 with milestones that require commencement of a Phase I clinical trial for the Company’s second product candidate by no later than June 30, 2010 and commencement of a Phase II clinical trial for one of the Company’s product candidates by no later than March 31, 2012.

Effective March 23, 2010, the Company entered into a Third Amendment to Exclusive License Agreement (the Third Amendment) with Cedars-Sinai. The Third Amendment amended the License Agreement to revise the milestones set forth in the License Agreement that the Company must achieve in order to maintain its license rights under that agreement. The revised milestones include the replacement of a milestone that required commencement of a Phase I clinical trial for the Company’s second product candidate by no later than June 30, 2010 and commencement of a Phase II clinical trial for one of the Company’s product candidates by no later than March 31, 2012 with a requirement that the Company by September 30, 2011 either commence a Phase II clinical trial for its dendritic cell vaccine candidate or a Phase I clinical trial for its cancer stem cell vaccine candidate. The amendment also added a requirement that the Company obtain certain defined forms of equity or other funding in the amount of at least $2,500,000 by December 31, 2010 and a total of at least $5,000,000 by September 30, 2011. These funding requirements were fully satisfied as of June 30, 2011.

Effective September 1, 2012, the Company entered into a new agreement with Cedars-Sinai whereby Cedars-Sinai will provide research support for CD133 experiments in support of ICT-121. The agreement extends through September 19, 2013, and provides for payments of approximately $330,000.

   

5. Commitments and Contingencies

Sponsored Research Agreements

In an effort to expand the Company’s intellectual property portfolio to use antigens to create personalized vaccines, the Company has entered into various intellectual property and research agreements. Those agreements are long-term in nature and are discussed below.

Aptiv Solutions

The Company has contracted with Aptiv Solutions to provide certain services related to the Company’s ICT-107 Phase II trial. The original agreement was entered into in August of 2010 and provided for estimated payments of approximately $3 million for services through September 2013. Subsequently, the Company and Aptiv entered into two contract amendments. Under the first amendment, effective January 20, 2011, Aptiv agreed to provide additional services in conjunction with the Phase II trial of ICT-107 for an additional fee of $469,807. The second amendment, effective February 4, 2012, extended the services to be provided by Aptiv and further increased the fees by $986,783. The second amendment also extended the term of the agreement to March 31, 2014. On January 11, 2013, the third amendment was finalized whereby the services were further extended and the fees were further increased by $608,201. The total aggregate fee pursuant to the original agreement and the three modifications is $5,078,169. As of June 30, 2013, the Company’s remaining obligation under the existing commitment is approximately $809,000.

 

 12 


University of Pennsylvania

On February 13, 2012, the Company entered into a Patent License Agreement with The Trustees of the University of Pennsylvania under which the Company acquired an exclusive, world-wide license relating to intellectual property for the production, use and cryopreservation of high-activity dendritic cell cancer vaccines, including ICT-107, its lead dendritic cell-based cancer vaccine candidate for the treatment of glioblastoma multiforme.

  Pursuant to the License Agreement, the Company paid an upfront licensing fee and will be obligated to pay annual license maintenance fees. In addition, the Company has agreed to make payments upon completion of specified milestones and to pay royalties of a specified percentage on net sales, subject to a specified minimum royalty, and sublicensing fees.

The Johns Hopkins University Licensing Agreement

On February 23, 2012, the Company entered into an Exclusive License Agreement, effective as of February 16, 2012, with The Johns Hopkins University (JHU) under which it received an exclusive, world-wide license to JHU’s rights in and to certain intellectual property related to mesothelin-specific cancer immunotherapies.

Pursuant to the License Agreement, the Company agreed to pay an upfront licensing fee, payable half in cash and half in shares of its common stock, within 30 days of the effective date of the License Agreement and upon issuance of the first U.S. patent covering the subject technology. In addition, the Company has agreed to pay milestone license fees upon completion of specified milestones, customary royalties based on a specified percentage of net sales, sublicensing payments and annual minimum royalties.

The University of Pittsburgh Patent License Agreement

On March 20, 2012, the Company entered into an Exclusive License Agreement with the University of Pittsburgh under which the Company has licensed intellectual property surrounding EphA2, a tyrosine kinase receptor that is highly expressed by ovarian cancer and other advanced and metastatic malignancies. The License Agreement grants a world-wide exclusive license to the intellectual property for ovarian and pancreatic cancers; and a world-wide non-exclusive license to the intellectual property for brain cancer. The Company intends to employ the intellectual property in the development and commercialization of ICT-140, a multivalent, dendritic cell-based vaccine for the treatment of ovarian cancer.

Pursuant to the License Agreement, the Company agreed to pay an upfront nonrefundable and noncreditable licensing fee and nonrefundable and noncreditable maintenance fees due annually starting 12 months from the anniversary of the effective date of the License Agreement. In addition, the Company has agreed to make certain milestone payments upon completion of specified milestones and to pay customary royalties based on a specified percentage of net sales and sublicensing payments, as applicable.

Torrey Pines

On October 1, 2012, the Company entered into a Contract Services Agreement with Torrey Pines under which the Company has engaged Torrey Pines to determine the immunogenicity of certain peptides that are used in conjunction with the Company’s ICT-107 Phase IIb trial and in the development of ICT-140. The Company agreed to pay an upfront nonrefundable and noncreditable fee and is obligated to pay the remainder at the conclusion of the contract. On April 1, 2013, the Company and Torrey Pines expanded the scope of work to be completed by Torrey Pines under an additional Contract Services Agreement. This supplemental agreement provides for the Company to pay an upfront fee and additional fees at the conclusion of the contract.

In connection with the Cedars-Sinai Medical Center License Agreement, the Company has certain commitments as described in Note 4.

Employment Agreements

The Company has one-year employment agreements with its management that provide for a base salary, bonus and stock option grants.  The aggregate annual base salary payable to this group is approximately $870,000 and the potential bonus is approximately $270,000.  Additionally, during the six months ended June 30, 2013, the Company issued an aggregate of 189,000 stock options to its management at a weighted average exercise price of $2.59 that vest over a period of four years.  

Operating Lease

The Company leased its former office space through June 30, 2013 at a monthly rental of $4,410. The Company entered into a lease for new office space effective June 15, 2013 and continuing through August 31, 2016 at an initial monthly rental of $8,063. The monthly rental will increase by 3% on each anniversary date of the lease. Rent expense was approximately $17,800 and $12,700 for the three months ended June 30, 2013 and 2012, respectively. Rent expense was approximately $31,000 and $26,000 for the six months ended June 30, 2013 and 2012, respectively.

 

 13 


   

6. Shareholders’ Equity

Common Stock

In March 2010, the Company raised $1,654,686 (after commissions and offering expenses) from the sale of 1,740,000 shares of common stock and warrants to purchase 696,000 shares of common stock at an exercise price of $1.15 per share, to various investors in a private placement. (See “Warrants and Warrant Liabilities” below.)

In May 2010, the Company raised $2,716,308 (after commissions and offering expenses) from the sale of 2,490,910 shares of common stock and warrants to purchase 1,245,455 shares of common stock at an exercise price of $1.50 per share, to various investors in a private placement. (See “Warrants and Warrant Liabilities” below)

In February 2011, the Company raised $7,460,129 (after commissions and offering expenses) from the sale of 5,219,768 shares of common stock and warrants to purchase 2,609,898 shares of common stock at an exercise price of $2.25 per share, to various investors in a private placement. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that certain future common stock issuances are made at a price less than $1.55. The January and October 2012 underwritten public offering (see below) provided for the issuance of shares at prices that were less than $1.55. Accordingly, the exercise price of these warrants was adjusted to $1.87 and the number of warrants was proportionally increased to 2,823,670 net of exercises. (See “Warrants and Warrant Liabilities” below)

In January 2012, the Company raised approximately $9,271,370 in an underwritten public offering, net of offering expenses of approximately $1.1 million, from the sale of 9,489,436 shares of common stock and warrants to purchase 4,744,718 shares of common stock at an exercise price of $1.41 per share, to various investors in an underwritten public offering. The warrants have a term of 60 months from the date of issuance. The warrants do not contain any features (such as net cash settlement or anti-dilution features) that would preclude the Company from accounting for these warrants as equity. Accordingly, the warrants are accounted for as equity.

In October 2012, the Company raised $19,359,553 in an underwritten public offering, net of offering expenses of approximately $1.6 million, from the sale of 10,000,000 shares of common stock and warrants to purchase 4,500,000 shares of common stock at an exercise price of $2.65 per share, to various investors in an underwritten public offering. The warrants have a term of 60 months from the date of issuance. The warrants do not contain any features (such as net cash settlement or anti-dilution features) that would preclude the Company from accounting for these warrants as equity. Accordingly, the warrants are accounted for as equity.

Stock Options

In February 2005, the Company adopted an Equity Incentive Plan (the Plan). Pursuant to the Plan, a committee appointed by the Board of Directors may grant, at its discretion, qualified or nonqualified stock options, stock appreciation rights and may grant or sell restricted stock to key individuals, including employees, nonemployee directors, consultants and advisors. Option prices for qualified incentive stock options (which may only be granted to employees) issued under the plan may not be less than 100% of the fair market value of the common stock on the date the option is granted (unless the option is granted to a person who, at the time of grant, owns more than 10% of the total combined voting power of all classes of stock of the Company; in which case the option price may not be less than 110% of the fair market value of the common stock on the date the option is granted). Option prices for nonqualified stock options issued under the Plan are at the discretion of the committee and may be equal to, greater or less than fair market value of the common stock on the date the option is granted. The options vest over periods determined by the Board of Directors and are exercisable no later than ten years from date of grant (unless they are qualified incentive stock options granted to a person owning more than 10% of the total combined voting power of all classes of stock of the Company, in which case the options are exercisable no later than five years from date of grant). Initially, the Company reserved 6,000,000 shares of common stock for issuance under the Plan. On October 24, 2011, the Company’s shareholders voted to increase the number of authorized shares reserved for the Plan to 8,000,000 shares. Options to purchase 3,609,656 common shares have been granted under the Plan and are outstanding as of June 30, 2013. As of June 30, 2013, there were 2,010,016 options available for issuance under the Plan.

The following is a summary of stock option grants issued outside the Plan:

In January 2007, the Company granted an option to purchase 1,500,000 shares of its common stock at an exercise price of $1.10 per share to the Chairman of the Company’s Scientific Advisory Board.

In November 2006, the Company granted an option to purchase 300,000 shares of its common stock at an exercise price of $1.00 per share to an affiliate of the Company’s then Chairman of the Board.

In November 2006, the Company granted an option to purchase 5,933,424 shares of its common stock at an exercise price of $1.00 per share to a Board member in connection with the Cedars-Sinai license acquisition.

 

 14 


The following table summarizes stock option activity for the Company during the six months ended June 30, 2013:

   

 

   

Options

   

      

Weighted
Average
Exercise
Price

   

      

Weighted
Average
Remaining
Contractual
Term

   

      

Aggregate
Intrinsic
Value

   

Outstanding December 31, 2012

10,581,194

   

      

$

1.16

      

      

   

0

      

      

   

0

      

Granted

267,287

   

      

   

2.61

      

      

   

0

      

      

   

0

      

Exercised

(200,401

)

      

   

1.04

      

      

   

0

      

      

   

0

      

Forfeited or expired

(5,000

)

      

   

1.95

      

      

   

0

      

      

   

0

      

Outstanding June 30, 2013

10,643,080

   

      

$

1.28

      

      

   

3.81

      

      

$

8,097,234

      

Vested or expected to vest at June 30, 2013

9,064,475

   

      

$

1.07

      

      

   

3.18

      

      

$

8,072,450

      

As of June 30, 2013, the total unrecognized compensation cost related to unvested stock options amounted to $1,724,906, which will be amortized over the weighted-average remaining requisite service period of approximately 21 months.

Warrants

In connection with the March 2010 common stock private placement, the Company issued to the investors warrants to purchase 696,000 shares of the Company’s common stock at $1.15 per share. The warrants had a term of 26 months from the date of issuance. As of June 30, 2013, these warrants have been fully exercised.

In connection with the May 2010 common stock private placement, the Company issued to the investors warrants to purchase 1,287,733 shares of the Company’s common stock at $1.50 per share. The warrants have a term of 36 months from the date of issuance. As of June 30, 2013, warrants to purchase 1,283,773 shares of the Company’s common stock were exercised related to this private placement and warrants to purchase 4,000 shares of the Company’s common stock expired. (See Warrant Liabilities below.)

In connection with the sale of Preferred Stock in May 2010, the Company issued warrants to purchase 1,350,000 shares of common stock at an exercise price of $2.50. The warrants have a term of five-years from the date of issuance. As of June 30, 2013, warrants to purchase 1,290,996 shares of the Company’s common stock at $2.50 were outstanding related to this private placement. (See “Warrant Liability” below.)

In connection with the February 2011 common stock private placement, the Company issued to the investors warrants to purchase 2,818,675 shares of the Company’s common stock at $2.25 per share. The warrants have a five-year term from the date of issuance and contain a provision that provides for an adjustment to the exercise price in the event the Company completes an equity financing at a per share price of its common stock that is less than $1.55. As a result of the January and October 2012 financings, the exercise price of the warrants was adjusted to $1.87 and the number of warrants was proportionately increased to 2,823,670 net of exercises. As of June 30, 2013, warrants to purchase 2,823,670 shares of the Company’s common stock were outstanding related to this private placement. (See “Warrant Liability” below.)

In connection with the January 2012 underwritten public offering, the Company issued to the investors warrants to purchase 4,744,718 shares of the Company’s common stock at $1.41 per share. The warrants have a five-year term from the date of issuance. These warrants qualify for equity treatment since they do not have any provisions that would require the Company to redeem them for cash or that would result in an adjustment to the number of warrants. As of June 30, 2013, warrants to purchase 2,731,146 shares of the Company’s common stock remain outstanding relating to this public offering.

In connection with the October 2012 underwritten public offering, the Company issued to the investors warrants to purchase 4,500,000 shares of the Company’s common stock at $2.65 per share. The warrants have a five-year term from the date of issuance. These warrants qualify for equity treatment since they do not have any provisions that would require the Company to redeem them for cash or that would result in an adjustment to the number of warrants. As of June 30, 2013, warrants to purchase 4,495,950 shares of the Company’s common stock remain outstanding relating to this public offering.

Warrant Liability

The Company’s warrant liability is adjusted to fair value each reporting period and is influenced by several factors including the price of the Company’s common stock as of the balance sheet date. On June 28, 2013, the price per share of Company’s common stock was $1.94 per share compared to $1.92 per share at December 31, 2012 and $3.75 per share on June 30, 2012.

In connection with the March 2010 common stock private placement, the Company issued to the investors warrants to purchase 696,000 shares of the Company’s common stock at $1.15 per share. Of the total proceeds from the March 2010 common stock private

 

 15 


placement, $257,520 was allocated to the freestanding warrants associated with the units based upon the fair value of the warrants determined under the Black Scholes option pricing model. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that future common stock issuances are made at a price less than $1.00. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability was adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. Prior to 2011, the Company had concluded that Black-Scholes method of valuing the price adjustment feature does not materially differ from the valuation of such warrants using the lattice simulation model, and therefore, the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. The assumptions used in the Black Scholes model for determining the initial fair value of the warrants were as follows: (i) dividend yield of 0%; (ii) expected volatility of 102%, (iii) risk-free interest rate of 1.00%, and (iv) contractual life of 26 months. During the year ended December 31, 2011, the Company determined that it was more appropriate to value the warrants using a binomial lattice simulation model. During the six months ended June 30, 2012, the remaining warrants were fully exercised; however, the Company recognized an expense of $45,570 as the Company revalued the warrants at the date of exercise.  For the three and six months ended June 30, 2012, the Company recorded a charge to other expense of $45,570 and $745,500, respectively.     

In connection with the May 2010 common stock private placement, the Company issued to the investors warrants to purchase 1,287,773 shares of the Company’s common stock at $1.50 per share. Of the total proceeds from the May 2010 common stock private placement, $834,455 was allocated to the freestanding warrants associated with the units based upon the fair value of the warrants determined under the Black Scholes option pricing model. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that future common stock issuances are made at a price less than $1.00. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability is adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. Prior to 2011, the Company had concluded that the Black-Scholes method of valuing the price adjustment feature does not materially differ from the valuation of such warrants using the binomial lattice simulation model, and therefore, the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. The assumptions used in the Black Scholes model for determining the initial fair value of the warrants were as follows: (i) dividend yield of 0%; (ii) expected volatility of 102%, (iii) risk-free interest rate of 1.375%, and (iv) contractual life of 36 months. Effective January 1, 2011, the Company determined that it was more appropriate to value the warrants using a binomial lattice simulation model. For the three and six months ended June 30, 2012, the Company recorded a charge to other expense of $805,944 and $1,926,853, respectively. During the six months ended June 30, 2013, the remaining warrants were fully exercised; however, the Company recognized a credit to other income of $403,665 as the Company revalued the warrants at the date of exercise.  For the three months ended June 30, 2013, the Company recorded a credit to other income of $403,665 and for the six months ended June 30, 2013, the Company recognized a charge to other expense of $583,134.

In connection with the sale of Preferred Stock in 2010, the Company vested warrants to purchase 1,350,000 shares of the Company’s common stock at an exercise price of $2.50 per share. Of the total proceeds from the May 2010 preferred stock sale, $5,710,500 was allocated to the freestanding warrants associated with the units based upon the fair value of these warrants determined under the Black Scholes option pricing model. The warrants contain a provision whereby the warrant may be settled for cash in connection with a change of control with a private company. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability is adjusted to fair value each reporting period and any change in value is recognized in the statement of operations. Prior to 2011, the Company concluded that the Black-Scholes method of valuing the price adjustment feature does not materially differ from the valuation of such warrants using the Monte Carlo or binomial lattice simulation models, and therefore, the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. The assumptions used in the Black Scholes model for determining the initial fair value of the warrants were as follows: (i) dividend yield of 0%; (ii) expected volatility of 102%, (iii) risk-free interest rate of 2.50%, and (iv) contractual life of 60 months. Effective January 1, 2011, the Company determined that it was more appropriate to value the warrants using a binomial lattice simulation model. For the three and six months ended June 30, 2012, the Company recorded a charge to other expense of $658,800 and $1,451,250, respectively. As of June 30, 2013, the Company revalued the warrants using the binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 71.5%; (iii) risk free rate of 0.33% and (iv) expected term of 1.84 years. For the three and six months ended June 30, 2013, the Company recorded a credit to other income of $480,250 and $2,582, respectively. As of June 30, 2013, the carrying value of the warrant liability is $586,113.

In connection with the February 2011 common stock private placement, the Company issued to the investors warrants to purchase 2,818,675 shares of the Company’s common stock at $2.25 per share. Of the total proceeds from the February 2011 common stock private placement, $2,476,790 was allocated to the freestanding warrants associated with the units based upon the fair value of the warrants determined under the Binomial lattice model. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that certain future common stock issuances are made at a price less than $1.55. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. As a result of the January and October 2012 financings, the exercise price of the warrants was adjusted to $1.87 and the number of warrants was proportionately increased to 2,823,670 net of exercises. The Company recorded a charge to financing expense of $397,294 to reflect the issuance of the additional warrants. The warrant liability is adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. The Company initially valued these warrants using a binomial lattice simulation

 

 16 


model assuming (i) dividend yield of 0%; (ii) expected volatility of 146%; (iii) risk free rate of 1.96% and (iv) expected term of 5 years. Based upon those calculations, the Company calculated the initial valuation of the warrants to be $2,476,790. For the three and six months ended June 30, 2012, the Company recorded a charge to other expense of $1,812,906 and $3,672,121, respectively. As of June 30, 2013, the Company revalued the warrants using the binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 66/5%; (iii) risk free rate of 0/55% and (iv) expected term of 2.64 years. For the three months ended June 30, 2013, the Company recorded a credit to other income of $1,143,597 and for the six months ended June 30, 2013, the Company recorded a charge to other expense of $23,619. As of June 30, 2013, the carrying value of the warrant liability is $1,725,278.

For the six months ended June 30, 2013, the expected volatility is based upon the historical volatility of the Company’s stock. For the six months ended June 30, 2012, the expected volatility is based on market prices of traded options for comparable entities within our industry.

The following reconciliation of the beginning and ending balances for all warrant liabilities measured at fair market value on a recurring basis using significant unobservable inputs (level 3) during the period ended June 30, 2013 and 2012:

   

 

   

June 30,
2013

   

      

June 30,
2012

   

Balance – January 1

$

2,852,880

   

      

$

2,157,408

   

Issuance of warrants and effect of repricing

   

0

   

      

   

368,524

   

Exercise of warrants

   

(1,145,660

)

      

   

(1,622,649

)

(Gain) or loss included in earnings

   

604,171

   

      

   

7,795,724

   

Transfers in and out/or out of Level 3

   

0

   

      

   

      

   

Balance – June 30

$

2,311,391

   

      

$

8,699,007

   

Controlled Equity Offering

On April 18, 2013, the Company into a Controlled Equity Offering SM Sales Agreement (the Sales Agreement) with Cantor Fitzgerald & Co., as agent (Cantor), pursuant to which the Company offer and sell, from time to time through Cantor, shares of our common stock having an aggregate offering price of up to $25.0 million (of which only $17.0 million is currently registered for offer and sale). Under the Sales Agreement, Cantor may sell shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act, as amended, including sales made directly on the NYSE MKT, on any other existing trading market for our common stock or to or through a market maker. The Company may instruct Cantor not to sell shares if the sales cannot be effected at or above the price designated by us from time to time. The Company is not obligated to make any sales of the shares under the Sales Agreement. The offering of shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. Cantor will receive a commission rate of 3.0% of the aggregate gross proceeds from each sale of shares and the Company has agreed to provide Cantor with customary indemnification and contribution rights. The Company will also reimburse Cantor for certain specified expenses in connection with entering into the Sales Agreement.  On April 22, 2013, NYSE MKT approved the listing of 10,593,220 shares of our common stock in connection with the Sales Agreement. Through June 30, 2013, we sold 172,988 shares of our common stock under the Sales Agreement that resulted in net proceeds to the Company of approximately $441,051, less offering expenses of approximately $37,000.  As of June 30, 2013, aggregate gross sales for additional common stock of approximately $16,554,838 remained available under the Sales Agreement.

   

7. 401(k) Profit Sharing Plan

During 2011, the Company adopted a Profit Sharing Plan that qualifies under Section 401(k) of the Internal Revenue Code. Contributions to the plan are at the Company’s discretion. The Company did not make any matching contributions during the three and six months ended June 30, 2013 or June 30, 2012.

   

8. Income Taxes

Deferred taxes represent the net tax effects of the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Temporary differences result primarily from the recording of tax benefits of net operating loss carry forwards and stock-based compensation.

As of June 30, 2013, the Company has an insufficient history to support the likelihood of ultimate realization of the benefit associated with its deferred tax assets. Accordingly, a valuation allowance has been established for the full amount of the net deferred tax asset.

 

 17 


The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows:

   

 

   

June 30, 

2013

   

   

June 30, 

2012

   

Income tax benefit at the federal statutory rate

   

-34

   

   

-34

State income tax benefit, net of federal tax benefit

   

-6

   

   

-6

Change in fair value of warrant liability

   

5

   

   

23

Change in valuation allowance for deferred tax assets

   

35

   

   

17

Total

   

0

   

   

0

   

   

 

   

June 30,
2013

   

      

December 31,
2012

   

Net operating loss carryforwards

$

14,492,100

      

      

$

12,821,749

      

Stock-based compensation

   

1,868,932

      

      

   

1,796,954

      

Less valuation allowance

   

(16,361,032

      

   

(14,618,703

Net deferred tax asset

$

0

      

      

$

—  

   

As of June 30, 2013 and December 31, 2012, the Company had federal and California income tax net operating loss carryforwards of approximately $36.2 million. These net operating losses will begin to expire in 2022 and 2016, respectively, unless previously utilized.

Section 382 of the Internal Revenue Code can limit the amount of net operating losses which may be utilized if certain changes to a company’s ownership occur. While the Company underwent an ownership change in 2012 as defined by Section 382 of the Internal Revenue Code, management estimated that the Company had not incurred any limitations on its ability to utilize its net operating losses under Section 382 of the Internal Revenue Code during 2012. The Company may incur limitations in the future if there is a change in ownership.

   

  9. Subsequent Events

Warrant Exercises

Subsequent to June 30, 2013, certain warrant holders exercised 9,900 warrants for cash and the Company received $26,235.

Controlled Equity Offering

Subsequent to June 30, 2013, the Company sold 770,508 shares of common stock under the Sales Agreement with Cantor, which resulted in net proceeds of approximately $2,081,938. (See Note 6). Aggregate gross sales for additional common stock of approximately $14,408,511 remain available under the Sales Agreement.

   

   

   

 

 18 


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Throughout this Quarterly Report on Form 10-Q, the terms “we,” “us,” “our,” and “our company” refer to ImmunoCellular Therapeutics, Ltd., a Delaware corporation.

Cautionary Statement Regarding Forward-Looking Statements

This Quarterly Report contains forward-looking statements, which reflect the views of our management with respect to future events and financial performance. These forward-looking statements are subject to a number of uncertainties and other factors that could cause actual results to differ materially from such statements. Forward-looking statements are identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “plans,” “projects,” “targets” and similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on the information available to management at this time and which speak only as of this date. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For a discussion of some of the factors that may cause actual results to differ materially from those suggested by the forward-looking statements, please read carefully the information under the heading “Risk Factors” in our Form 10-K for the year ended December 31, 2012. The identification in this Quarterly Report of factors that may affect future performance and the accuracy of forward-looking statements is meant to be illustrative and by no means exhaustive. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty.

Overview

ImmunoCellular Therapeutics, Ltd. (the “Company”) is a development stage company that is seeking to develop and commercialize new therapeutics to fight cancer using the immune system.

Since the Company’s inception on February 25, 2004, the Company has been primarily engaged in the acquisition of certain intellectual property, together with development of its product candidates and the recent clinical testing activities for one of its vaccine product candidates, and has not generated any recurring revenues. The Company’s lead product candidate, ICT-107 is in Phase II clinical development. The Company has two other candidates, ICT-140 and ICT-121, that each have investigational new drug (IND) applications for initiation of clinical development. The Company has sustained operating losses and, as of June 30, 2013, the Company had an accumulated deficit of $48,292,950. The Company expects to incur significant research, development and administrative expenses before any of its products can be launched and recurring revenues generated.

On January 31, 2006, we completed a merger pursuant to which Spectral Molecular Imaging, Inc. became our wholly owned subsidiary. At the time of the merger, we had virtually no assets or liabilities, and we had not conducted any business operations for several years. In connection with the merger, we changed our name from Patco Industries, Ltd. to Optical Molecular Imaging, Inc. and replaced our officers and directors with those of Spectral Molecular Imaging. Although we acquired Spectral Molecular Imaging in the merger, for accounting purposes the merger was treated as a reverse merger since the stockholders of Spectral Molecular Imaging acquired a majority of our outstanding shares of common stock and the directors and executive officers of Spectral Molecular Imaging became our directors and executive officers. Accordingly, our financial statements contained in this Report and the description of our results of operations and financial condition reflect the operations of Spectral Molecular Imaging through September 2006, when we sold that subsidiary and all of its operations to a third party.

In November 2006, we acquired an exclusive, worldwide license from Cedars-Sinai Medical Center for certain cellular-based therapy technology that we are developing for the potential treatment of brain tumors and other forms of cancer and neurodegenerative disorders. We have completed a Phase I clinical trial of a vaccine product candidate for the treatment of glioblastoma multiforme based on this technology and in January 2011, we initiated a Phase II clinical trial. During 2012 we completed our patient enrollment for this trial.

In February 2008, we acquired certain monoclonal antibody related technology owned by Molecular Discoveries LLC. This technology consists of (1) a platform technology referred to by Molecular Discoveries as DIAAD for the potentially rapid discovery of targets (antigens) and monoclonal antibodies for diagnosis and treatment of diverse human diseases and (2) certain monoclonal antibody candidates for the potential detection and treatment of multiple myeloma, small cell lung, pancreatic and ovarian cancers. These monoclonal antibody programs are at a pre-clinical stage of development and will require further development before an IND can be potentially filed for human testing. We expect our potential partners or licensees to do this development work.

In February 2012, we acquired an exclusive world-wide license from the University of Pennsylvania related to intellectual property for the production, use and cryopreservation of high-activity dendritic cell cancer vaccines, including ICT-107, the company’s lead dendritic cell-based cancer vaccine candidate for the treatment of glioblastoma multiforme.

 

 19 


Also in February 2012, we acquired an exclusive, worldwide license from The John Hopkins University (“JHU”) to certain intellectual property related to mesothelin-specific cancer immunotherapies.

In January 2013, the US Food and Drug Administration allowed our IND for a clinical trial for ICT-140 Phase II open-label safety study to initially enroll 30 ovarian cancer patients with an option to enroll another 30 patients at our discretion.  The study is designed with a 2-to-1 randomization, whereby for every 2 patients who will receive the treatment 1 patient will receive the current standard of care.  All of the patients participating in the study will have been previously treated with standard chemotherapeutic agents. This trial is expected to include four or five clinical sites in the United States and we expect to initiate the trial in the first quarter of 2014.

On July 30, 2013, we announced the initiation of a Phase I clinical trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme.

Plan of Operation

We are a development stage company that is seeking to develop and commercialize new therapeutics to fight cancer using the immune system.

Since our company’s inception on February 25, 2004, we have been primarily engaged in the acquisition of certain intellectual property, together with the recent clinical testing activities for our vaccine product candidates, and have not generated any recurring revenues. As a result, we have incurred operating losses and, as of June 30, 2013 we had an accumulated deficit of $48,292,950. We expect to incur significant research, development and administrative expenses before any of our products can be launched and recurring revenues, if ever, are generated.

Critical Accounting Policies

Management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to impairment of long-lived assets, including finite lived intangible assets, accrued liabilities, fair value of warrant derivatives and certain expenses. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.

Our significant accounting policies are summarized in Note 2 of our financial statements for the period from February 25, 2004 to June 30, 2013. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our financial statements:

Development Stage Enterprise

We are a development stage enterprise as defined by FASB ASC Topic 915, “Accounting and Reporting by Development Stage Enterprises.” We are devoting substantially all of our present efforts to research and development. All losses accumulated since inception are considered as part of our development stage activities.

Research and Development Costs

Although we believe that our research and development activities and underlying technologies have continuing value, the amount of future benefits to be derived from them is uncertain. Research and development costs are therefore expensed as incurred rather than capitalized. During the six months ended June 30, 2013 and 2012 we recorded an expense of $2,628,831 and $4,188,169, respectively related to research and development activities. We expect our research and development expenses during the remainder of 2013 to remain relatively constant with the first half of the year.

Stock-Based Compensation

Stock-based compensation expense is estimated as of the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally equals the vesting period, based on the number of awards that are expected to vest. Estimating the fair value for stock options requires judgment, including the expected term of our stock options, volatility of our stock, expected dividends, risk-free interest rates over the expected term of the options and the expected forfeiture rate. In

 

 20 


connection with our performance based programs, we make assumptions principally related to the number of awards that are expected to vest after assessing the probability that certain performance criteria will be met.

Income Taxes

The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. The Company recognizes in its financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. The Company is not currently under examination by any taxing authority nor has it been notified of an impending examination. The Company’s tax returns for the years ended December 31, 2012, 2011 and 2010, remain open for possible review.

Fair Value of Financial Instruments

The carrying amounts reported in the balance sheets for cash, cash equivalents, and accounts payable approximate their fair values due to their quick turnover. The fair value of warrant liability is estimated using the Binomial Lattice option valuation model.

Results of Operations

Three months ended June 30, 2013 and 2012

Revenues

We did not have any revenue during the three months ended June 30, 2013 and 2012 and we do not expect to have any revenue in 2013.

Expenses

General and administrative expenses for the three months ended June 30, 2013 and 2012 were $788,420 and $837,322, respectively. During the three months ended June 30, 2013, we reduced our expenses in the areas of investor relations, travel and legal expenses. These decreases were partially offset by additional wages.

Research and development expenses for the three months ended June 30, 2013 and 2012 were $1,213,570 and $2,189,633, respectively. During the three months ended June 30, 2012, we enrolled 72 new patients in our Phase II clinical trial of ICT-107 bringing the total number of enrolled patients to 231. Additionally, we had two manufacturing facilities and 25 Phase II trial clinical sites that were operational. Since we completed our ICT-107 patient enrollment during the third quarter of 2012, we did not incur certain expenses related to product manufacturing or quality control during the three months ended June 30, 2013. However, we continued to incur other trial related expenses related to ICT-107. The decrease in the amounts expended for ICT-107 was partially offset by certain pre-clinical expenses we incurred related to ICT-121 and ICT-140. We expect our research and development expenses to remain relatively constant during the second half of 2013.

We had $190,788 of non-cash expenses during the three months ended June 30, 2013, consisting of $179,946 of stock based compensation and $10,842 of depreciation expense. We also recognized non-cash income of $2,027,517 related to the decrease in our warrant liabilities.  We had $3,438,281 of non-cash expenses for the three months ended June 30, 2012, consisting of $3,323,220 related to the increase in our warrant liability, $103,617 of stock based compensation and $11,444 of depreciation expense.

Net Loss

We incurred a net loss of $150,329 and $6,451,817 for the three months ended June 30, 2013 and 2012, respectively. The decrease in the net loss is primarily due to reductions in research and development expenses and a reduced charge to other expense related to the increase in the fair value of the warrant liability.

Six months ended June 30, 2013 and 2012

Revenues

We did not have any revenue during the six months ended June 30, 2013 and 2012 and we do not expect to have any revenue in 2013.

 

 21 


Expenses

General and administrative expenses for the six months ended June 30, 2013 and 2012 were $1,557,687 and $1,643,120, respectively. During the six months ended June 30, 2013, we reduced our expenses in the areas of investor relations, travel and legal expenses.  These decreases were partially offset by additional wages.

Research and development expenses for the six months ended June 30, 2013 and 2012 were $2,628,831 and $4,188,169, respectively. During the six months ended June 30, 2012, we enrolled 140 new patients in our Phase II clinical trial of ICT-107 bringing the total number of enrolled patients to 231.  Additionally, we had two manufacturing facilities and 25 Phase II trial clinical sites that were operational.  Since we completed our ICT-107 patient enrollment during the third quarter of 2012, we did not incur certain expenses related to product manufacturing or quality control during the six months ended June 30, 2013.  However, we continued to incur other trial related expenses related to ICT-107.  The decrease in the amounts expended for ICT-107 was partially offset by certain pre-clinical expenses we incurred related to ICT-121 and ICT-140.  We expect our research and development expenses to increase during the remainder of 2013 as we incur on-going expenses related to our Phase II  trial of ICT-107 and as we begin enrolling patients in our clinical trials for ICT-121 and ICT-140.  

We had $969,928 of non-cash expenses during the six months ended June 30, 2013, consisting of $604,170 related to the increase in our warrant liabilities, $344,074 of stock based compensation and $21,684 of depreciation expense. We had $8,167,336 of non-cash expenses for the six months ended June 30, 2012, consisting of $7,795,724 related to the increase in our warrant liability, $348,724 of stock based compensation and $22,888 of depreciation expense.

Net Loss

We incurred a net loss of $5,124,120 and $14,341,252 for the six months ended June 30, 2013 and 2012, respectively. The decrease in the net loss is primarily due to reductions in research and development expenses and a reduced charge to other expense related to the increase in the fair value of the warrant liability.

Liquidity and Capital Resources

As of June 30, 2013, we had working capital of $25,031,191, compared to working capital of $25,832,869 as of December 31, 2012. The estimated cost of completing the development of either of our current vaccine product candidates and of obtaining all required regulatory approvals to market either of those product candidates is substantially greater than the amount of funds we currently have available. However, we believe that our existing cash balances will be sufficient to fund our operations for at least the next twelve months, although there is no assurance that such proceeds will be sufficient.

On April 18, 2013, we entered into a Controlled Equity Offering SM Sales Agreement (the Sales Agreement) with Cantor Fitzgerald & Co., as agent (Cantor), pursuant to which we may offer and sell, from time to time through Cantor, shares of our common stock having an aggregate offering price of up to $25.0 million (of which only $17.0 million was initially registered for offer and sale). Under the Sales Agreement, Cantor may sell shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act, as amended, including sales made directly on the NYSE MKT, on any other existing trading market for our common stock or to or through a market maker. We may instruct Cantor not to sell shares if the sales cannot be effected at or above the price designated by us from time to time. We are not obligated to make any sales of the shares under the Sales Agreement. The offering of shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. We will pay Cantor a commission rate of 3.0% of the aggregate gross proceeds from each sale of shares and have agreed to provide Cantor with customary indemnification and contribution rights. We will also reimburse Cantor for certain specified expenses in connection with entering into the Sales Agreement. On April 22, 2013, NYSE MKT approved the listing of 10,593,220 shares of our common stock in connection with the Sales Agreement. During the six months ended June 30, 2013, we issued 172,988 shares and received net proceeds of $404,208.  As of June 30, 2013, we had $16,554,838 remaining under the registration statement.  See additional discussion in Note 6 to the unaudited condensed financial statements which are included in Part 1 of this Form 10-Q.

In October 2012, we raised $19,359,553 in an underwritten public offering, net of offering expenses of approximately $1.6 million, of 10 million units priced at $2.10 per unit. Each unit consisted of one share of common stock and a warrant to purchase .45 of a share of our common stock at an exercise price of $2.65 per share. In January 2012, we raised approximately $9,271,370 in an underwritten public offering, net of offering expenses of approximately $1.1 million, of 9,489,436 units at a price of $1.10 per unit. Each unit consists of one share of stock and a warrant to purchase 0.5 of a share of our common stock at an exercise price of $1.41 per share. In February 2011, we raised $7,460,129 (after commissions and offering expenses) from the sale of 5,219,768 units at a price of $1.55 per unit, with each unit consisting of one share of our common stock and a warrant to purchase 0.5 of a share of our common stock at an exercise price of $2.25 per share. In May 2010, we raised $2,716,308 (after commissions and offering expenses) from the sale of 2,490,910 shares of common stock and warrants to purchase 1,245,455 shares of common stock at an exercise price of $1.50

 

 22 


per share. In March 2010, we raised $1,654,686 (after commissions and offering expenses) from the sale of 1,740,000 shares of common stock and warrants to purchase 696,000 shares of common stock at an exercise price of $1.15 per share.

We may also seek to obtain funding through strategic alliances with larger pharmaceutical or biomedical companies. We cannot be sure that we will be able to obtain any additional funding from either financings or alliances, or that the terms under which we may be able to obtain such funding will be beneficial to us. If we are unsuccessful or only partly successful in our efforts to secure additional financing, we may find it necessary to suspend or terminate some or all of our product development and other activities.

As of June 30, 2013, we did not have any bank credit lines, long-term debt obligations, capital lease obligations, or other similar long-term liabilities. We have various purchase commitments for sponsored research and license fees. We have no financial guarantees, debt or lease agreements or other arrangements that could trigger a requirement for an early payment or that could change the value of our assets, and we do not engage in trading activities involving non-exchange traded contracts.

Contractual Obligations

The following is a summary of our contractual obligations including those entered into subsequent to June 30, 2013.

   

 

   

Total

   

   

Less than
1 year

   

   

1-3
years

   

   

3-5
years

   

   

More than
5 years

   

Unconditional purchase obligations

$

420,421

   

   

$

420,421

   

   

$

—  

   

   

$

—  

   

   

$

—  

   

Operating lease obligation

$

299,063

   

   

   

97,482

   

   

   

201,581

   

   

   

—  

   

   

   

—  

   

   

$

719,484

   

   

$

517,903

   

   

$

201,581

   

   

$

—  

   

   

$

—  

   

Cash Flows

We used $4,117,822 of cash in our operations for the six months ended June 30, 2013, compared to $6,889,220 for the six months ended June 30, 2012. During the six months ended June 30, 2012, we greatly expanded our research and development activities, hired additional personnel and expanded our investor relations program. Additionally, we expanded our manufacturing activities, licensed the rights to key antigens and initiated efforts to expand our intellectual property portfolio. Since we completed our ICT-107 patient enrollment during the third quarter of 2012, we did not incur certain expenses related to product manufacturing or quality control during the six months ended June 30, 2013. During the six months ended June 30, 2013, we incurred non-cash expenses consisting primarily of a valuation adjustment to our warrant liabilities of $604,171 and stock based compensation of $344,074. During the six months ended June 30, 2012, we incurred non-cash expenses consisting primarily of a valuation adjustment to our warrant liabilities of $7,795,724 and stock based compensation of $348,724. Additionally, during the six months ended June 30, 2012, we recorded a non-cash financing expense of $368,524 related to the issuance of additional warrants triggered by the January 2012 stock issuance.

We used $34,441 cash from our investing activities during the six months ended June 30, 2013 primarily to purchase computer equipment and a telephone system. During the six months ended June 30, 2012, we used $5,668 of cash from our investing activities to acquire office equipment.

During the six months ended June 30, 2013, we received net proceeds of $84,131 from the exercise of stock options and $3,049,638 from the exercise of warrants. We also received $404,208 in net proceeds from our controlled equity offering.  During the six months ended June 30, 2012, we received net proceeds of $9,271,370, excluding $100,000 of deferred offering costs that were previously advanced by the Company, from the issuance of common stock and warrants and we received $2,199,193 of proceeds from the exercise of warrants.

Inflation and changing prices have had no effect on our income or losses from operations over our two most recent fiscal years.

Off-Balance Sheet Arrangements

We are not party to any off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

   

Item 3. Quantitative and Qualitative Disclosures About Market Risk

During the three months ended June 30, 2013, there were no material changes to our market risk disclosures as set forth in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, 2012, filed on March 11, 2013 with the SEC.

 

 23 


   

  Item 4. Controls a nd Procedures

As of the end of the fiscal quarter covered by this report, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, regarding the effectiveness of the design and operation of our disclosure controls and procedures pursuant to SEC Rule 15d-15(b) of the Exchange Act. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of June 30, 2013, (i) our disclosure controls and procedures were effective to ensure that information that is required to be disclosed by us in reports that we file under the Exchange Act is recorded, processed, summarized and reported or submitted within the time period specified in the rules and forms of the SEC and (ii) our disclosure controls and procedures were effective to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under the Exchange Act was accumulated and communicated to our management as appropriate to allow timely decisions regarding required disclosure. There were no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We do not expect that our disclosure controls and procedures and internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. The design of any system of controls also is based in part upon assurance that any design will succeed in achieving its stated goals under all potential future conditions. However, controls may become inadequate because of changes in conditions or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

   

   

 

 24 


PART II

OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

You should read and consider the risk factors included under Item 1A. of our Annual Report on Form 10-K for the year ended December 31, 2012, filed on March 11, 2013 with the SEC.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information about the Company’s repurchases of its common stock during the quarter ended June 30, 2013.

   

 

Month

Total Number of
Shares (or Units)
Purchased (1)

   

      

Average Price
Paid per Share

(or Unit)

   

      

Total Number of Shares
(or Units) Purchased as
Part of
Publicly Announced
Plans or
Programs

   

      

Maximum
Number (or
Approximate Dollar
Value) of Shares

(or Units)

that May Yet be
Purchased Under
the Plans or
Programs

   

April

   

99,208

   

      

$

—  

      

      

   

—  

   

      

   

—  

   

May

   

12,984

   

      

$

—  

      

      

   

—  

   

      

   

—  

   

June

   

—  

      

      

$

—  

      

      

   

—  

   

      

   

—  

   

   

   

112,192

      

      

$

—  

      

      

   

—  

   

      

   

—  

   

 

(1)

These shares are deemed to be repurchased through the cashless exercise of warrants and stock options during the quarter ended June 30, 2013.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

   

 

 25 


  Item 6. Exh ibits

   

 

Exhibit No.

      

Description

   

   

10.1

      

Office Lease dated May 13, 2013 between Calabasas/Sorrento Square, LLC and ImmunoCellular Therapeutics, Ltd.

   

   

10.2

      

Master Services Agreement dated September 1, 2010 between Averion International Corp. and ImmunoCellular Therapeutics, Ltd.

   

   

31.1

      

Certification of the Registrant’s Principal Executive Officer under Exchange Act Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

   

   

31.2

      

Certification of the Registrant’s Principal Financial Officer under Exchange Act Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

   

   

32.1

      

Certification of the Registrant’s Principal Executive Officer under 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

   

   

32.2

      

Certification of the Registrant’s Principal Financial Officer under 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

   

   

101.INS#

      

XBRL Instance Document

   

   

101.SCH#

      

XBRL Taxonomy Extension Schema Document

   

   

101.CAL#

      

XBRL Taxonomy Extension Calculation Linkbase Document

   

   

101.LAB#

      

XBRL Taxonomy Extension Labels Linkbase Document

   

   

101.PRE#

      

XBRL Taxonomy Extension Presentation Linkbase Document

   

   

101.DEF#

      

XBRL Taxonomy Extension Definition Linkbase Document

 

#

Pursuant to applicable securities laws and regulations, the Registrant is deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and is not subject to liability under any anti-fraud provisions of the federal securities laws as long as the Registrant has made a good faith attempt to comply with the submission requirements and promptly amends the interactive data files after becoming aware that the interactive data files fails to comply with the submission requirements. These interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section  18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

   

   

 

 26 


SIGNA TURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

   

 

Dated: August 7, 2013

IMMUNOCELLULAR THERAPEUTICS, LTD.

   

   

   

By:

      

/s/ Andrew Gengos

   

   

      

   

      

   

Name:

      

Andrew Gengos

   

Title:

      

President and Chief Executive Officer

(Principal Executive Officer)

   

   

   

   

By:

      

/s/ David Fractor

   

   

      

   

      

   

Name:

      

David Fractor

   

Title:

      

Principal Accounting Officer

(Principal Financial and Accounting Officer)

   

   

 

 27 


EXHIBIT INDEX

IMMUNOCELLULAR THERAPEUTICS, LTD.

FORM 10-Q FOR QUARTER ENDED JUNE 30, 2013

   

 

Exhibit No.

      

Description

   

   

10.1

      

Office Lease dated May 13, 2013 between Calabasas/Sorrento Square, LLC and ImmunoCellular Therapeutics, Ltd.

   

   

10.2

      

Master Services Agreement dated September 1, 2010 between Averion International Corp. and ImmunoCellular Therapeutics, Ltd.

   

   

31.1

      

Certification of the Registrant’s Principal Executive Officer under Exchange Act Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

   

   

31.2

      

Certification of the Registrant’s Principal Financial Officer under Exchange Act Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

   

   

32.1

      

Certification of the Registrant’s Principal Executive Officer under 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

   

   

32.2

      

Certification of the Registrant’s Principal Financial Officer under 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

   

   

101.INS#

      

XBRL Instance Document

   

   

101.SCH#

      

XBRL Taxonomy Extension Schema Document

   

   

101.CAL#

      

XBRL Taxonomy Extension Calculation Linkbase Document

   

   

101.LAB#

      

XBRL Taxonomy Extension Labels Linkbase Document

   

   

101.PRE#

      

XBRL Taxonomy Extension Presentation Linkbase Document

   

   

101.DEF#

      

XBRL Taxonomy Extension Definition Linkbase Document

 

#

Pursuant to applicable securities laws and regulations, the Registrant is deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and is not subject to liability under any anti-fraud provisions of the federal securities laws as long as the Registrant has made a good faith attempt to comply with the submission requirements and promptly amends the interactive data files after becoming aware that the interactive data files fails to comply with the submission requirements. These interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section  18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

   

   

 

 28 


EXHIBIT 10.1

LOGO

STANDARD MULTI-TENANT OFFICE LEASE—GROSS

AIR COMMERCIAL REAL ESTATE ASSOCIATION

1. Basic Provisions (“Basic Provisions”) .

1.1 Parties : This Lease (“ Lease ”), dated for reference purposes only May 13, 2013, is made by and between CALABASAS/SORRENTO SQUARE, LLC, a Delaware limited liability company (“ Lessor ”) and Immunocellular Therapeutics, LTD., a Delaware corporation (“ Lessee ”), (collectively the “ Parties ”, or individually a “ Party ”).

1.2(a) Premises : That certain portion of the Project (as defined below), known as Suite Numbers(s) 300, Third floor(s), consisting of approximately deemed to consist of 3431 rentable square feet and approximately N/A useable square feet (“ Premises ”). The Premises are located at: 23622 Calabasas Road, in the City of Calabasas, County of Los Angeles, State of California, with zip code 91302. In addition to Lessee’s rights to use and occupy the Premises as hereinafter specified, Lessee shall have non-exclusive rights to the Common Areas (as defined in Paragraph 2.7 below) as hereinafter specified, but shall not have any rights to the roof, the exterior walls, the area above the dropped ceilings, or the utility raceways of the building containing the Premises (“ Building ”) or to any other buildings in the Project. The Premises, the Building, the Common Areas, the land upon which they are located, along with all other buildings and improvements thereon, are herein collectively referred to as the “ Project .” The Project consists of approximately 83,375 rentable square feet. (See also Paragraph 2)

1.2(b) Parking : Total parking spaces per Lease Agreement: Eleven (11) surface, unreserved at a monthly cost of $0.00; and In the subterranean parking structure located at 23622 Calabasas Road Four unreserved vehicle parking spaces at a monthly cost of *$0.00 per unreserved space and N $ N/A per reserved space. See Rules and Regulations Items 18. and 19. for additional information and (See Paragraph 2.6)

1.3 Term : – – – – – – – – – – years and Thirty Eight (38) months and Sixteen (16) Days (“ Original Term ”) commencing *June 15, 2013 (“ Commencement Date ”) and ending August 31, 2016 (“ Expiration Date ”). (See also Paragraph 3). *The later of June 15, 2013 or upon substantial completion of Tls.

Substantial completion of Tl’s, defined: For the purposes of this document, substantial completion of Tl’s shall mean that tenant may occupy the premises, or a portion thereof, for its intended use, but items may remain on the punchlist that will not adversely affect Lessee’s business.

1.4 Early Possession : N/A (“ Early Possession Date ”). (See also Paragraphs 3.2 and 3.3)

1.5 Base Rent : $8,063.00 per month (“ Base Rent )”, payable on the First day of each month commencing June 15, 2013. (See also Paragraph 4)

 

x

If this box is checked, there are provisions in this Lease for the Base Rent to be adjusted.

1.6 Lessee’s Share of Operating Expense Increase : – – – – – – – – – – percent ( 4.12 %) (“ Lessee’s Share ”). Lessee’s Share has been calculated by dividing the approximate rentable square footage of the Premises by the total approximate square footage of the rentable space contained in the Project and shall not be subject to revision except in connection with an actual change in the size of the Premises, or a change in the space available for lease in the Project.

1.7 Base Rent and Other Monies Paid Upon Execution :

 

(a)

Base Rent : $4,241.00 for the period 6/15/13 through 6/30/13.

 

(b)

Security Deposit : $17,108.00 (“ Security Deposit ”). (See also Paragraph 5)

 

(c)

Parking : $ N/A for the period 6/15/13 through 6/30/13.

 

(d)

Other : $1.00 for Bill of Sale for existing furnishings.

 

(e)

Total Due Upon Execution of this Lease : $21,350.00.

1.8 Agreed Use : General offices and any other legally permitted use, excluding “Medical” (doctor, dermatologist, etc.). (See also Paragraph 6)

1.9 Base Year; Insuring Party . The Base Year is 2013. Lessor is the “ Insuring Party ”. (See also Paragraphs 4.2 and 8)

1.10 Real Estate Brokers : (See also Paragraph 15)

(a) Representation : The following real estate brokers (the “ Brokers ”) and brokerage relationships exist in this transaction (check applicable boxes):

 

x

CBRE represents Lessor exclusively ( Lessor’s Broker ”);

 

x

Bailes  & Associates, Inc. represents Lessee exclusively (“ Lessee’s Broker ”); or

 

¨

N/A represents both Lessor and Lessee ( Dual Agency ”).

 

 1 

   


(b) Payment to Brokers: Upon execution and delivery of this Lease by both Parties, Lessor shall pay to the Brokers the brokerage fee agreed to in a separate written agreement (or if there is no such agreement, the sum of                                           or 5                 % of the total Base Rent for the brokerage services rendered by the Brokers).

1.11 Guarantor . The obligations of the Lessee under this Lease shall be guaranteed by N/A (“ Guarantor ”). (See also Paragraph 37)

1.12 Business Hours for the Building : 8:00 a.m. to 6:00 p.m., Mondays through Fridays (except Building Holidays) and 8:00 a.m. to 1:00 p.m. on Saturdays (except Building Holidays). “ Building Holidays ” shall mean the dates of observation of New Year’s Day, President’s Day, Memorial Day, Independence Day, Labor Day, Thanks giving Day, Christmas Day, and   – – – – – – – – – – .

1.13 Lessor Supplied Services . Notwithstanding the provisions of Paragraph 11.1, Lessor is NOT obligated to provide the following:

¨    Janitorial services

¨    Electricity

¨    Other (specify): N/A

1.14 Attachments . Attached hereto are the following, all of which constitute a part of this Lease:

x    an Addendum consisting of Paragraphs 1 through 7;

x    a plot plan depicting the Premises; Exhibit “A”

x    a current set of the Rules and Regulations and Parking Rules and Regulations;

¨    a Work Letter;

¨    a janitorial schedule;

x    other (specify): As Built Suite Plan Exhibit “B”; Preliminary Renovation Plan Exhibit “C”; Hazardous Waste Exhibit “D”; Bill of Sale for existing furnishings Exhibit “E”; Rent Concession Agreement; Option to Renew.

2. Premises .

2.1 Letting. Lessor hereby leases to Lessee, and Lessee hereby leases from Lessor, the Premises, for the term, at the rental, and upon all of the terms, covenants and conditions set forth in this Lease. Unless otherwise provided herein, any statement of size set forth in this Lease, or that may have been used in calculating Rent, is an approximation which the Parties agree is reasonable and any payments based thereon are not subject to revision whether or not the actual size is more or less. Note: Lessee is advised to verify the actual size prior to executing this Lease.

2.2 Condition. Lessor shall deliver the Premises to Lessee in a clean condition on the Commencement Date or the Early Possession Date, whichever first occurs (“ Start Date ”), and warrants that the existing electrical, plumbing, *fire sprinkler *(Subterranean Parking Garage only), lighting, heating, ventilating and air conditioning systems (“ HVAC ”), and all other items which the Lessor is obligated to construct pursuant to the Work Letter attached hereto, if any, other than those constructed by Lessee, shall be in good operating condition on said date, that the structural elements of the roof, bearing walls and foundation of the Unit shall be free of material defects, and that the Premises do not contain hazardous levels of any mold or fungi defined as toxic under applicable state or federal law that Lessor is aware of.

2.3 Compliance. Lessor warrants to the best of its knowledge that the improvements comprising the Premises and the Common Areas comply with the building codes that were in effect at the time that each such improvement, or portion thereof, was constructed, and also with all applicable laws, covenants or restrictions of record, regulations, and ordinances (“ Applicable Requirements ”) in effect on the Start Date. Said warranty does not apply to the use to which Lessee will put the Premises, modifications which may be required by the Americans with Disabilities Act or any similar laws as a result of Lessee’s use (see Paragraph 49), or to any Alterations or Utility Installations (as defined in Paragraph 7.3(a)) made or to be made by Lessee. NOTE: Lessee is responsible for determining whether or not the zoning, applicable laws, covenants or restrictions of record, regulations and ordinances (“Applicable Requirements”), and any other Applicable Requirements are appropriate for Lessee’s intended use, and acknowledges that past uses of the Premises may no longer be allowed . If the Premises do not comply with said warranty, Lessor shall, except as otherwise provided, promptly after receipt of written notice from Lessee setting forth with specificity the nature and extent of such non-compliance, rectify the same. If the Applicable Requirements are hereafter changed so as to require during the term of this Lease the construction of an addition to or an alteration of the Premises, the remediation of any Hazardous Substance, or the reinforcement or other physical modification of the Premises (“ Capital Expenditure ”), Lessor and Lessee shall allocate the cost of such work as follows:

(a) Subject to Paragraph 2.3(c) below, if such Capital Expenditures are required as a result of the specific and unique use of the Premises by Lessee as compared with uses by tenants in general, Lessee shall be fully responsible for the cost thereof., provided, however that if such Capital Expenditure is required during the last 2 years of this Lease and the cost thereof exceeds 6 months’ Base Rent, Lessee may instead terminate this Lease unless Lessor notifies Lessee, in writing, within 10 days after receipt of Lessee’s termination notice that Lessor has elected to pay the difference between the actual cost thereof and the amount equal to 6 months’ Base Rent. If Lessee elects termination, Lessee shall immediately cease the use of the Premises which requires such Capital Expenditure and deliver to Lessor written notice specifying a termination date at least 90 days thereafter. Such termination date shall, however, in no event be earlier than the last day that Lessee could legally utilize the Premises without commencing such Capital Expenditure.

(b) If such Capital Expenditure is not the result of the specific and unique use of the Premises by Lessee (such as, governmentally mandated seismic modifications), then Lessor and Lessee shall allocate the cost of such Capital Expenditure as follows: Lessor shall advance the funds necessary for such Capital Expenditure but Lessee shall be obligated to pay, each month during the remainder of the term of this Lease, on the date on which Base Rent is due, an amount equal to the product of multiplying Lessee’s share of the cost of such Capital Expenditure (the percentage specified in Paragraph 1.6 by a fraction, the numerator of which is one, and the denominator of which is 144 (ie. 1/144th of the cost per month). Lessee shall pay interest on the unamortized balance of Lessee’s share at a rate that is commercially reasonable in the judgment of Lessor’s accountants. Lessee may, however, prepay its obligation at any time. Provided, however, that if such Capital Expenditure is required during the last 2 years of this Lease or if Lessor reasonably determines that it is not economically feasible to pay its share thereof, Lessor shall have the option to terminate this Lease upon 90 days prior written notice to Lessee unless Lessee notifies Lessor, in writing, within 10 days after receipt of Lessor’s termination notice that Lessee will pay for such Capital Expenditure. If Lessor does not elect to terminate, and fails to tender its share

 

 2 

   


of any such Capital Expenditure, Lessee may advance such funds and deduct same, with Interest, from Rent until Lessor’s share of such costs have been fully paid. If Lessee is unable to finance Lessor’s share, or if the balance of the Rent due and payable for the remainder of this Lease is not sufficient to fully reimburse Lessee on an offset basis, Lessee shall have the right to terminate this Lease upon 30 days written notice to Lessor.

(c) Notwithstanding the above, the provisions concerning Capital Expenditures are intended to apply only to nonvoluntary, unexpected, and new Applicable Requirements. If the Capital Expenditures are instead triggered by Lessee as a result of an actual or proposed change in use, change in intensity of use, or modification to the Premises then, and in that event, Lessee shall either: (i) immediately cease such changed use or intensity of use and/or take such other steps as may be necessary to eliminate the requirement for such Capital Expenditure, or (ii) complete such Capital Expenditure at its own expense. Lessee shall not have any right to terminate this Lease.

2.4 Acknowledgements . Lessee acknowledges that: (a) Lessee has been advised by Lessor and/or Brokers to satisfy itself with respect to the condition of the Premises (including but not limited to the electrical, HVAC and fire sprinkler systems (sprinklers in subterranean parking structure only), security, environmental aspects, and compliance with Applicable Requirements), and their suitability for Lessee’s intended use, (b) Lesseee has made such investigation as it deems necessary with reference to such matters and assumes all responsibility therefor as the same relate to its occupancy of the Premises, and (c) neither Lessor, Lessor’s agents, nor Brokers have made any oral or written representations or warranties with respect to said matters other than as set forth in this Lease. In addition, Lessor acknowledges that: (i) Brokers have made no representations, promises or warranties concerning Lessee’s ability to honor the Lease or suitability to occupy the Premises, and (ii) it is Lessor’s sole responsibility to investigate the financial capability and/or suitability of all proposed tenants.

2.5 Lessee as Prior Owner/Occupant . The warranties made by Lessor in Paragraph 2 shall be of no force or effect if immediately prior to the Start Date, Lessee was the owner or occupant of the Premises. In such event, Lessee shall be responsible for any necessary corrective work.

2.6 Vehicle Parking . So long as Lessee is not in default, beyond the applicable cure period, and subject to the Rules and Regulations attached hereto, and as established by Lessor from time to time, Lessee shall be entitled to rent and use the number of parking spaces specified in

 

 3 

   


Paragraph 1.2(b) at the rental rate applicable from time to time for monthly parking as set by Lessor and/or its licensee, for the initial lease term and in accordance with Paragraph 18 and 19 of the Rules and Regulations.

(a) If Lessee commits, permits or allows any of the prohibited activities described in the Lease or the rules then in effect, then Lessor shall have the right, without notice, in addition to such other rights and remedies that it may have, to remove or tow away the vehicle involved and charge the cost to Lessee, which cost shall be immediately payable upon demand by Lessor.

(b) The monthly rent per parking space specified in Paragraph 1.2(b) is *subject to change upon 30 days prior written notice to Lessee. The rent for the parking is payable one month in advance prior to the first day of each calendar month. * For the initial term of the lease, the monthly parking rate, and the cost of future subterranean parking spaces shall be in accordance with Paragraph 16 of the Rules and Regulations

2.7 Common Areas—Definition . The term “ Common Areas ” is defined as all areas and facilities outside the Premises and within the exterior boundary line of the Project and interior utility raceways and installations within the Premises that are provided and designated by the Lessor from time to time for the general nonexclusive use of Lessor, Lessee and other tenants of the Project and their respective employees, suppliers, shippers, customers, contractors and invitees, including, but not limited to, common entrances, lobbies, corridors, stairwells, public restrooms, elevators, parking areas, loading and unloading areas, trash areas, roadways, walkways, driveways and landscaped areas.

2.8 Common Areas—Lessee’s Rights . Lessor grants to Lessee, for the benefit of Lessee and its employees, suppliers, shippers, contractors, customers and invitees, during the term of this Lease, the nonexclusive right to use, in common with others entitled to such use, the Common Areas as they exist from time to time, subject to any rights, powers, and privileges reserved by Lessor under the terms hereof or under the terms of any rules and regulations or restrictions governing the use of the Project. Under no circumstances shall the right herein granted to use the Common Areas be deemed to include the right to store any property, temporarily or permanently, in the Common Areas. Any such storage shall be permitted only by the prior written consent of Lessor or Lessor’s designated agent, which consent may be revoked at any time. In the event that any unauthorized storage shall occur then Lessor shall have the right, without notice, in addition to such other rights and remedies that it may have, to remove the property and charge the cost to Lessee, which cost shall be immediately payable upon demand by Lessor.

2.9 Common Areas—Rules and Regulations . Lessor or such other person(s) as Lessor may appoint shall have the exclusive control and management of the Common Areas and shall have the right, from time to time, to adopt, modify, amend and enforce reasonable rules and regulations (“ Rules and Regulations ”) for the management, safety, care, and cleanliness of the grounds, the parking and unloading of vehicles and the preservation of good order, as well as for the convenience of other occupants or tenants of the Building and the Project and their invitees. The Lessee agrees to abide by and conform to all such Rules and Regulations, and shall use its best efforts to cause its employees, suppliers, shippers, customers, contractors and invitees to so abide and conform. Lessor shall not be responsible to Lessee for the noncompliance with said Rules and Regulations by other tenants of the Project.

2.10 Common Areas—Changes. Provided that Lessee’s use of and access to the Premises and the parking are is not adversely affected, and Lessor does not discriminate against Lessee, Lessor shall have the right, in Lessor’s sole discretion, from time to time:

(a) To make changes to the Common Areas, including, without limitation, changes in the location, size, shape and number of the lobbies, windows, stairways, air shafts, elevators, escalators, restrooms, driveways, entrances, parking spaces, parking areas, loading and unloading areas, ingress, egress, direction of traffic, landscaped areas, walkways and utility raceways;

(b) To close temporarily any of the Common Areas for maintenance purposes so long as reasonable access to the Premises remains available;

(c) To designate other land outside the boundaries of the Project to be a part of the Common Areas;

(d) To add additional buildings and improvements to the Common Areas;

(e) To use the Common Areas while engaged in making additional improvements, repairs or alterations to the Project, or any portion thereof; and

(f) To do and perform such other acts and make such other changes in, to or with respect to the Common Areas and Project as Lessor may, in the exercise of sound business judgment, deem to be appropriate.

3. Term .

3.1 Term . The Commencement Date, Expiration Date and Original Term of this Lease are as specified in Paragraph 1.3.

3.2 Early Possession . If Lessee totally or partially occupies the Premises prior to the Commencement Date, the obligation to pay Base Rent shall be abated for the period of such early possession. All other terms of this Lease (including but not limited to the obligations to pay Lessee’s Share of the Operating Expense Increase) shall be in effect during such period. Any such early possession shall not affect the Expiration Date.

3.3 Delay In Possession . Lessor agrees to use its best commercially reasonable efforts to deliver possession of the Premises to Lessee by the Commencement Date. If, despite said efforts, Lessor is unable to deliver possession by such date, Lessor shall not be subject to any liability therefor, nor shall such failure affect the validity of this Lease. Lessee shall not, however, be obligated to pay Rent or perform its other obligations until Lessor delivers possession of the Premises and any period of rent abatement that Lessee would otherwise have enjoyed shall run from the date of delivery of possession and continue for a period equal to what Lessee would otherwise have enjoyed under the terms hereof, but minus any days of delay caused by the acts or omissions of Lessee. If possession is not delivered within 60 days after the Commencement Date, as the same may be extended under the terms of any Work Letter executed by Parties, Lessee may, at its option, by notice in writing within 10 days after the end of such 60 day period, cancel this Lease, in which event the Parties shall be discharged from all obligations hereunder. If such written notice is not received by Lessor within said 10 day period, Lessee’s right to cancel shall terminate. If possession of the Premises is not delivered within 120 days after the Commencement Date, this Lease shall terminate unless other agreements are reached between Lessor and Lessee, in writing, and Lessor shall promptly return advance rent and security deposit upon any termination under this Section 3.3.

3.4 Lessee Compliance . Lessor shall not be required to deliver possession of the Premises to Lessee until Lessee complies with its obligation to provide evidence of insurance (Paragraph 8.5). Pending delivery of such evidence, Lessee shall be required to perform all of its obligations under this Lease from and after the Start Date, including the payment of Rent, notwithstanding Lessor’s election to withhold possession pending receipt of such evidence of insurance. Further, if Lessee is required to perform any other conditions

 

 4 

   


prior to or concurrent with the Start Date, the Start Date shall occur but Lessor may elect to withhold possession until such conditions are satisfied.

3.5 Uncertain Commencement: In the event commencement of the Lease term is defined as the substantial completion of the improvements, Lessee and Lessor shall execute an amendment to this Lease establishing the date of Possession (reasonable access to the Premises) or the actual taking of possession by Lessee, whichever first occurs, as the Commencement Date.

4. Rent .

4.1. Rent Defined . All monetary obligations of Lessee to Lessor under the terms of this Lease, including but not limited to, Base Rent, Lessee’s Share of Operating Expenses, estimated CAM, parking charges, late charges, service fees and all other sums and charges of whatever nature, (except for the Security Deposit) are deemed to be rent (“ Rent ”).

4.2 Operating Expense Increase . Lessee shall pay to Lessor during the term hereof, in addition to the Base Rent, Lessee’s Share of the amount by which all Operating Expenses for each Comparison Year exceeds the amount of all Operating Expenses for the Base Year, such excess being hereinafter referred to as the “ Operating Expense Increase ”, in accordance with the following provisions:

(a) “ Base Year ” is as specified in Paragraph 1.9.

(b) “ Comparison Year ” is defined as each calendar year during the term of this Lease subsequent to the Base Year; provided, however, Lessee shall have no obligation to pay a share of the Operating Expense Increase applicable to the first 12 months of the Lease Term (other than such as are mandated by a governmental authority, as to which government mandated expenses Lessee shall pay Lessee’s Share, notwithstanding they occur during the first twelve (12) months). Lessee’s Share of the Operating Expense Increase for the first and last Comparison Years of the Lease Term shall be prorated according to that portion of such Comparison Year as to which Lessee is responsible for a share of such increase.

(c) “ Operating Expenses ” include all costs incurred by Lessor relating to the ownership and operation of the Project, calculated as if the Project was at least 95% occupied, including, but not limited to, the following:

(i) The operation, repair, and maintenance in neat, clean, safe, good order and condition, but not the replacement (see subparagraph (g)), of the following:

(aa) The Common Areas, including their surfaces, coverings, decorative items, carpets, drapes and window coverings, and including parking areas, loading and unloading areas, trash areas, roadways, sidewalks, walkways, stairways, parkways, driveways, landscaped areas, striping, bumpers, irrigation systems, Common Area lighting facilities, building exteriors and roofs, fences and gates;

(bb) All heating, air conditioning, plumbing, electrical systems, life safety equipment, communication systems and other equipment used in common by, or for the benefit of, lessees or occupants of the Project, including elevators and escalators, tenant directories, fire detection systems including sprinkler system maintenance and repair.

 

 5 

   


(ii) Trash disposal, janitorial and security services, pest control services, and the costs of any environmental inspections;

(iii) Any other service to be provided by Lessor that is elsewhere in this Lease stated to be an “Operating Expense”;

(iv) The cost of the premiums for the insurance policies maintained by Lessor pursuant to paragraph 8 and any deductible portion of an insured loss concerning the Building or the Common Areas;

(v) The amount of the *Real Property Taxes payable by Lessor pursuant to paragraph 10; See para 10 for additional information.

(vi) The cost of water, sewer, gas, electricity, and other publicly mandated services not separately metered;

(vii) Labor, salaries, and applicable fringe benefits and costs, materials, supplies and tools, used in maintaining and/or cleaning the Project and accounting and management fees attributable to the operation of the Project;

(viii) The cost of any capital improvement to the Building or the Project not covered under the provisions of Paragraph 2.3 provided; however, that Lessor shall allocate the cost of any such capital improvement over a 12 year period and Lessee shall not be required to pay more than Lessee’s Share of 1/144th of the cost of such Capital Expenditure in any given month;

(ix) Replacement of equipment or improvements that have a useful life for accounting purposes of 5 years or less.

(d) Any item of Operating Expense that is specifically attributable to the Premises, the Building or to any other building in the Project or to the operation, repair and maintenance thereof, shall be allocated entirely to such Premises, Building, or other building. However, any such item that is not specifically attributable to the Building or to any other building or to the operation, repair and maintenance thereof, shall be equitably allocated by Lessor to all buildings in the Project.

(e) The inclusion of the improvements, facilities and services set forth in Subparagraph 4.2(c) shall not be deemed to impose an obligation upon Lessor to either have said improvements or facilities or to provide those services unless the Project already has the same, Lessor already provides the services, or Lessor has agreed elsewhere in this Lease to provide the same or some of them.

(f) Lessee’s Share of Operating Expense Increase is payable monthly on the same day as the Base Rent is due hereunder. The amount of such payments shall be based on Lessor’s estimate of the Operating Expense Expenses. Within 60 days after written request (but not more than once each year) Lessor shall deliver to Lessee a reasonably detailed statement showing Lessee’s Share of the actual Common Area Operating Expenses incurred during the preceding year a reasonably detailed statement showing Lessee’s Share of the actual Operating Expense Increase incurred during such year. If Lessee’s payments during such Year exceed Lessee’s Share, Lessee shall credit the amount of such over-payment against Lessee’s future payments. If Lessee’s payments during such Year were less than Lessee’s Share, Lessee shall pay to Lessor the amount of the deficiency within 10 days after delivery by Lessor to Lessee of said statement. Lessor and Lessee shall forthwith adjust between them by cash payment any balance determined to exist with respect to that portion of the last Comparison Year for which Lessee is responsible as to Operating Expense Increases, notwithstanding that the Lease term may have terminated before the end of such Comparison Year.

(g) Operating Expenses shall not include the costs of replacement for equipment or capital components such as the roof, foundations, exterior walls or a Common Area capital improvement, such as the parking lot paving, elevators, fences that have a useful life for accounting purposes of 5 years or more unless it is of the type described in paragraph 4.2(c) (viii), in which case their cost shall be included as above provided; Hazmat remediation; upgrades required to conform with ADA; marketing costs or broker’s commissions.

(h) Operating Expenses shall not include any expenses paid by any tenant directly to third parties, or as to which Lessor is otherwise reimbursed by any third party, other tenant, or by insurance proceeds.

(i) If said Operating Expense increase is greater than Five Percent (5%) Lessee or its representatives may audit during the term hereof and for a period of two (2) years after expiration or termination of this Lease, at any reasonable time during normal business hours and upon at least ten (10) days prior written notice to Lessor, the books and records of Lessor needed to verify any Operating Expenses (including any common area operating expenses) hereunder. If as a result of such audit, an overpayment by Lessee is revealed, Lessor shall promptly refund such amount to Lessee and reimburse Lessee for the cost of such audit.

4.3 Payment . Lessee shall cause payment of Rent to be received by Lessor in lawful money of the United States on or before the day on which it is due, without offset or deduction (except as specifically permitted in this Lease). All monetary amounts shall be rounded to the nearest whole dollar. In the event that any invoice prepared by Lessor is inaccurate such inaccuracy shall not constitute a waiver and Lessee shall be obligated to pay the amount set forth in this Lease. Rent for any period during the term hereof which is for less than one full calendar month shall be prorated based upon the actual number of days of said month. Payment of Rent shall be made to Lessor at its address stated herein or to such other persons or place as Lessor may from time to time designate in writing. Acceptance of a payment which is less than the amount then due shall not be a waiver of Lessor’s rights to the balance of such Rent, regardless of Lessor’s endorsement of any check so stating. In the event that any check, draft, or other instrument of payment given by Lessee to Lessor is dishonored for any reason, Lessee agrees to pay to Lessor the sum of $25 in addition to any Late Charge and Lessor, at its option, may require all future Rent be paid by cashier’s check. Payments will be applied first to accrued late charges and attorney’s fees, second to accrued interest, then to Base Rent and Common Area Operating Expenses, Base Rent, second to Common Area Operating Expenses, then to accrued Late Charges, attorney’s fees, accrued interest, if required to be paid by Lessee hereunder, and any remaining amount to any other outstanding charges or costs.

OBLIGATION OF FURNISHER OF CREDIT INFORMATION: Pursuant to Civil code, Section 1785.26, the Lessee is hereby notified that a negative credit report reflecting on Lessee’s credit report may be submitted in the future to a credit reporting agency if Lessee fails to fulfill the terms of the rental/credit obligations or if Lessee defaults, which defaults are not cured within the applicable cure period, in those obligations in any way.

5. Security Deposit . Lessee shall deposit with Lessor upon execution hereof the Security Deposit as security for Lessee’s faithful performance of its obligations under this Lease. If Lessee fails to pay Rent, or otherwise Defaults under this Lease, Lessor may use, apply or retain all or any portion of said Security Deposit for the payment of any amount due Lessor or to reimburse or compensate Lessor for any liability, expense, loss or damage which Lessor may suffer or incur by reason thereof. If Lessor uses or applies all or any portion of the Security Deposit, Lessee shall within 10 days after written request therefor, deposit monies with Lessor sufficient to restore said Security Deposit to the full amount required by this Lease. If the Base Rent increases during the term of this Lease, Lessee

 

 6 

   


shall, upon written request from Lessor, *deposit additional moneys with Lessor so that the total amount of the Security Deposit shall at all times bear the same proportion to the increased Base Rent as the initial Security Deposit bore to the initial Base Rent, *The Security Deposit shall remain the same through the initial term of the Lease. Should the Agreed Use be amended to accommodate a material change in the business of Lessee or to accommodate a sublessee or assignee, Lessor shall have the right to increase the Security Deposit to the extent necessary, in Lessor’s reasonable judgment, to account for any increased wear and tear that the Premises may suffer as a result thereof. If a change in control of Lessee occurs during this Lease and following such change the financial condition of Lessee is, in Lessor’s reasonable judgment, significantly reduced, Lessee shall deposit such additional monies with Lessor as shall be sufficient to cause the Security Deposit to be at a commercially reasonable level based on such change in financial condition. Lessor shall not be required to keep the Security Deposit separate from its general accounts. Within 14 days after the expiration or termination of this Lease, if Lessor elects to apply the Security Deposit only to unpaid Rent, and otherwise within 30 days after the Premises have been vacated pursuant to Paragraph 7.4(c) below, Lessor shall return that portion of the Security Deposit not used or applied by Lessor. No part of the Security Deposit shall be considered to be held in trust, to bear interest or to be prepayment for any monies to be paid by Lessee under this Lease.

Notwithstanding the restrictions contained within California Civil Code Section 1950.7, Lessor may utilize the security deposit for any and all debt owed by Lessee to Lessor, including, (but not limited to), future rental or worth at the time of the awarded damages as codified in Civil Code Section 1951.2, or rent as it accrues pursuant to Civil Code Section 1951.4. To the extent that this right is inconsistent with California Civil Code Section 1950.7, Lessee waives the protections of Civil Code Section 1950.7, Lessee waives any rights under California Civil Code Section 3275 and California Civil Code Section 1174 (c) and 1179 and any and all current or future laws which give Lessee a right to redeem, reinstate, or restore this lease after it is terminated as a result of the Lessee’s breach.

6. Use .

6.1 Use . Lessee shall use and occupy the Premises only for the Agreed Use, or any other legal use which is reasonably comparable

 

 7 

   


thereto, but shall not include Medical use, and for no other purpose. Lessee shall not use or permit the use of the Premises in a manner that is unlawful, creates damage, waste or a nuisance, or that disturbs occupants of or causes damage to neighboring premises or properties. Other than guide, signal and seeing eye dogs service animals for the disabled, Lessee shall not keep or allow in the Premises any pets, animals, birds, fish, or reptiles. Lessor shall not unreasonably withhold or delay its consent to any written request for a modification of the Agreed Use, so long as the same will not impair the structural integrity of the improvements of the Building, will not adversely affect the mechanical, electrical, HVAC, and other systems of the Building, and/or will not affect the exterior appearance of the Building. If Lessor elects to withhold consent, Lessor shall within 7 days after such request give written notification of same., which notice shall include an explanation of Lessor’s objections to the change in the Agreed Use.

6.2 Hazardous Substances .

(a) Reportable Uses Require Consent . The term “Hazardous Substance” as used in this Lease shall mean any product, substance, or waste whose presence, use, manufacture, disposal, transportation, or release, either by itself or in combination with other materials expected to be on the Premises, is either: (i) potentially injurious to the public health, safety or welfare, the environment or the Premises, (ii) regulated or monitored by any governmental authority, or (iii) a basis for potential liability of Lessor to any governmental agency or third party under any applicable statute or common law theory. Hazardous Substances shall include, but not be limited to, hydrocarbons, petroleum, gasoline, and/or crude oil or any products, byproducts or fractions thereof. Lessee shall not engage in any activity in or on the Premises which constitutes a Reportable Use of Hazardous Substances without the express prior written consent of Lessor and timely compliance (at Lessee’s expense) with all Applicable Requirements. “ Reportable Use ” shall mean (i) the installation or use of any above or below ground storage tank, (ii) the generation, possession, storage, use, transportation, or disposal of a Hazardous Substance that requires a permit from, or with respect to which a report, notice, registration or business plan is required to be filed with, any governmental authority, and/or (iii) the presence at the Premises of a Hazardous Substance with respect to which any Applicable Requirements requires that a notice be given to persons entering or occupying the Premises or neighboring properties. Notwithstanding the foregoing, Lessee may use any ordinary and customary materials reasonably required to be used in the normal course of the Agreed Use such as ordinary office supplies (copier toner, liquid paper, glue, etc.) and common household cleaning materials, so long as such use is in compliance with all Applicable Requirements, is not a Reportable Use, and does not expose the Premises or neighboring property to any meaningful risk of contamination or damage or expose Lessor to any liability therefor. In addition, Lessor may condition its consent to any Reportable Use upon receiving such additional assurances as Lessor reasonably deems necessary to protect itself, the public, the Premises and/or the environment against damage, contamination, injury and/or liability, including, but not limited to, the installation (and removal on or before Lease expiration or termination) of protective modifications (such as concrete encasements) and/or increasing the Security Deposit.

(b) Duty to Inform Lessor . If Lessee knows, or has reasonable cause to believe, that a Hazardous Substance has come to be located in, on, under or about the Premises, other than as previously consented to by Lessor, Lessee shall immediately give written notice of such fact to Lessor, and provide Lessor with a copy of any report, notice, claim or other documentation which it has concerning the presence of such Hazardous Substance.

(c) Lessee Remediation . Lessee shall not cause or permit any Hazardous Substance to be spilled or released in, on, under, or about the Premises (including through the plumbing or sanitary sewer system) and shall promptly, at Lessee’s expense, comply with all Applicable Requirements and take all investigatory and/or remedial action reasonably recommended, whether or not formally ordered or required, for the cleanup of any contamination of, and for the maintenance, security and/or monitoring of the Premises or neighboring properties, that was caused or materially contributed to by Lessee, or pertaining to or involving any Hazardous Substance brought onto the Premises during the term of this Lease, by or for Lessee, or any third party.

(d) Lessee Indemnification . Lessee shall indemnify, defend and hold Lessor, its agents, employees, lenders and ground lessor, if any, harmless from and against any and all loss of rents and/or damages, liabilities, judgments, claims, expenses, penalties, and attorneys’ and consultants’ fees to the extent arising out of or involving any Hazardous Substance brought onto the Premises by or for Lessee, or any third party (provided, however, that Lessee shall have no liability under this Lease with respect to underground migration of any Hazardous Substance under the Premises from areas outside of the Project not caused or contributed to by Lessee). Lessee’s obligations shall include, but not be limited to, the effects of any contamination or injury to person, property or the environment created or suffered by Lessee, and the cost of investigation, removal, remediation, restoration and/or abatement, and shall survive the expiration or termination of this Lease. No termination, cancellation or release agreement entered into by Lessor and Lessee shall release Lessee from its obligations under this Lease with respect to Hazardous Substances, unless specifically so agreed by Lessor in writing at the time of such agreement. Lessor shall give Lessee prompt written notice of any claim for which indemnification is sought.

(e) Lessor Indemnification . Lessor and its successors and assigns shall indemnify, defend, reimburse and hold Lessee, its employees and lenders, harmless from and against any and all environmental damages, including the cost of remediation, which result from Hazardous Substances which existed on the Premises prior to Lessee’s occupancy or which are caused by the gross negligence or willful misconduct of Lessor, its agents or employees. Lessor’s obligations, as and when required by the Applicable Requirements, shall include, but not be limited to, the cost of investigation, removal, remediation, restoration and/or abatement, and shall survive the expiration or termination of this Lease.

(f) Investigations and Remediations . Lessor shall retain the responsibility and pay for any investigations or remediation measures required by governmental entities having jurisdiction with respect to the existence of Hazardous Substances on the Premises prior to Lessee’s occupancy, unless , If such remediation measures is are required as a result of Lessee’s use (including “Alterations”, as defined in paragraph 7.3(a) below) of the Premises, in which event Lessee shall be responsible for such payment. Lessee shall cooperate fully in any such activities at the request of Lessor, including allowing Lessor and Lessor’s agents to have reasonable access to the Premises at reasonable times during business hours in order to carry out Lessor’s investigative and remedial responsibilities. Although notice i s not required, Lessor will attempt to provide verbal notice of intent to enter.

(g) Lessor Termination Option . If a Hazardous Substance Condition (see Paragraph 9.1 (e)) occurs during the term of this Lease, unless Lessee is legally responsible therefor (in which case Lessee shall make the investigation and remediation thereof required by the Applicable Requirements and this Lease shall continue in full force and effect, but subject to Lessor’s rights under Paragraph 6.2(d) and Paragraph 13), Lessor may, at Lessor’s option, either (i) investigate and remediate such Hazardous Substance Condition, if required, as soon as reasonably possible at Lessor’s expense, in which event this Lease shall continue in full force and effect, or (ii) if the estimated cost to remediate such condition exceeds 12 times the then monthly Base Rent or $100,000, whichever is greater, give written notice to Lessee, within 30 days after receipt by Lessor of knowledge of the occurrence of such Hazardous Substance Condition, of Lessor’s desire to terminate this Lease as of the date 60 days following the date of such notice. In the event Lessor elects to give a termination notice, Lessee may, within 10 days thereafter, give written notice to Lessor of Lessee’s commitment to pay the amount by which the cost of the remediation of such Hazardous Substance Condition exceeds an amount equal

 

 8 

   


to 12 times the then monthly Base Rent or $100,000, whichever is greater. Lessee shall provide Lessor with said funds or satisfactory assurance thereof within 30 days following such commitment. In such event, this Lease shall continue in full force and effect, and Lessor shall proceed to make such remediation as soon as reasonably possible after the required funds are available. If Lessee does not give such notice and provide the required funds or assurance thereof within the time provided, this Lease shall terminate as of the date specified in Lessor’s notice of termination.

6.3 Lessee’s Compliance with Applicable Requirements . Except as otherwise provided in this Lease, Lessee shall, at Lessee’s sole expense, fully, diligently and in a timely manner, materially comply with all Applicable Requirements, the requirements of any applicable fire insurance underwriter or rating bureau, and the recommendations of Lessor’s engineers and/or consultants which relate in any manner to the Premises, without regard to whether said requirements are now in effect or become effective after the Start Date. Lessee shall, within 10 days after receipt of Lessor’s written request, provide Lessor with copies of all permits and other documents, and other information evidencing Lessee’s compliance with any Applicable Requirements specified by Lessor, and shall immediately upon receipt, notify Lessor in writing (with copies of any documents involved) of any threatened or actual claim, notice, citation, warning, complaint or report pertaining to or involving the failure of Lessee or the Premises to comply with any Applicable Requirements. Likewise, Lessee shall immediately give written notice to Lessor of: (i) any water damage to the Premises and any suspected seepage, pooling, dampness or other condition conducive to the production of mold; or (ii) any mustiness or other odors that might indicate the presence of mold in the Premises.

6.4 Inspection; Compliance . Lessor and Lessor’s “Lender ” (as defined in Paragraph 30) and consultants shall have the right to enter into Premises at any time, in the case of an emergency, and otherwise at reasonable times, after reasonable notice, during business hours, for the purpose of inspecting the condition of the Premises and for verifying compliance by Lessee with this Lease. The cost of any such inspections shall be paid by Lessor, unless a violation of Applicable Requirements, or a Hazardous Substance Condition (see paragraph 9.1e) is found to exist or be imminent, or the inspection is requested or ordered by a governmental authority. In such case, Lessee shall upon request reimburse Lessor for the cost of such inspection, so long as such inspection is reasonably related to the violation or contamination. In addition, Lessee shall provide copies of all relevant material safety data sheets (MSDS) to Lessor within 10 days of the receipt of written request therefor.

7. Maintenance; Repairs; Utility Installations; Trade Fixtures and Alterations .

7.1 Lessee’s Obligations . Notwithstanding Lessor’s obligation to keep the Premises in good condition and repair, Lessee shall be

 

 9 

   


responsible for payment of the cost thereof to Lessor as additional rent for that portion of the cost of any maintenance and repair of the Premises, or any equipment (wherever located) that serves only Lessee or the Premises, to the extent such cost is attributable to causes beyond normal wear and tear. Lessee shall be responsible for the cost of painting, repairing or replacing wall coverings, and to repair or replace any improvements with the Premises, and only to the extent that such costs are attributed to causes beyond Lessee’s normal wear and tear. Lessor may, at its option, upon reasonable notice, elect to have Lessee perform any particular such maintenance or repairs the cost of which is otherwise Lessee’s responsibility hereunder.

7.2 Lessor’s Obligations. Subject to the provisions of Paragraphs 2.2 (Condition), 2.3 (Compliance), 4.2 (Operating Expenses), 6 (Use), 7.1 (Lessee’s Obligations), 9 (Damage or Destruction) and 14 (Condemnation), Lessor, subject to reimbursement pursuant to Paragraph 4.2, shall keep in good order, condition and repair the foundations, exterior walls, structural condition of interior bearing walls, exterior roof, *fire sprinkler system, fire alarm and/or smoke detection systems, fire hydrants, and the Common Areas. Lessee expressly waives the benefit of any statute now or hereafter in effect to the extent it is inconsistent with the terms of this Lease . *fire sprinkler system located in subterranean parking structure only.

7.3 Utility Installations; Trade Fixtures; Alterations and all Building Systems (i.e., HVAC, Electrical, Plumbing, Life Safety).

(a) Definitions . The term “ Utility Installations ” refers to all floor and window coverings, air lines, vacuum lines, power panels, electrical distribution, security and fire protection systems, communication cabling, lighting fixtures, HVAC equipment, and plumbing in or on the Premises. The term “ Trade Fixtures ” shall mean Lessee’s machinery and equipment that can be removed without doing material damage to the Premises. The term “ Alterations ” shall mean any modification of the improvements, other than Utility Installations or Trade Fixtures, whether by addition or deletion. “ Lessee Owned Alterations and/or Utility Installations ” are defined as Alterations and/or Utility Installations made by Lessee that are not yet owned by Lessor pursuant to Paragraph 7.4(a).

(b) Consent . Lessee shall not make any Alterations or Utility Installations to the Premises without Lessor’s prior written consent. Lessee may, however, make non-structural Utility Installations to the interior of the Premises (excluding the roof) without such consent but upon notice to Lessor, as long as they are not visible from the outside, do not involve puncturing, relocating or removing the roof, ceilings, floors or any existing walls, will not affect the electrical, plumbing, HVAC, and/or life safety systems, and the cumulative cost thereof during this Lease as extended does not exceed $2000. Notwithstanding the foregoing, Lessee shall not make or permit any roof penetrations and/or install anything on the roof without the prior written approval of Lessor. Lessor may, as a precondition to granting such approval, require Lessee to utilize a contractor chosen and/or approved by Lessor. All plumbing, mechanical, HVAC, electrical wiring and ceiling work are to be done only by contractors designated by Lessor. Any Alterations or Utility Installations that Lessee shall desire to make and which require the consent of the Lessor shall be presented to Lessor in written form with detailed plans. Consent shall be deemed conditioned upon Lessee’s: (i) acquiring all applicable governmental permits, (ii) furnishing Lessor with copies of both the permits and the plans and specifications prior to commencement of the work, and (iii) compliance with all conditions of said permits and other Applicable Requirements in a prompt and expeditious manner. (iv)  provide Lessor with an additional security deposit that shall be determined by Lessor in its sole and asolute discretion and to charge the Security Deposit for the actual cost of Lessor’s vendor to monitor inspect or repair any work done by Lesse’s vendor. If Lessor’s actual costs exceed the amount held in Security Deposit, Lessee shall reimburse Lessor for actual cost(s) upon demand. If all or any portion of the Security Deposit is used, Lessee shall replenish said deposit which shall be held by Lessor until Lessee’s tenancy has ended and/or equipment has been removed. Any Alterations or Utility Installations shall be performed in a workmanlike manner with good and sufficient materials. Lessee shall promptly upon completion furnish Lessor with asbuilt plans and specifications. For work which costs an amount in excess of one month’s Base Rent, Lessor may condition its consent upon Lessee providing a lien and completion bond in an amount equal to 150% of the estimated cost of such Alteration or Utility Installation and/or upon Lessee’s posting an additional Security Deposit with Lessor.

(c) Liens; Bonds . Lessee shall pay, when due, all claims for labor or materials furnished or alleged to have been furnished to or for Lessee at or for use on the Premises, which claims are or may be secured by any mechanic’s or materialmen’s lien against the Premises or any interest therein. Lessee shall give Lessor not less than 10 days notice prior to the commencement of any work in, on or about the Premises, and Lessor shall have the right to post notices of non-responsibility. If Lessee shall contest the validity of any such lien, claim or demand, then Lessee shall, at its sole expense defend and protect itself, Lessor and the Premises against the same and shall pay and satisfy any such adverse judgment that may be rendered thereon before the enforcement thereof. If Lessor shall require, Lessee shall furnish a surety bond in an amount equal to 150% of the amount of such contested lien, claim or demand, indemnifying Lessor against liability for the same. If Lessor elects to participate in any such action, Lessee shall pay Lessor’s reasonable and documented attorneys’ fees and costs.

7.4 Ownership; Removal; Surrender; and Restoration.

(a) Ownership . Subject to Lessor’s right to require removal or elect ownership as hereinafter provided, all Alterations and Utility Installations made by Lessee shall be the property of Lessee, but considered a part of the Premises. Lessor may, at any time, elect in writing to be the owner of all or any specified part of the Lessee Owned Alterations and Utility Installations. Unless otherwise instructed per paragraph 7.4(b) hereof, all Lessee Owned Alterations and Utility Installations shall, at the expiration or termination of this Lease, become the property of Lessor and be surrendered by Lessee with the Premises.

(b) Removal . By delivery to Lessee of written notice from Lessor not earlier than 90 and not later than 30 days prior to the end of the term of this Lease, Lessor may require that any or all Lessee Owned Alterations or Utility Installations be removed by the expiration or termination of this Lease. Lessor may require the removal at any time of all or any part of any Lessee Owned Alterations or Utility Installations made without the required consent.

(c) Surrender; Restoration . Lessee shall surrender the Premises by the Expiration Date or any earlier termination date, with all of the improvements, parts and surfaces thereof clean and free of debris, and in good operating order, condition and state of repair, ordinary wear and tear excepted. “Ordinary wear and tear” shall not include any damage or deterioration that would have been prevented by good maintenance practice. Notwithstanding the foregoing, if this Lease is for 12 months or less, then Lessee shall surrender the Premises in the same condition as delivered to Lessee on the Start Date with NO allowance for ordinary wear and tear. Lessee shall repair any damage occasioned by the installation, maintenance or removal of Trade Fixtures, Lessee owned Alterations and/or Utility Installations, furnishings, and equipment as well as the removal of any storage tank installed by or for Lessee. Lessee shall also completely remove from the Premises any and all Hazardous Substances brought onto the Premises by or for Lessee, or any third party (except Hazardous Substances which were deposited via underground migration from areas outside of the Premises) even if such removal would require Lessee to perform or pay for work that exceeds statutory requirements. Trade Fixtures shall remain the property of Lessee and shall be removed by Lessee. Any personal property of Lessee not removed on or before the Expiration Date or any earlier termination date shall be deemed to have been abandoned by Lessee and may be disposed of or retained by Lessor as Lessor may desire. The failure by Lessee to timely vacate the Premises pursuant to this Paragraph 7.4(c) without the express written

 

 10 

   


consent of Lessor shall constitute a holdover under the provisions of Paragraph 26 below. *Lessee shall not be obligated to restore Premises to the condition existing before Lessor and Lessee’s initial Tenant Improvements.

8. Insurance; Indemnity .

8.1 Insurance Premiums . The cost of the premiums for the insurance policies maintained by Lessor pursuant to paragraph 8 are included as Operating Expenses (see paragraph 4.2 (c)(iv)). Said costs shall include increases in the premiums resulting from additional coverage related to requirements of the holder of a mortgage or deed of trust covering the Premises, Building and/or Project, increased valuation of the Premises, Building and/or Project, and/or a general premium rate increase. Said costs shall not, however, include any premium increases resulting from the nature of the occupancy of any other tenant of the Building. If the Project was not insured for the entirety of the Base Year, then the base premium shall be the lowest annual premium reasonably obtainable for the required insurance as of the Start Date, assuming the most nominal use possible of the Building and/or Project. In no event, however, shall Lessee be responsible for any portion of the premium cost attributable to liability insurance coverage in excess of $2,000,000 procured under Paragraph 8.2(b).

8.2 Liability Insurance.

(a) Carried by Lessee . Lessee shall obtain and keep in force a Commercial General Liability policy of insurance protecting Lessee and Lessor as an additional insured against claims for bodily injury, personal injury and property damage based upon or arising out of the ownership, use, occupancy or maintenance of the Premises and all areas appurtenant thereto. Such insurance shall be on an occurrence basis providing single limit coverage in an amount not less than $1,000,000 per occurrence with an annual aggregate of not less than $2,000,000. Lessee shall add Lessor and Mid Valley Management as an additional insureds by means of an endorsement at least as broad as the Insurance Service Organization’s “Additional Insured-Managers or Lessors of Premises” Endorsement and coverage shall also be extended to include damage caused by heat, smoke or fumes from a hostile fire. The policy shall not contain any intra-insured exclusions as between insured persons or organizations, but shall include coverage for liability assumed under this Lease as an “ insured contract ” for the performance of Lessee’s indemnity obligations under this Lease and subject to the exclusions in said policy. The limits of said insurance shall not, however, limit the liability of Lessee nor relieve Lessee of any obligation hereunder. Lessee shall provide an endorsement on its liability policy(ies) which provides that its insurance shall be primary to and not contributory with any similar insurance carried by Lessor, whose insurance shall be considered excess insurance only.

 

 11 

   


   

(b) Carried by Lessor . Lessor shall maintain liability insurance as described in Paragraph 8.2(a), in addition to, and not in lieu of, the insurance required to be maintained by Lessee. Lessee shall not be named as an additional insured therein.

8.3 Property Insurance—Building, Improvements and Rental Value.

(a) Building and Improvements . Lessor shall obtain and keep in force a policy or policies of insurance in the name of Lessor, with loss payable to Lessor, any ground-lessor, and to any Lender insuring loss or damage to the Building and/or Project. The amount of such insurance shall be equal to the full insurable replacement cost of the Building and/or Project, as the same shall exist from time to time, or the amount required by any Lender, but in no event more than the commercially reasonable and available insurable value thereof. Lessee Owned Alterations and Utility Installations, Trade Fixtures, and Lessee’s personal property shall be insured by Lessee under Paragraph 8.4. If the coverage is available and commercially appropriate, such policy or policies shall insure against all risks of direct physical loss or damage (except the perils of flood and/or earthquake unless required by a Lender), including coverage for debris removal and the enforcement of any Applicable Requirements requiring the upgrading, demolition, reconstruction or replacement of any portion of the Premises as the result of a covered loss. Said policy or policies shall also contain an agreed valuation provision in lieu of any coinsurance clause, waiver of subrogation, and inflation guard protection causing an increase in the annual property insurance coverage amount by a factor of not less than the adjusted U.S. Department of Labor Consumer Price Index for All Urban Consumers for the city nearest to where the Premises are located. If such insurance coverage has a deductible clause, the deductible amount shall not exceed $1,000 per occurrence.

(b) Rental Value . Lessor shall also obtain and keep in force a policy or policies in the name of Lessor with loss payable to Lessor and any Lender, insuring the loss of the full Rent for one year with an extended period of indemnity for an additional 180 days (“Rental Value insurance”) . Said insurance shall contain an agreed valuation provision in lieu of any coinsurance clause, and the amount of coverage shall be adjusted annually to reflect the projected Rent otherwise payable by Lessee, for the next 12 month period.

(c) Adjacent Premises . Lessee shall pay for any increase in the premiums for the property insurance of the Building and for the Common Areas or other buildings in the Project if said increase is caused by Lessee’s acts, omissions, use or occupancy of the Premises.

(d) Lessee’s Improvements . Since Lessor is the Insuring Party, Lessor shall not be required to insure Lessee Owned Alterations and Utility Installations unless the item in question has become the property of Lessor under the terms of this Lease.

8.4 Lessee’s Property; Business Interruption Insurance.

(a) Property Damage . Lessee shall obtain and maintain insurance coverage on all of Lessee’s personal property, Trade Fixtures, and Lessee Owned Alterations and Utility Installations. Such insurance shall be full replacement cost coverage with a deductible of not to exceed $1,000 per occurrence. The proceeds from any such insurance shall be used by Lessee for the replacement of personal property, Trade Fixtures and Lessee Owned Alterations and Utility Installations. Lessee shall provide Lessor with written evidence that such insurance is in force.

(b) Business Interruption . Lessee shall obtain and maintain loss of income and extra expense insurance in amounts as will or-attributable to-prevention of-access to the Premises as a-result of such porils.

(c) No Representation of Adequate Coverage . Lessor makes no representation that the limits or forms of coverage of insurance specified herein are adequate to cover Lessee’s property, business operations or obligations under this Lease.

8.5 Insurance Policies . Insurance required herein shall be by companies duly licensed or admitted to transact business in the state where the Premises are located, and maintaining during the policy term a “General Policyholders Rating” of at least A-, VI, as set forth in the most current issue of “Best’s Insurance Guide”, or such other rating as may be required by a Lender. Lessee shall not do or permit to be done anything which invalidates the required insurance policies. Lessee shall, prior to the Start Date, deliver to Lessor certified copies of policies of such insurance or certificates evidencing the existence and amounts of the required insurance. No such policy shall be cancelable or subject to modification except after 10 days prior written notice to Lessor. Lessee shall, at least 30 days prior to the expiration of such policies, furnish Lessor with evidence of renewals or “insurance binders” evidencing renewal thereof, or Lessor may order such insurance and charge the cost thereof to Lessee, which amount shall be payable by Lessee to Lessor upon demand. Such policies shall be for a term of at least one year, or the length of the remaining term of this Lease, whichever is less. If either Party shall fail to procure and maintain the insurance required to be carried by it, the other Party may, but shall not be required to, procure and maintain the same.

         8.6 Waiver of Subrogation . Without affecting any other rights or remedies, Lessee and Lessor each hereby release and relieve the other, and waive their entire right to recover damages against the other, for loss of or damage to its property arising out of or incident to the perils required to be insured against herein. The effect of such releases and waivers is not limited by the amount of insurance carried or required, or by any deductibles applicable hereto. The Parties agree to have their respective property damage insurance carriers waive any right to subrogation that such companies may have against Lessor or Lessee, as the case may be, so long as the insurance is not Invalidated thereby.

8.7 Indemnity . Except for Lessor’s sole negligence, gross negligence or willful misconduct, Lessee shall indemnify, protect, defend and hold harmless the Premises, Lessor and its agents, Lessor’s master or ground lessor, partners and Lenders, from and against any and all claims, loss of rents and/or damages, liens, judgments, penalties, attorneys’ and consultants’ fees, expenses and/or liabilities arising out of, involving, or in connection with, the use and/or occupancy of the Premises by Lessee. If any action or proceeding is brought against Lessor by reason of any of the foregoing matters. Lessee shall upon notice defend the same at Lessee’s expense by counsel reasonably satisfactory to Lessor and Lessor shall cooperate with Lessee in such defense. Lessor need not have first paid any such claim in order to be defended or indemnified.

8.8 Exemption of Lessor and its Agents from Liability . Notwithstanding the negligence or breach of this Lease by Lessor or its agents, neither Lessor nor its agents shall be liable under any circumstances for: (i) injury or damage to the person or goods, wares, merchandise or other property of Lessee, Lessee’s employees, Contractors, invitees, customers, or any other person in or about the Premises , whether such damage or injury is caused by or results from fire, steam, electricity, gas, water or rain, indoor air quality, the presence of mold or from the breakage, leakage, obstruction or other defects of pipes, fire sprinklers, wires, appliances, plumbing, HVAC or lighting fixtures, or from any other cause, whether the said injury or damage results from conditions arising upon the Premises or upon other portions of the Building, or from other sources or places, (ii) any damages to Lessee’s property arising from any act or neglect of any other tenant of Lessor or from the failure of Lessor or its agents to enforce the provisions of any other lease

 

 12 

   


in the Project, or (iii) injury to Lessee’s business or for any loss of income or profit therefrom. Instead, it is intended that Lessee’s sole recourse in the event of such damages or injury be to file a claim on the insurance policy(ies) that Lessee is required to maintain pursuant to the provisions of paragraph 8. Lessor’s non liability will apply irrespective of the active or passive negligence of Lessor, its agent, partners, or Lenders.

8.9 Failure to Provide Insurance . Lessee acknowledges that any failure on its part to obtain or maintain the insurance required herein will expose Lessor to risks and potentially cause Lessor to incur costs not contemplated by this Lease, the extent of which will be extremely difficult to ascertain. Accordingly, for any month or portion thereof that Lessee does not maintain the required insurance and/or does not provide Lessor with the required binders or certificates evidencing the existence of the required insurance, the Base Rent shall be automatically increased, without any requirement for notice to Lessee, by an amount equal to 10% of the then existing Base Rent or $100, whichever is greater. The parties agree that such increase in Base Rent represents fair and reasonable compensation for the additional risk/costs that Lessor will incur by reason of Lessee’s failure to maintain the required insurance. Such increase in Base Rent shall in no event constitute a waiver of Lessee’s Default or Breach with respect to the failure to maintain such insurance, prevent the exercise of any of the other rights and remedies granted hereunder, nor relieve Lessee of its obligation to maintain the insurance specified in this Lease.

9. Damage or Destruction.

9.1 Definitions.

(a) “ Premises Partial Damage ” shall mean damage or destruction to the improvements on the Premises, other than Lessee Owned Alterations and Utility Installations, which can reasonably be repaired in 3 months or less from the date of the damage or destruction, and the cost thereof does not exceed a sum equal to 6 month’s Base Rent. Lessor shall notify Lessee in writing within 30 days from the date of the damage or destruction as to whether or not the damage is Partial or Total.

(b) “ Premises Total Destruction ” shall mean damage or destruction to the improvements on the Premises, other than Lessee Owned Alterations and Utility Installations and Trade Fixtures, which cannot reasonably be repaired in 3 months or less from the date of the damage or destruction and/or the cost thereof exceeds a sum equal to 6 month’s Base Rent. Lessor shall notify Lessee in writing within 30 days from the date of the damage or destruction as to whether or not the damage is Partial or Total.

(c) “ Insured Loss ” shall mean damage or destruction to improvements on the Premises, other than Lessee Owned Alterations and Utility Installations and Trade Fixtures, which was caused by an event required to be covered by the insurance described in Paragraph 8.3{a), irrespective of any deductible amounts or coverage limits involved.

(d) “ Replacement Cost ” shall mean the cost to repair or rebuild the improvements owned by Lessor at the time of the occurrence to their condition existing immediately prior thereto, including demolition, debris removal and upgrading required by the operation of Applicable Requirements, and without deduction for depreciation.

 

 13 

   


   

(e) “ Hazardous Substance Condition ” shall mean the occurrence or discovery of a condition involving the presence of, or a contamination by, a Hazardous Substance as defined in Paragraph 6.2(a), in, on, or under the Premises which requires repair, remediation, or restoration.

9.2 Partial Damage—Insured Loss . If a Premises Partial Damage that is an Insured Loss occurs, then Lessor shall, at Lessor’s expense, repair such damage (but not Lessee’s Trade Fixtures or Lessee Owned Alterations and Utility Installations) as soon as reasonably possible and this Lease shall continue in full force and effect; provided, however, that Lessee shall, at Lessor’s election, make the repair of any damage or destruction the total cost to repair of which is $5,000 or less, and, in such event, Lessor shall make any applicable insurance proceeds available to Lessee on a reasonable basis for that purpose. Notwithstanding the foregoing, if the required insurance was not in force or the insurance proceeds are not sufficient to effect such repair, the Insuring Party shall promptly contribute the shortage in proceeds as and when required to complete said repairs. In the event, however, such shortage was due to the fact that, by reason of the unique nature of the improvements, full replacement cost insurance coverage was not commercially reasonable and available, Lessor shall have no obligation to pay for the shortage in insurance proceeds or to fully restore the unique aspects of the Premises unless Lessee provides Lessor with the funds to cover same, or adequate assurance thereof, within 10 days following receipt of written notice of such shortage and request therefor. If Lessor receives said funds or adequate assurance thereof within said 10 day period, the party responsible for making the repairs shall complete them as soon as reasonably possible and this Lease shall remain in full force and effect. If such funds or assurance are not received, Lessor may nevertheless elect by written notice to Lessee within 10 days thereafter to: (i) make such restoration and repair as is commercially reasonable with Lessor paying any shortage in proceeds, in which case this Lease shall remain in full force and effect, or (ii) have this Lease terminate 30 days thereafter. Lessee shall not be entitled to reimbursement of any funds contributed by Lessee to repair any such damage or destruction. Premises Partial Damage due to flood or earthquake shall be subject to Paragraph 9.3, notwithstanding that there may be some insurance coverage, but the net proceeds of any such insurance shall be made available for the repairs if made by either Party.

9.3 Partial Damage—Uninsured Loss . If a Premises Partial Damage that is not an Insured Loss occurs, unless caused by a negligent or willful act of Lessee (in which event Lessee shall make the repairs at Lessee’s expense), Lessor may either: (i) repair such damage as soon as reasonably possible at Lessor’s expense, in which event this Lease shall continue in full force and effect, or (ii) terminate this Lease by giving written notice to Lessee within 30 days after receipt by Lessor of knowledge of the occurrence of such damage. Such termination shall be effective 60 days following the date of such notice. In the event Lessor elects to terminate this Lease, Lessee shall have the right within 10 days after receipt of the termination notice to give written notice to Lessor of Lessee’s commitment to pay for the repair of such damage without reimbursement from Lessor. Lessee shall provide Lessor with said funds or satisfactory assurance thereof within 30 days after making such commitment. In such event this Lease shall continue in full force and effect, and Lessor shall proceed to make such repairs as soon as reasonably possible after the required funds are available. If Lessee does not make the required commitment, this Lease shall terminate as of the date specified in the termination notice.

9.4 Total Destruction . Notwithstanding any other provision hereof, if a Premises Total Destruction occurs, this Lease shall terminate 60 days following such Destruction. If the damage or destruction was caused solely or primarily by the gross negligence or willful misconduct of Lessee, Lessor shall have the right to recover Lessor’s damages from Lessee, except as provided in Paragraph 8.6.

9.5 Damage Near End of Term . If at any time during the last 6 months of this Lease there is damage for which the cost to repair exceeds one month’s Base Rent, whether or not an Insured Loss, Lessor may terminate this Lease effective 60 days following the date of occurrence of such damage by giving a written termination notice to Lessee within 30 days after the date of occurrence of such damage. Notwithstanding the foregoing, if Lessee at that time has an exercisable option to extend this Lease or to purchase the Premises, then Lessee may preserve this Lease by, (a) exercising such option and (b) providing Lessor with any shortage in insurance proceeds (or adequate assurance thereof) needed to make the repairs on or before the earlier of (i) the date which is 10 days after Lessee’s receipt of Lessor’s written notice purporting to terminate this Lease, or (ii) the day prior to the date upon which such option expires. If Lessee duly exercises such option during such period and provides Lessor with funds (or adequate assurance thereof) to cover any shortage in insurance proceeds, Lessor shall, at Lessor’s commercially reasonable expense, repair such damage as soon as reasonably possible and this Lease shall continue in full force and effect. If Lessee fails to exercise such option and provide such funds or assurance during such period, then this Lease shall terminate on the date specified in the termination notice and Lessee’s option shall be extinguished.

9.6 Abatement of Rent; Lessee’s Remedies.

(a) Abatement . In the event of Premises Partial Damage or Premises Total Destruction or a Hazardous Substance Condition for which Lessee is not responsible under this Lease, the Rent payable by Lessee for the period required for the repair, remediation or restoration of such damage shall be abated in proportion to the degree to which Lessee’s use or access of the Premises is impaired, but not to exceed the proceeds received from the Rental Value insurance. All other obligations of Lessee hereunder shall be performed by Lessee, and Lessor shall have no liability for any such damage, destruction, remediation, repair or restoration except as provided herein.

(b) Remedies . If Lessor shall be obligated to repair or restore the Premises and does not commence, in a substantial and meaningful way, such repair or restoration within 90 60 days after such obligation shall accrue, Lessee may, at any time prior to the commencement of such repair or restoration, give written notice to Lessor and to any Lenders of which Lessee has actual notice, of Lessee’s election to terminate this Lease on a date not less than 60 days following the giving of such notice. If Lessee gives such notice and such repair or restoration is not commenced within 30 days thereafter, this Lease shall terminate as of the date specified in said notice. If the repair or restoration is commenced within such 30 days, this Lease shall continue in full force and effect. “Commence” shall mean either the unconditional authorization of the preparation of the required plans, or the beginning of the actual work on the Premises, whichever first occurs.

9.7 Termination; Advance Payments . Upon termination of this Lease pursuant to Paragraph 6.2(g) or Paragraph 9, an equitable adjustment shall be made concerning advance Base Rent and any other advance payments made by Lessee to Lessor. Lessor shall, in addition, return to Lessee so much of Lessee’s Security Deposit as has not been, or is not then required to be, used by Lessor.

9.8 Waive Statutes . Lessor and Lessee agree that the terms of this Lease shall govern the effect of any damage to or destruction of the Premises with respect to the termination of this Lease and hereby waive the provisions of any present or future statute to the extent inconsistent herewith.

10. Real Property Taxes.

 

 14 

   


10.1 Definitions . As used herein, the term “ Real Property Taxes ” shall include any form of assessment; real estate, general, special, ordinary or extraordinary, or rental levy or tax (other than inheritance, personal income or estate taxes); improvement bond; and/or license fee imposed upon or levied against any legal or equitable interest of Lessor in the Project, Lessor’s right to other income therefrom, and/or Lessor’s business of leasing, by any authority having the direct or indirect power to tax and where the funds are generated with reference to the Project address and where the proceeds so generated are to be applied by the city, county or other local taxing authority of a jurisdiction within which the Project is located. “ Real Property Taxes ” shall also include any tax, fee, levy, assessment or charge, or any increase therein: (i) imposed by reason of events occurring during the term of this Lease, including but not limited to, a change in the ownership of the Project, (ii) a change in the improvements thereon, and/or (iii) levied or assessed on machinery or equipment provided by Lessor to Lessee pursuant to this Lease.

*10.2 Payment of Taxes . Except as otherwise provided in Paragraph 10.3, Lessor shall pay the Real Property Taxes applicable to the Project, and said payments shall be included in the calculation of Operating Expenses in accordance with the provisions of Paragraph 4.2. *Lessee shall not be responsible for increase in property taxes due to change in ownership.

10.3 Additional Improvements . Operating Expenses shall not include Real Property Taxes specified in the tax assessor’s records and work sheets as being caused by additional improvements placed upon the Project by other lessees or by Lessor for the exclusive enjoyment of such other lessees. Notwithstanding Paragraph 10.2 hereof, Lessee shall, however, pay to Lessor at the time Operating Expenses are payable under Paragraph 4.2, the entirety of any increase in Real Property Taxes if assessed solely by reason of Alterations, Trade Fixtures or Utility Installations placed upon the Premises by Lessee or at Lessee’s request or by reason of any alterations or improvements to the Premises made by Lessor subsequent to the execution of this Lease by the Parties.

10.4 Joint Assessment . If the Building is not separately assessed, Real Property Taxes allocated to the Building shall be an equitable proportion of the Real Property Taxes for all of the land and improvements included within the tax parcel assessed, such proportion to be determined by Lessor from the respective valuations assigned in the assessor’s work sheets or such other information as may be reasonably available. Lessor’s reasonable determination thereof, in good faith, shall be conclusive.

10.5 Personal Property Taxes . Lessee shall pay prior to delinquency all taxes assessed against and levied upon Lessee Owned Alterations and Utility Installations, Trade Fixtures, furnishings, equipment and all personal property of Lessee contained in the Premises. When possible, Lessee shall cause its Lessee Owned Alterations and Utility Installations, Trade Fixtures, furnishings, equipment and all other personal property to be assessed and billed separately from the real property of Lessor. If any of Lessee’s said property shall be assessed with Lessor’s real property, Lessee shall pay Lessor the taxes attributable to Lessee’s property within 10 days after receipt of a written statement setting forth the taxes applicable to Lessee’s property.

 

 15 

   


   

11. Utilities and Services.

11.1 Services Provided by Lessor. Lessor shall provide heating, ventilation, air conditioning, reasonable amounts of electricity for normal lighting and office machines, * water for reasonable and normal drinking and lavatory use* in the common areas in connection with an office, and replacement light bulbs and/or fluorescent tubes and ballasts for standard overhead fixtures. Lessor shall also provide janitorial services to the Premises and Common Areas 5 times per week, excluding Building Holidays, or pursuant to the attached janitorial schedule, if any. Lessor shall not , however, be required to provide janitorial services to kitchens or storage areas included within the Premises. Lessee shall be responsible for providing its personal supplies and paper goods to the Premises.

11.2 Services Exclusive to Lessee. Lessee shall pay for all water, gas, heat, light, power, telephone and other utilities and services specially or exclusively supplied and/or metered exclusively to the Premises or to Lessee, together with any taxes thereon. If a service is deleted by Paragraph 1.13 and such service is not separately metered to the Premises, Lessee shall pay at Lessor’s option, either Lessee’s Share or a reasonable proportion to be determined by Lessor of all charges for such jointly metered service.

11.3 Hours of Service. Said services and utilities shall be provided during times set forth in Paragraph 1.12. Utilities and services required at other times shall be subject to advance request and reimbursement by Lessee to Lessor of the cost thereof.

11.4 Excess Usage by Lessee. Lessee shall not make connection to the utilities except by or through existing outlets and shall not install or use machinery or equipment in or about the Premises that uses excess water, lighting or power, or suffer or permit any act that causes extra burden upon the utilities or services, including but not limited to security and trash services, over standard office usage for the Project. Lessor shall require Lessee to reimburse Lessor for any excess expenses or costs that may arise out of a breach of this subparagraph by Lessee. Lessor may, in its sole discretion, install at Lessee’s expense supplemental equipment and/or separate metering applicable to Lessee’s excess usage or loading.

11.5 Interruptions. There shall be no abatement of rent and Lessor shall not be liable in any respect whatsoever for the inadequacy, stoppage, interruption or discontinuance of any utility or service due to riot, strike, labor dispute, breakdown, accident, repair or other cause beyond Lessor’s reasonable control or in cooperation with governmental request or directions.

12. Assignment and Subletting .

12.1 Lessor’s Consent Required .

(a) Lessee shall not voluntarily or by operation of law assign, transfer, mortgage or encumber (collectively, “ assign or assignment ”) or sublet all or any part of Lessee’s interest in this Lease or in the Premises, except to an affiliate company, person or entity that controls, shares common control with or is controlled by Lessee, and agrees to the terms and conditions of this Lease Agreement, without Lessor’s prior written consent.

(b) Unless Lessee is a corporation and its stock is publicly traded on a national stock exchange, a change in the control of Lessee shall constitute an assignment requiring consent. The transfer, on a cumulative basis, of 25% 51% or more of the voting control of Lessee shall constitute a change in control for this purpose.

(c) The involvement of Lessee or its assets in any transaction, or series of transactions (by way of merger, sale, acquisition, financing, transfer, leveraged buyout or otherwise), whether or not a formal assignment or hypothecation of this Lease or Lessee’s assets occurs, which results or will result in a reduction of the Net Worth of Lessee by an amount greater than 25% 51% of such Net Worth as it was represented at the time of the execution of this Lease or at the time of the most recent assignment to which Lessor has consented, or as it exists immediately prior to said transaction or transactions constituting such reduction, whichever was or is greater, shall be considered an assignment of this Lease to which Lessor may withhold its consent. “ Net Worth of Lessee ” shall mean the net worth of Lessee (excluding any guarantors) established under generally accepted accounting principles.

(d) An assignment or subletting without consent shall, at Lessor’s option, be a Default curable after notice per Paragraph 13.1(c), or a noncurable Breach without the necessity of any notice and grace period. If Lessor elects to treat such unapproved assignment or subletting as a noncurable Breach, Lessor may either: (i) terminate this Lease, or (ii) upon 30 days written notice, increase the monthly Base Rent to 110% of the Base Rent then in effect. Further, in the event of such Breach and rental adjustment, (i) the purchase price of any option to purchase the Premises held by Lessee shall be subject to similar adjustment to 110% of the price previously in effect, and (ii) all fixed and non-fixed rental adjustments scheduled during the remainder of the Lease term shall be increased to 110% of the scheduled adjusted rent.

(e) Lessee’s remedy for any breach of Paragraph 12.1 by Lessor shall be limited to compensatory damages and/or injunctive relief.

(f) Lessor may reasonably withhold consent to a proposed assignment or subletting if Lessee is in Default, beyond any applicable cure period, at the time consent is requested.

(g) Notwithstanding the foregoing, allowing a diminimus portion of the Premises, i e. 20 square feet or less, to be used by a third party vendor in connection with the installation of a vending machine or payphone shall not constitute a subletting.

(h) Lessee’s acquisition by an affiliate company, see Section 12.1(a) that does not require Lessor’s consent, shall not void the Lease .

12.2 Terms and Conditions Applicable to Assignment and Subletting .

(a) Regardless of Lessor’s consent, no assignment or subletting shall: (i) be effective without the express written assumption by such assignee or sublessee of the obligations of Lessee under this Lease, (ii) release Lessee of any obligations hereunder, or (iii) alter the primary liability of Lessee for the payment of Rent or for the performance of any other obligations to be performed by Lessee.

(b) Lessor may accept Rent or performance of Lessee’s obligations from any person other than Lessee pending approval or disapproval of an assignment. Neither a delay in the approval or disapproval of such assignment nor the acceptance of Rent or performance shall constitute a waiver or estoppel of Lessor’s right to exercise its remedies for Lessee’s Default or Breach.

 

 16 

   


(c) Lessor’s consent to any assignment or subletting shall not constitute a consent to any subsequent assignment or subletting.

(d) In the event of any Default or Breach by Lessee, Lessor may proceed directly against Lessee, any Guarantors or anyone else responsible for the performance of Lessee’s obligations under this Lease, including any assignee or sublessee, without first exhausting Lessor’s remedies against any other person or entity responsible therefore to Lessor, or any security held by Lessor.

(e) Each request for consent to an assignment or subletting shall be in writing, accompanied by information relevant to Lessor’s determination as to the financial and operational responsibility and appropriateness of the proposed assignee or sublessee, including but not limited to the intended use and/or required modification of the Premises, if any, together with a fee of $500 as consideration for Lessor’s considering and processing said request. Lessee agrees to provide Lessor with such other or additional information and/or documentation as may be reasonably requested. (See also Paragraph 36)

(f) Any assignee of, or sublessee under, this Lease shall, by reason of accepting such assignment, entering into such sublease, or entering into possession of the Premises or any portion thereof, be deemed to have assumed and agreed to conform and comply with each and every term, covenant, condition and obligation herein to be observed or performed by Lessee during the term of said assignment or sublease, other than such obligations as are contrary to or inconsistent with provisions of an assignment or sublease to which Lessor has specifically consented to in writing.

(g) Lessor’s consent to any assignment or subletting shall not transfer to the assignee or sublessee any Option granted to the original Lessee by this Lease unless such transfer is specifically consented to by Lessor in writing. (See Paragraph 39.2)

12.3 Additional Terms and Conditions Applicable to Subletting . The following terms and conditions shall apply to any subletting by Lessee of all or any part of the Premises and shall be deemed included in all subleases under this Lease whether or not expressly incorporated therein:

(a) Lessee hereby assigns and transfers to Lessor all of Lessee’s interest in all Rent payable on any sublease, and Lessor may collect such Rent and apply same toward Lessee’s obligations under this Lease; provided, however, that until a Breach shall occur in the performance of Lessee’s obligations, Lessee may collect said Rent. In the event that the amount collected by Lessor exceeds Lessee’s then outstanding obligations any such excess shall be refunded to Lessee. Any Lessee payment or other sums received by Lessee or any other person in connection with this Lease shall be conclusively presumed to have been paid by Lessee or on Lessee’s behalf. If, as a result of any proposed Assignment or Sublease, Lessee receives rent or other consideration, either initially or over the term of the Assignment or Sublease, in excess of the rent called for hereunder, or in the case of the Sublease of a portion of the Premises, in excess of the rent allocable to such portion, Lessee shall pay to Lessor as additional rent hereunder, 50% of net profits of each such payment of rent or other consideration received by Lessee promptly after its receipt. Lessor shall not, by reason of the foregoing or any assignment of such sublease, nor by reason of the collection of Rent, be deemed liable to the sublessee for any failure of Lessee to perform and comply with any of Lessee’s obligations to such sublessee. Lessee hereby irrevocably authorizes and directs any such sublessee, upon receipt of a written notice from Lessor stating that a Breach exists in the performance of Lessee’s obligations under this Lease, to pay to Lessor all Rent due and to become due under the sublease. Sublessee shall rely upon any such notice from Lessor and shall pay all Rents to Lessor without any obligation or right to inquire as to whether such Breach exists, notwithstanding any claim from Lessee to the contrary.

(b) In the event of a Breach by Lessee, Lessor may, at its option, require sublessee to attorn to Lessor, in which event Lessor shall undertake the obligations of the sublessor under such sublease from the time of the exercise of said option to the expiration of such sublease; provided, however, Lessor shall not be liable for any prepaid rents or security deposit paid by such sublessee to such sublessor or for any prior Defaults or Breaches of such sublessor.

(c) Any matter requiring the consent of the sublessor under a sublease shall also require the consent of Lessor.

 

 17 

   


   

(d) No sublessee shall further assign or sublet all or any part of the Premises without Lessor’s prior written consent.

(e) Lessor shall deliver a copy of any notice of Default or Breach by Lessee to the sublessee, who shall have the right to cure the Default of Lessee within the grace period, if any, specified in such notice. The sublessee shall have a right of reimbursement and offset from and against Lessee for any such Defaults cured by the sublessee.

13. Default; Breach; Remedies.

13.1 Default; Breach. A “ Default ” is defined as a failure by the Lessee to comply with or perform any of the terms, covenants, conditions or Rules and Regulations under this Lease. A “Breach” is defined as the occurrence of one or more of the following Defaults, and the failure of Lessee to cure such Default within any applicable grace period:

(a) The abandonment of the Premises; or the vacating of the Premises without providing a commercially reasonable level of security, or where the coverage of the property insurance described in Paragraph 8.3 is jeopardized as a result thereof, or without providing reasonable assurances to minimize potential vandalism.

(b) The failure of Lessee to make any payment of Rent or any Security Deposit required to be made by Lessee hereunder, whether to Lessor or to a third party, when due, to provide reasonable evidence of insurance or surety bond, or to fulfill any obligation under this Lease which endangers or threatens life or property, where such failure continues for a period of 3 business days following written notice to Lessee.

(c) The commission of waste, act or acts constituting public or private nuisance, and/or an illegal activity on the Premises by Lessee, where such actions continue for a period of 3 business days following written notice to Lessee.

(d) The failure by Lessee to provide (i) reasonable written evidence of compliance with Applicable Requirements, (ii) the service contracts, (iii) the rescission of an unauthorized assignment or subletting, (iv) an Estoppel Certificate, (v) a requested subordination, (vi) evidence concerning any guaranty and/or Guarantor, (vii) any document requested under Paragraph 41, (viii) material data safety sheets (MSDS), or (ix) any other documentation or information which Lessor may reasonably require of Lessee under the terms of this Lease, where any such failure continues for a period of 10 days following written notice to Lessee.

(e) A Default by Lessee as to the terms, covenants, conditions or provisions of this Lease, or of the rules adopted under Paragraph 2.9 hereof, other than those described in subparagraphs 13.1(a) : (b) or (c), above, where such Default continues for a period of 30 days after written notice; provided, however, that if the nature of Lessee’s Default is such that more than 30 days are reasonably required for its cure, then it shall not be deemed to be a Breach if Lessee commences such cure within said 30 day period and thereafter diligently prosecutes such cure to completion.

(f) The occurrence of any of the following events: (i) the making of any general arrangement or assignment for the benefit of creditors; (ii) becoming a “ debtor ” as defined in 11 U.S.C. § 101 or any successor statute thereto (unless, in the case of a petition filed against Lessee, the same is dismissed within 60 days); (iii) the appointment of a trustee or receiver to take possession of substantially all of Lessee’s assets located at the Premises or of Lessee’s interest in this Lease, where possession is not restored to Lessee within 30 days; or (iv) the attachment, execution or other judicial seizure of substantially all of Lessee’s assets located at the Premises or of Lessee’s interest in this Lease, where such seizure is not discharged within 30 days; provided, however, in the event that any provision of this subparagraph is contrary to any applicable law, such provision shall be of no force or effect and not affect the validity of the remaining provisions.

(g) The discovery that any financial statement of Lessee or of any Guarantor given to Lessor was materially false.

(h) If the performance of Lessee’s obligations under this Lease is guaranteed: (i) the death of a Guarantor, (ii) the termination of a Guarantor’s liability with respect to this Lease other than in accordance with the terms of such guaranty, (iii) a Guarantor’s becoming insolvent or the subject of a bankruptcy filing, (iv) a Guarantor’s refusal to honor the guaranty, or (v) a Guarantor’s breach of its guaranty obligation on an anticipatory basis, and Lessee’s failure, within 60 days following written notice of any such event, to provide written alternative assurance or security, which, when coupled with the then existing resources of Lessee, equals or exceeds the combined financial resources of Lessee and the Guarantors that existed at the time of execution of this Lease.

13.2 Remedies . If Lessee fails to perform any of its affirmative duties or obligations, within 10 days after written notice (or in case of an emergency, without notice), Lessor may, at its option, perform such duty or obligation on Lessee’s behalf, including but not limited to the obtaining of reasonably required bonds, insurance policies, or governmental licenses, permits or approvals. Lessee shall pay to Lessor an amount equal to 115% of the reasonable and documented costs and expenses incurred by Lessor in such performance upon receipt of an invoice therefor. In the event of a Breach, Lessor may, with or without further notice or demand, and without limiting Lessor in the exercise of any right or remedy which Lessor may have by reason of such Breach:

(a) Terminate Lessee’s right to possession of the Premises by any lawful means, in which case this Lease shall terminate and Lessee shall immediately surrender possession to Lessor. In such event Lessor shall be entitled to recover from Lessee: (i) the unpaid Rent which had been earned at the time of termination; (ii) the worth at the time of award of the amount by which the unpaid rent which would have been earned after termination until the time of award exceeds the amount of such rental loss that the Lessee proves could have been reasonably avoided; (iii) the worth at the time of award of the amount by which the unpaid rent for the balance of the term after the time of award exceeds the amount of such rental loss that the Lessee proves could be reasonably avoided; and (iv) any other amount necessary to compensate Lessor for all the detriment proximately caused by the Lessee’s failure to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, including but not limited to the cost of recovering possession of the Premises, expenses of reletting, including necessary renovation and alteration of the Premises, reasonable attorneys’ fees, and that portion of any leasing commission paid by Lessor in connection with this Lease applicable to the unexpired term of this Lease. The worth at the time of award of the amount referred to in provision (iii) of the immediately preceding sentence shall be computed by discounting such amount at the discount rate of the Federal Reserve Bank of the District within which the Premises are located at the time of award plus one percent. Efforts by Lessor to mitigate damages caused by Lessee’s Breach of this Lease shall not waive Lessor’s right to recover damages under Paragraph 12. If termination of this Lease is obtained through the provisional remedy of unlawful detainer, Lessor shall have the right to recover in such proceeding any unpaid Rent and damages as are recoverable therein, or Lessor may reserve the right to recover all or any part thereof in a separate suit. If a notice and grace period required under Paragraph 13.1 was not previously given, a notice to pay rent or quit, or to perform or quit given to Lessee under the unlawful detainer statute shall also constitute the notice required by Paragraph 13.1. In such case, the applicable grace period required by Paragraph 13.1 and the unlawful detainer statute shall run concurrently, and the failure of Lessee to cure the Default within the

 

 18 

   


greater of the two such grace periods shall constitute both an unlawful detainer and a Breach of this Lease entitling Lessor to the remedies provided for in this Lease and/or by said statute.

(b) Continue the Lease and Lessee’s right to possession and recover the Rent as it becomes due, in which event Lessee may sublet or assign, subject only to reasonable limitations. Acts of maintenance, efforts to relet, and/or the appointment of a receiver to protect the Lessor’s interests, shall not constitute a termination of the Lessee’s right to possession.

(c) Pursue any other remedy now or hereafter available under the laws or judicial decisions of the state wherein the Premises are located. The expiration or termination of this Lease and/or the termination of Lessee’s right to possession shall not relieve Lessee from liability under any indemnity provisions of this Lease as to matters occurring or accruing during the term hereof or by reason of Lessee’s occupancy of the Premises.

13.3 Inducement Recapture . Any agreement for free or abated rent or other charges, or for the giving or paying by Lessor to or for Lessee of any cash or other bonus, inducement or consideration for Lessee’s entering into this Lease, all of which concessions are hereinafter referred to as “ Inducement Provisions ”, shall be deemed conditioned upon Lessee’s full and faithful performance of all of the terms, covenants and conditions of this Lease. Upon Breach of this Lease by Lessee, any such Inducement Provision shall automatically be deemed deleted from this Lease and of no further force or effect, and any rent, other charge, bonus, inducement or consideration theretofore abated, given or paid by Lessor under such an Inducement Provision shall be immediately due and payable by Lessee to Lessor, notwithstanding any subsequent cure of said Breach by Lessee. The acceptance by Lessor of rent or the cure of the Breach which initiated the operation of this paragraph shall not be deemed a waiver by Lessor of the provisions of this paragraph unless specifically so stated in writing by Lessor at the time of such acceptance.

13.4 Late Charges . Lessee hereby acknowledges that late payment by Lessee of Rent will cause Lessor to incur costs not contemplated by this Lease, the exact amount of which will be extremely difficult to ascertain. Such costs include, but are not limited to, processing and accounting charges, and late charges which may be imposed upon Lessor by any Lender. Accordingly, if any Rent shall not be received by Lessor within 5 10 days after such amount shall be due, then, without any requirement for notice to Lessee, Lessee shall immediately pay to Lessor a one-time late charge equal to 10% of each such overdue amount or $100, whichever is greater. The parties hereby agree that such late charge represents a fair and reasonable estimate of the costs Lessor will incur by reason of such late payment. Acceptance of such late charge by Lessor shall in no event constitute a waiver of Lessee’s Default or Breach with respect to such overdue amount, nor prevent the exercise of any of the other rights and remedies granted hereunder. In the event that a late charge is payable hereunder, whether or not collected, for 3 consecutive installments of Base Rent, then notwithstanding any provision of this Lease to the contrary, Base Rent shall, at Lessor’s option, become due and payable quarterly in advance.

13.5 Interest . Any monetary payment due Lessor hereunder, other than late charges, not received by Lessor, when due as to scheduled payments (such as Base Rent) or within 30 days following the date on which it was due for nonscheduled payment, shall bear interest from the date when due, as to scheduled payments, or the 31st day after it was due as to nonscheduled payments. The interest (“ Interest ”) charged shall be computed at the rate of 10% per annum but shall not exceed the maximum rate allowed by law. Interest is payable in addition to the potential late charge provided for in Paragraph 13.4.

 

 19 

   


   

13.6 Breach by Lessor .

(a) Notice of Breach. Lessor shall not be deemed in breach of this Lease unless Lessor fails within a reasonable time to perform an obligation required to be performed by Lessor. For purposes of this Paragraph, a reasonable time shall in no event be less than 30 days after receipt by Lessor, and any Lender whose name and address shall have been furnished Lessee in writing for such purpose , of written notice specifying wherein such obligation of Lessor has not been performed; provided, however, that if the nature of Lessor’s obligation is such that more than 30 days are reasonably required for its performance, then Lessor shall not be in breach if performance is commenced within such 30 day period and thereafter diligently pursued to completion.

(b) Performance by Lessee on Behalf of Lessor . In the event that neither Lessor nor Lender cures said breach within 30 days after receipt of said notice, or if having commenced said cure they do not diligently pursue it to completion, then Lessee may elect to cure said broach at Lessee’s expense and offset from Rent the actual and reasonable cost to perform such sure, provided however, that such offset shall not exceed an amount equal to the greater of one month’s Base Rent or the Security Deposit, reserving Lessee’s right to seek reimbursement from Lessor for any such expense in excess of such offset. Lessee shall document the cost of said cure and supply said documentation to Lessor.

14. Condemnation . If the Premises or any portion thereof are taken under the power of eminent domain or sold under the threat of the exercise of said power (collectively “ Condemnation ”), this Lease shall terminate as to the part taken as of the date the condemning authority takes title or possession, whichever first occurs. If more than 10% of the rentable floor area of the Premises, or more than 25% of Lessee’s Reserved Parking Spaces, if any, are taken by Condemnation, Lessee may, at Lessee’s option, to be exercised in writing within 10 days after Lessor shall have given Lessee written notice of such taking (or in the absence of such notice, within 10 days after the condemning authority shall have taken possession) terminate this Lease as of the date the condemning authority takes such possession. If Lessee does not terminate this Lease in accordance with the foregoing, this Lease shall remain in full force and effect as to the portion of the Premises remaining, except that the Base Rent shall be reduced in proportion to the reduction in utility of the Premises caused by such Condemnation. Condemnation awards and/or payments shall be the property of Lessor, whether such award shall be made as compensation for diminution in value of the leasehold, the value of the part taken, or for severance damages; provided, however, that Lessee shall be entitled to any compensation for Lessee’s relocation expenses, loss of business goodwill and/or Trade Fixtures, without regard to whether or not this Lease is terminated pursuant to the provisions of this Paragraph. All Alterations and Utility Installations made to the Premises by Lessee, for purposes of Condemnation only, shall be considered the property of the Lessee and Lessee shall be entitled to any and all compensation which is payable therefor. In the event that this Lease is not terminated by reason of the Condemnation, Lessor shall repair any damage to the Premises caused by such Condemnation.

15. Brokerage Fees .

15.1 Additional Commission . In addition to the payments owed pursuant to Paragraph 1.10 above, and unless Lessor and the Brokers otherwise agree in writing. Lessor agrees that: (a) if Lessee exercises any Option, (b) if Lessee acquires from Lessor any rights to the Premises or other premises owned by Lessor and located within the Project, (c) if Lessee remains in possession of the Premises, with the consent of Lessor, after the expiration of this Lease, or (d) if Base Rent is increased, whether by agreement or operation of an escalation clause herein, then, Lessor shall pay Brokers a fee in accordance with the schedule of the Brokers in effect at the time of the execution of this Lease.

15.2 Assumption of Obligations . Any buyer or transferee of Lessor’s interest in this Lease shall be deemed to have assumed Lessor’s obligation hereunder. Brokers shall be third party beneficiaries of the provisions of Paragraphs 1.10; 15, 22 and 31. If Lessor fails to pay to Brokers any amounts due as and for brokerage fees pertaining to this Lease when due, then such amounts shall accrue Interest. In addition, if Lessor fails to pay any amounts to Lessee’s Broker when due, Lessee’s Broker may send written notice to Lessor and Lessee of such failure and if Lessor fails to pay such amounts within 10 days after said notice, Lessee shall pay said monies to its Broker and offset such amounts against Rent. In addition Lessee’s Broker shall be deemed to be a third party beneficiary of any commission agreement entered into by and/or between Lessor and Lessor’s Broker for the limited purpose of collecting any brokerage fee owed.

15.3 Representations and Indemnities of Broker Relationships . Lessee and Lessor each represent and warrant to the other that it has had no dealings with any person, firm, broker or finder (other than the Brokers, if any) in connection with this Lease, and that no one other than said named Brokers is entitled to any commission or finder’s fee in connection herewith. Lessee and Lessor do each hereby agree to indemnify, protect, defend and hold the other harmless from and against liability for compensation or charges which may be claimed by any such unnamed broker, finder or other similar party by reason of any dealings or actions of the indemnifying Party, including any costs, expenses, attorneys’ fees reasonably incurred with respect thereto.

16. Estoppel Certificates.

(a) Each Party Lessee, (as “ Responding Party ”) shall within 10 days after written notice from the other Party, Lessor, or Lessor’s representatives, (the “ Requesting Party ”) execute, acknowledge and deliver to the Requesting Party a statement in writing in form similar to the then most current “ Estoppel Certificate ” form published by the AIRCommercial Real Estate Association, plus such additional information, confirmation and/or statements as may be reasonably requested by the Requesting Party.

(b) If the Responding Party shall fail to execute or deliver the Estoppel Certificate within such 10 day period, the Requesting Party may execute an Estoppel Certificate stating that: (i) the Lease is in full force and effect without modification except as may be represented by the Requesting Party , (ii) there are no uncured defaults in the Requesting Party’s performance, and (iii)  if Lessor is the Requesting Party , not more than one month’s rent has been paid in advance. Prospective purchasers and encumbrancers may rely upon the Requesting Party’s Estoppel Certificate, and the Responding Party shall be estopped from denying the truth of the facts contained in said Certificate.

(c) If Lessor desires to finance, refinance, or sell the Premises, or any part thereof, Lessee and all Guarantors shall deliver to any potential lender or purchaser designated by Lessor such financial statements as may be reasonably required by such lender or purchaser, including but not limited to Lessee’s financial statements for the past 3 years, and updated credit data of any type previously provided by Lessee, but only one time per year , All such financial statements shall be received by Lessor and such lender or purchaser in confidence and shall be used only for the purposes herein set forth.

17. Definition of Lessor . The term “ Lessor ” as used herein shall mean the owner or owners at the time in question of the fee title to the Premises, or, if this is a sublease, of the Lessee’s interest in the prior lease. In the event of a transfer of Lessor’s title or interest in

 

 20 

   


the Premises or this Lease, Lessor shall deliver to the transferee or assignee (in cash or by credit) any unused Security Deposit held by Lessor. Except as provided in Paragraph 15, upon such transfer or assignment and delivery of the Security Deposit, as aforesaid, the prior Lessor shall be relieved of all liability with respect to the obligations and/or covenants under this Lease thereafter to be performed by the Lessor. Subject to the foregoing, the obligations and/or covenants in this Lease to be performed by the Lessor shall be binding only upon the Lessor as hereinabove defined.

18. Severability . The invalidity of any provision of this Lease, as determined by a court of competent jurisdiction, shall in no way affect the validity of any other provision hereof.

19. Days . Unless otherwise specifically indicated to the contrary, the word “ days ” as used in this Lease shall mean and refer to calendar days.

20. Limitation on Liability . The obligations of Lessor under this Lease shall not constitute personal obligations of Lessor or its partners, members, directors, officers or shareholders, and Lessee shall look to the Project, and to no other assets of Lessor, for the satisfaction of any liability of Lessor with respect to this Lease, and shall not seek recourse against Lessor’s partners, members, directors, officers or shareholders, or any of their personal assets for such satisfaction.

21. Time of Essence . Time is of the essence with respect to the performance of all obligations to be performed or observed by the Parties under this Lease.

22. No Prior or Other Agreements; Broker Disclaimer. This Lease contains all agreements between the Parties with respect to any matter mentioned herein, and no other prior or contemporaneous agreement or understanding shall be effective. Lessor and Lessee each represents and warrants to the Brokers that it has made, and is relying solely upon, its own investigation as to the nature, quality, character and financial responsibility of the other Party to this Lease and as to the use, nature, quality and character of the Premises. Brokers have no responsibility with respect thereto or with respect to any default or breach hereof by either Party. The liability (including court costs and attorneys’ fees) of any Broker with respect to negotiation, execution, delivery or performance by either Lessor or Lessee under this Lease or any amendment or modification hereto shall be limited to an amount up to the fee received by such Broker pursuant to this Lease; provided, however, that the foregoing limitation on each Broker’s liability shall not be applicable to any gross negligence or willful misconduct of such Broker.

23. Notices.

23.1 Notice Requirements . All notices required or permitted by this Lease or applicable law shall be in writing and may be delivered in person (by hand or by courier) or may be sent by regular, certified or registered mail or U.S. Postal Service Express Mail, with postage prepaid, or by facsimile transmission, and shall be deemed sufficiently given if served in a manner specified in this Paragraph 23. The addresses noted adjacent to a Party’s Lessee’s signature on this Lease shall be that Party’s Lessee’s address for delivery or mailing of notices. The address listed in Paragraph 4 of the Addendum I will be the Lessor’s address for delivery or mailing of notices to Lessor. Either Party may by written notice to the other specify a different address for notice, except that upon Lessee’s taking possession of the Premises, the Premises shall constitute Lessee’s address for notice. A copy of all notices to Lessor shall be concurrently transmitted to such party or parties at such addresses as Lessor may from time to time hereafter designate in writing.

23.2 Date of Notice . Any notice sent by registered or certified mail, return receipt requested, shall be deemed given on the date of delivery

 

 21 

   


shown on the receipt card, or if no delivery date is shown, the postmark thereon. If sent by regular mail the notice shall be deemed given 72 hours after the same is addressed as required herein and mailed with postage prepaid. Notices delivered by United States Express Mail or overnight courier that guarantee next day delivery shall be deemed given 24 hours after delivery of the same to the Postal Service or courier. Notices transmitted by facsimile transmission or similar means shall be deemed delivered upon telephone confirmation of receipt (confirmation report from fax machine is sufficient), provided a copy is also delivered via delivery or mail. If notice is received on a Saturday, Sunday or legal holiday, it shall be deemed received on the next business day.

24. Waivers . No waiver by Lessor of the Default or Breach of any term, covenant or condition hereof by Lessee, shall be deemed a waiver of any other term, covenant or condition hereof, or of any subsequent Default or Breach by Lessee of the same or of any other term, covenant or condition hereof. Lessor’s consent to, or approval of, any act shall not be deemed to render unnecessary the obtaining of Lessor’s consent to, or approval of, any subsequent or similar act by Lessee, or be construed as the basis of an estoppel to enforce the provision or provisions of this Lease requiring such consent. The acceptance of Rent by Lessor shall not be a waiver of any Default or Breach by Lessee. Any payment by Lessee may be accepted by Lessor on account of moneys or damages due Lessor, notwithstanding any qualifying statements or conditions made by Lessee in connection therewith, which such statements and/or conditions shall be of no force or effect whatsoever unless specifically agreed to in writing by Lessor at or before the time of deposit of such payment.

25. Disclosures Regarding The Nature of a Real Estate Agency Relationship .

(a) When entering into a discussion with a real estate agent regarding a real estate transaction, a Lessor or Lessee should from the outset understand what type of agency relationship or representation it has with the agent or agents in the transaction. Lessor and Lessee acknowledge being advised by the Brokers in this transaction, as follows:

(i) Lessor’s Agent. A Lessor’s agent under a listing agreement with the Lessor acts as the agent for the Lessor only. A Lessor’s agent or subagent has the following affirmative obligations: To the Lessor: A fiduciary duty of utmost care, integrity, honesty, and loyalty in dealings with the Lessor. To the Lessee and the Lessor: a. Diligent exercise of reasonable skills and care in performance of the agent’s duties. b. A duty of honest and fair dealing and good faith. c. A duty to disclose all facts known to the agent materially affecting the value or desirability of the property that are not known to, or within the diligent attention and observation of, the Parties. An agent is not obligated to reveal to either Party any confidential information obtained from the other Party which does not involve the affirmative duties set forth above.

(ii) Lessee’s Agent. An agent can agree to act as agent for the Lessee only. In these situations, the agent is not the Lessor’s agent, even if by agreement the agent may receive compensation for services rendered, either in full or in part from the Lessor. An agent acting only for a Lessee has the following affirmative obligations. To the Lessee: A fiduciary duty of utmost care, integrity, honesty, and loyalty in dealings with the Lessee. To the Lessee and the Lessor: a. Diligent exercise of reasonable skills and care in performance of the agent’s duties. b. A duty of honest and fair dealing and good faith. c. A duty to disclose all facts known to the agent materially affecting the value or desirability of the property that are not known to, or within the diligent attention and observation of, the Parties. An agent is not obligated to reveal to either Party any confidential information obtained from the other Party which does not involve the affirmative duties set forth above.

(iii) Agent Representing Both Lessor and Lessee. A real estate agent, either acting directly or through one or more associate licenses, can legally be the agent of both the Lessor and the Lessee in a transaction, but only with the knowledge and consent of both the Lessor and the Lessee. In a dual agency situation, the agent has the following affirmative obligations to both the Lessor and the Lessee: a. A fiduciary duty of utmost care, integrity, honesty and loyalty in the dealings with either Lesser or the Lessee. b. Other duties to the Lessor and the Lessee as stated above in subparagraphs (i) or (ii). In representing both Lessor and Lessee, the agent may not without the express permission of the respective Party, disclose to the other Party that the Lessor will accept rent in an amount less than that indicated in the listing or that the Lessee is willing to pay a higher rent than that offered. The above duties of the agent in a real estate transaction do not relieve a Lessor or Lessee from the responsibility to protect their own interests. Lessor and Lessee should carefully read all agreements to assure that they adequately express their understanding of the transaction. A real estate agent is a person qualified to advise about real estate. If legal or tax advise is desired, consult a competent professional.

(b) Brokers have no responsibility with respect to any default or breach hereof by either Party. The Parties agree that no lawsuit or other legal proceeding involving any breach of duty, error or omission relating to this Lease may be brought against Broker more than one year after the Start Date and that the liability (including court costs and attorneys’ fees), of any Broker with respect to any such lawsuit and/or legal proceeding shall not exceed the fee received by such Broker pursuant to this Lease; provided, however, that the foregoing limitation on each Broker’s liability shall not be applicable to any gross negligence or willful misconduct of such Broker.

(c) Buyer and Seller agree to identify to Brokers as “Confidential” any communication or information given Brokers that is considered by such Party to be confidential.

26. No Right To Holdover. Lessee has no right to retain possession of the Premises or any part thereof beyond the expiration or termination of this Lease. In the event that Lessee holds over, then the Base Rent shall be increased to 150% of the Base Rent applicable immediately preceding the expiration or termination. In the event that Lessee holds over in violation of this paragraph, then in addition to the increase in Base Rent and all additional rent, Lessee shall be liable to Lessor for all costs, losses, claims or liabilities (including attorney’s fees) which Lessor may incur as a result of Lessee’s failure to surrender possession of the Premises to Lessor upon the expiration or earlier termination of this Lease. Nothing contained herein shall be construed as consent by Lessor to any holding over by Lessee.

27. Cumulative Remedies . No remedy or election hereunder shall be deemed exclusive but shall, wherever possible, be cumulative with all other remedies at law or in equity.

28. Covenants and Conditions; Construction of Agreement . All provisions of this Lease to be observed or performed by Lessee are both covenants and conditions. In construing this Lease, all headings and titles are for the convenience of the Parties only and shall not be considered a part of this Lease. Whenever required by the context, the singular shall include the plural and vice versa. This Lease shall not be construed as if prepared by one of the Parties, but rather according to its fair meaning as a whole, as if both Parties had prepared it.

29. Binding Effect; Choice of Law . This Lease shall be binding upon the Parties, their personal representatives, successors and assigns and be governed by the laws of the State in which the Premises are located. Any litigation between the Parties hereto concerning this Lease shall be initiated in the county in which the Premises are located.

 

 22 

   


30. Subordination; Attornment; Non-Disturbance.

30.1 Subordination . This Lease and any Option granted hereby shall be subject and subordinate to any ground lease, mortgage, deed of trust, or other hypothecation or security device (collectively, “ Security Device ”), now or hereafter placed upon the Premises, to any and all advances made on the security thereof, and to all renewals, modifications, and extensions thereof. Lessee agrees that the holders of any such Security Devices (in this Lease together referred to as “ Lender ”) shall have no liability or obligation to perform any of the obligations of Lessor under this Lease. Any Lender may elect to have this Lease and/or any Option granted hereby superior to the lien of its Security Device by giving written notice thereof to Lessee, whereupon this Lease and such Options shall be deemed prior to such Security Device, notwithstanding the relative dates of the documentation or recordation thereof.

30.2 Attornment . In the event that Lessor transfers title to the Premises, or the Premises are acquired by another upon the foreclosure or termination of a Security Device to which this Lease is subordinated (i) Lessee shall, subject to the non-disturbance provisions of Paragraph 30.3, attorn to such new owner, and upon request, enter into a new lease, containing all of the terms and provisions of this Lease, with such new owner for the remainder of the term hereof, or, at the election of the new owner, this Lease will automatically become a new lease between Lessee and such new owner, and (ii) Lessor shall thereafter be relieved of any further obligations hereunder and such new owner shall assume all of Lessor’s obligations, except that such new owner shall not: (a) be liable for any act or omission of any prior lessor or with respect to events occurring prior to acquisition of ownership; (b) be subject to any offsets or defenses which Lessee might have against any prior lessor, (c) be bound by prepayment of more than one month’s rent, or (d) be liable for the return of any security deposit paid to any prior lessor.

30.3 Non-Disturbance . With respect to Security Devices entered into by Lessor after the execution of this Lease, Lessee’s subordination of this Lease shall be subject to receiving a commercially reasonable non-disturbance agreement (a “ Non-Disturbance Agreement ”) from the Lender which Non-Disturbance Agreement provides that Lessee’s possession of the Premises, and this Lease, including any options to extend the term hereof, will not be disturbed so long as Lessee is not in Breach hereof and attorns to the record owner of the Premises. Further, within 60 days after the execution of this Lease, Lessor shall use its commercially reasonable efforts to obtain a Non-Disturbance Agreement from the holder of any pre-existing Security Device which is secured by the Premises. In the event that Lessor is unable to provide the Non-Disturbance Agreement within said 60 days, then Lessee may, at Lessee’s option, directly contact Lender and attempt to negotiate for the execution and delivery of a Non-Disturbance Agreement.

30.4 Self-Executing . The agreements contained in this Paragraph 30 shall be effective without the execution of any further documents; provided, however, that, upon written request from Lessor or a Lender in connection with a sale, financing or refinancing of the Premises, Lessee and Lessor shall execute such further writings as may be reasonably required to separately document any subordination, attornment and/or Non-Disturbance Agreement provided for herein.

31. Attorneys’ Fees . If any Party or Broker brings an action or proceeding involving the Premises whether founded in tort, contract or equity, or to declare rights hereunder, the Prevailing Party (as hereafter defined) in any such proceeding, action, or appeal thereon, shall be entitled to reasonable

 

 23 

   


attorneys’ fees. Such fees may be awarded in the same suit or recovered in a separate suit, whether or not such action or proceeding is pursued to decision or judgment. The term, “Prevailing Party” shall include, without limitation, a Party or Broker who substantially obtains or defeats the relief sought, as the case may be, whether by compromise, settlement, judgment, or the abandonment by the other Party or Broker of its claim or defense. The attorneys’ fees award shall not be computed in accordance with-any court fee schedule, but shall be such as to fully reimburse all attorneys fees reasonably incurred. In addition, Lessor shall be entitled to attorneys’ fees, costs and expenses incurred in the preparation and service of notices of Default and consultations in connection therewith, whether or not a legal action is subsequently commenced in connection with such Default or resulting Breach ($200 $500.00 is a reasonable minimum per occurrence for-such services and consultation).

32. Lessor’s Access; Showing Premises; Repairs . Lessor and Lessor’s agents shall have the right to enter the Premises at any time, in the case of an emergency, and otherwise at reasonable times after reasonable prior notice for the purpose of showing the same to prospective purchasers, lenders, or tenants, and making such alterations, repairs, improvements or additions to the Premises as Lessor may deem necessary or desirable and the erecting, using and maintaining of utilities, services, pipes and conduits through the Premises and/or other premises as long as there is no material adverse effect on Lessee’s use of the Premises. All such activities shall be without abatement of rent or liability to Lessee.

33. Auctions . Lessee shall not conduct, nor permit to be conducted, any auction upon the Premises without Lessor’s prior written consent. Lessor shall not be obligated to exercise any standard of reasonableness in determining whether to permit an auction.

34. Signs . Lessor may place on the Premises ordinary “For Sale” signs at any time and ordinary “For Lease” signs during the last 6 months of the term hereof.

35. Termination; Merger . Unless specifically stated otherwise in writing by Lessor, the voluntary or other surrender of this Lease by Lessee, the mutual termination or cancellation hereof, or a termination hereof by Lessor for Breach by Lessee, shall automatically terminate any sublease or lesser estate in the Premises; provided, however, that Lessor may elect to continue any one or all existing subtenancies. Lessor’s failure within 10 days following any such event to elect to the contrary by written notice to the holder of any such lesser interest, shall constitute Lessor’s election to have such event constitute the termination of such interest.

36. Consents . Except as otherwise provided herein, wherever in this Lease the consent of a Party is required to an act by or for the other Party, such consent shall not be unreasonably withheld, conditioned or delayed. Lessor’s actual reasonable costs and expenses (including but not limited to architects’, attorneys’, engineers’ and other consultants’ fees) incurred in the consideration of, or response to, a request by Lessee for any Lessor consent, including but not limited to consents to an assignment, a subletting or the presence or use of a Hazardous Substance, shall be paid by Lessee upon receipt of an invoice and supporting documentation therefor. Lessor’s consent to any act, assignment or subletting shall not constitute an acknowledgment that no Default or Breach by Lessee of this Lease exists, nor shall such consent be deemed a waiver of any then existing Default or Breach, except as may be otherwise specifically stated in writing by Lessor at the time of such consent. The failure to specify herein any particular condition to Lessor’s consent shall not preclude the imposition by Lessor at the time of consent of such further or other conditions as are then reasonable with reference to the particular matter for which consent is being given. In the event that either Party disagrees with any determination made by the other hereunder and reasonably requests the reasons for such determination, the determining party shall furnish its reasons in writing and in reasonable detail within 10 business days following such request.

37. Guarantor .

37.1 Execution . The Guarantors, if any, shall each execute a guaranty in the form similar to the most recently published by the AIR Commercial Real Estate Association.

37.2 Default . It shall constitute a Default of the Lessee if any Guarantor fails or refuses, upon request to provide: (a) evidence of the execution of the guaranty, including the authority of the party signing on Guarantor’s behalf to obligate Guarantor, and in the case of a corporate Guarantor, a certified copy of a resolution of its board of directors authorizing the making of such guaranty, (b) current financial statements, (c) an Estoppel Certificate, or (d) written confirmation that the guaranty is still in effect.

38. Quiet Possession . Subject to payment by Lessee of the Rent and performance of all of the covenants, conditions and provisions on Lessee’s part to be observed and performed under this Lease, Lessee shall have quiet possession and quiet enjoyment of the Premises during the term hereof.

39. Options . If Lessee is granted an Option, as defined below, then the following provisions shall apply.

39.1 Definition . “ Option ” shall mean: (a) the right to extend the term of or renew this Lease; or to extend or renew any lease that Lessee has on other property of Lessor; (b) the right of first refusal or first offer to tease either the Premises or other property of Lessor; (c) the right to purchase or the right of first refusal to purchase the Premises or other-property of lessor.

39.2 Options Personal To Original Lessee . Any Option granted to Lessee in this Lease is personal to the original Lessee, and cannot be assigned or exercised by anyone other than said original Lessee and only while the original Lessee is in full possession of the Premises and, if requested by Lessor, with Lessee certifying that Lessee has no intention of thereafter assigning or subletting.

39.3 Multiple Options . In the event that Lessee has any multiple Options to extend or renew this Lease, a later Option cannot be exercised unless the prior Options have been validly exercised.

39.4 Effect of Default on Options .

(a) Lessee shall have no right to exercise an Option: (i) during the period commencing with the giving of any notice of Default and continuing until said Default is cured, (ii) during the period of time any Rent is unpaid (without regard to whether notice thereof is given Lessee), (iii) during the time Lessee is in Breach of this Lease, or (iv) in the event that Lessee has been given 3 or more notices of separate Default, whether or not the Defaults are cured, during the 12 month period immediately preceding the exercise of the Option.

(b) The period of time within which an Option may be exercised shall not be extended or enlarged by reason of Lessee’s inability to exercise an Option because of the provisions of Paragraph 39.4(a).

(c) An Option shall terminate and be of no further force or effect, notwithstanding Lessee’s due and timely exercise of the Option, if, after such exercise and prior to the commencement of the extended term or completion of the purchase, (i) Lessee fails to pay Rent for a period of 30 days after such Rent becomes due (without any necessity of Lessor to give notice thereof), or (ii) if Lessee commits a Breach of this Lease.

 

 24 

   


40. Security Measures . Lessee hereby acknowledges that the Rent payable to Lessor hereunder does not include the cost of guard service or other security measures, and that Lessor shall have no obligation whatsoever to provide same. Lessee assumes all responsibility for the protection of the Premises, Lessee, its agents and invitees and their property from the acts of third parties. In the event, however, that Lessor should elect to provide security services, then the cost thereof shall be an Operating Expense. The Project Is not a full security property and Lessor does not guarantee or warrant the personal security or safety of Lessee or its invitees. However, any cautionary measures that Lessor takes (whether a Courtesy Patrol Service, gate, cameras or otherwise) which may presently exist or later be installed on the Property are neither a guarantee nor warranty against criminal acts of others on the Project or otherwise.

41. Reservations .

(a) Lessor reserves the right: (i) to grant, without the consent or joinder of Lessee, such easements, rights and dedications that Lessor deems necessary, (ii) to cause the recordation of parcel maps and restrictions, (iii) to create and/or install new utility raceways, so long as such easements, rights, dedications, maps, restrictions, and utility raceways do not unreasonably interfere with the use, access to, quiet enjoyment of or possession of the Premises by Lessee. Lessor may also: change the name, address or title of the Building or Project upon at least 90 days prior written notice; provide and install, at Lessee’s expense, Building standard graphics on the door of the Premises and such portions of the Common Areas as Lessor shall reasonably deem appropriate; grant to any lessee the exclusive right to conduct any business as long as such exclusive right does not conflict with any rights expressly given herein; and to place such signs, notices or displays as Lessor reasonably deems necessary or advisable upon the roof, exterior of the Building or the Project or on pole signs in the Common Areas. Lessee agrees to sign any documents reasonably requested by Lessor to effectuate such rights. The obstruction of Lessee’s view, air, or light by any structure erected in the vicinity of the Building, whether by Lessor or third parties, shall in no way affect this Lease or impose any liability upon Lessor.

(b) Lessor also reserves the right to move Lessee to other space of comparable size in the Building or Project. Lessor must provide at least 45 days prior written notice of such move, and the new space mast contain improvements of comparable quality to those contained within the Premises. Lessor shall pay the reasonable out of pocket costs that Lessee incurs with regard to such relocation, including the expenses of moving and necessary stationary revision costs. In no event, however, shall Lessor be required to pay an amount in excess of two months Base-Rent Lessee may not be relocated more than once during the term of this Lease.

(c) Lessee shall not: (i) use a representation (photographic or otherwise) of the Building or Project or their name(s) in connection with Lessee’s business; or (ii) suffer or permit anyone, except in emergency, to go upon the roof of the Building.

(d) Lessor reserves the right, exercisable with sixty (60) days notice, and without liability to Lessee, to change the name and address (The address of the Premises would ONLY be changed if required by the City or any other public agency requiring a change of address) of the Premises. Said sixty (60) day notice shall conclusively be deemed reasonable notice to Lessee.

 

 25 

   


(e) Lessor reserves the right to re-run Lessee’s credit at a later date if Lessee is in default and default is not cured within allowed cure period.

42. Performance Under Protest . If at any time a dispute shall arise as to any amount or sum of money to be paid by one Party to the other under the provisions hereof, the Party against whom the obligation to pay the money is asserted shall have the right to make payment “under protest” and such payment shall not be regarded as a voluntary payment and there shall survive the right on the part of said Party to institute suit for recovery of such sum. If it shall be adjudged that there was no legal obligation on the part of said Party to pay such sum or any part thereof, said Party shall be entitled to recover such sum or so much thereof as it was not legally required to pay. A Party who does not initiate suit for the recovery of sums paid “under protest” within 6 months shall be deemed to have waived its right to protest such payment.

43. Authority; Multiple Parties; Execution

(a) If either Party hereto is a corporation, trust, limited liability company, partnership, or similar entity, each individual executing this Lease on behalf of such entity represents and warrants that he or she is duly authorized to execute and deliver this Lease on its behalf. Each Party shall, within 30 days after request, deliver to the other Party satisfactory evidence of such authority.

(b) If this Lease is executed by more than one person or entity as “Lessee”, each such person or entity shall be jointly and severally liable hereunder. It is agreed that any one of the named Lessees shall be empowered to execute any amendment to this Lease, or other document ancillary thereto and bind all of the named Lessees, and Lessor may rely on the same as if all of the named Lessees had executed such document.

(c) This Lease may be executed by the Parties in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument.

44. Conflict . Any conflict between the printed provisions of this Lease and the typewritten or handwritten provisions shall be controlled by the typewritten or handwritten provisions.

45. Offer . Preparation of this Lease by either party or their agent and submission of same to the other Party shall not be deemed an offer to lease to the other Party. This Lease is not intended to be binding until executed and delivered by all Parties hereto.

46. Amendments . This Lease may be modified only in writing, signed by the Parties in interest at the time of the modification. As long as they do not materially change Lessee’s obligations hereunder, Lessee agrees to make such reasonable nonmonetary modifications to this Lease as may be reasonably required by a Lender in connection with the obtaining of normal financing or refinancing of the Premises.

47. Waiver of Jury Trial. THE PARTIES HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO TRIAL BY JURY to the extent provided by law, IN ANY ACTION OR PROCEEDING INVOLVING THE PROPERTY OR ARISING OUT OF THIS AGREEMENT.

48. Mediation and Arbitration of Disputes . An Addendum requiring the Mediation and/or the Arbitration of all disputes between the Parties and/or Brokers arising out of this Lease ¨ is þ is not attached to this Lease.

49. Americans with Disabilities Act . Since compliance with the Americans with Disabilities Act (ADA) is dependent upon Lessee’s specific use of the Premises, Lessor makes no warranty or representation as to whether or not the Premises comply with ADA or any similar legislation. In the event that Lessee’s use of the Premises requires modifications or additions to the Premises in order to be in ADA compliance, Lessee agrees to make any such necessary modifications and/or additions at Lessee’s expense.

50. NONDISCRIMINATION AND NONSEGREGATION COVENANT. Lessee herein covenants by and for himself or herself, his or her heirs, executors, administrators, assigns, and for all persons claiming under or through him or her. This Lease is made and accepted upon and subject to the following conditions.

That there shall be no discrimination against or segregation of any person or group of persons on account of race, color, creed, religion, sex, marital status, national origin or ancestry, in the Leasing, Subleasing, transferring, use, occupancy, tenure and enjoyment of the Premises herein Leased; nor shall Lessee himself, or any person claiming under or through him or her, establish or permit any such practice or practices of discrimination and/or segregation with reference to the selection, location, number, use and occupancy of Lessees, Tenants, Sublessees, Subtenants, Assignees and/or Vendees in the Premises herein Leased.

51. PROPOSITION 65 WARNING: The State of California requires that we warn you that the property contains chemicals known to the State of California to cause cancer and birth deects, and other reproductive harm. These chemicals may be contained in emissions and fumes from building materials, products and materials used to maintain the property, and emissions, fumes, and smoke from lessee and invitees activities, including but not limited to the use of motor vehicles, and tobacco products. These chemicals may include, but are not limited to, carbon monoxide, formaldehyde, tobacco smoke, unleaded gasoline, soots, tarsand mineral oils.

LESSOR AND LESSEE HAVE CAREFULLY READ AND REVIEWED THIS LEASE AND EACH TERM AND PROVISION CONTAINED HEREIN, AND BY THE EXECUTION OF THIS LEASE SHOW THEIR INFORMED AND VOLUNTARY CONSENT THERETO. THE PARTIES HEREBY AGREE THAT, AT THE TIME THIS LEASE IS EXECUTED, THE TERMS OF THIS LEASE ARE COMMERCIALLY REASONABLE AND EFFECTUATE THE INTENT AND PURPOSE OF LESSOR AND LESSEE WITH RESPECT TO THE PREMISES.

ATTENTION: NO REPRESENTATION OR RECOMMENDATION IS MADE BY THE AIR COMMERCIAL REAL ESTATE ASSOCIATION OR BY ANY BROKER AS TO THE LEGAL SUFFICIENCY, LEGAL EFFECT, OR TAX CONSEQUENCES OF THIS LEASE OR THE TRANSACTION TO WHICH IT RELATES. THE PARTIES ARE URGED TO:

1. SEEK ADVICE OF COUNSEL AS TO THE LEGAL AND TAX CONSEQUENCES OF THIS LEASE.

2. RETAIN APPROPRIATE CONSULTANTS TO REVIEW AND INVESTIGATE THE CONDITION OF THE PREMISES. SAID INVESTIGATION SHOULD INCLUDE BUT NOT BE LIMITED TO: THE POSSIBLE PRESENCE OF HAZARDOUS SUBSTANCES, THE ZONING AND SIZE OF THE PREMISES, THE STRUCTURAL INTEGRITY, THE CONDITION OF THE ROOF AND OPERATING SYSTEMS, COMPLIANCE WITH THE AMERICANS WITH DISABILITIES ACT AND THE SUITABILITY OF THE PREMISES FOR LESSEE’S INTENDED USE.

 

 26 

   


WARNING: IF THE PREMISES ARE LOCATED IN A STATE OTHER THAN CALIFORNIA, CERTAIN PROVISIONS OF THE LEASE MAY NEED TO BE REVISED TO COMPLY WITH THE LAWS OF THE STATE IN WHICH THE PREMISES ARE LOCATED.

The parties hereto have executed this Lease at the place and on the dates specified above their respective signatures.

   

 

   

   

   

   

   

   

   

   

   

Executed at: Calabasas, CA

   

   

   

Executed at: CALABASAS, CA

On: 5/24/13

   

   

   

On: 5-24-13

   

   

   

By LESSOR:

   

   

   

By LESSEE:

   

   

   

Calabasas/Sorrento Square, LLC, a Delaware

   

   

   

Immunocellular Therapeutics, LTD.

limited liability company By The Ezralow

   

   

   

   

      

Company, LLC, a Delaware limited liability company dba Mid

   

   

   

   

Valley Management Its Managing Agent

   

   

   

  By:

   

/s/ Andrew Gengos

      

   

   

   

   

   

   

  Name Printed:

   

Andrew Gengos

      

By:

   

/s/ Candace McCusker

      

   

   

   

Title:

   

President & CEO

      

Name Printed:

   

Candace McCusker

         

   

   

   

   

   

   

Title:

   

Authorized Agent

      

   

   

   

By:

   

/s/ David Fractor

      

   

   

   

   

   

   

  Name Printed:

   

David Fractor

      

   

 

 27 

   


   

 

   

   

   

   

   

   

   

   

By:

   

      

   

   

   

   

Title:

   

VP OF FINANCE

      

Name Printed:

   

   

      

   

   

   

Address:

   

   

      

Title:

   

   

      

   

   

   

      

   

Address:

   

23603 Park Sorrento, Suite 102

      

   

   

   

   

      

Calabasas, CA 91302

      

   

   

   

Telephone: (            )

   

   

      

      

   

   

   

   

Facsimile: (            )

   

   

      

Telephone:

   

(818) 222-7411

      

   

   

   

Federal ID No.

   

   

      

Facsimile:

   

(818) 222-7417

      

   

   

   

   

   

   

Federal ID No.

   

   

      

   

   

   

   

   

   

   

   

   

LESSOR’S BROKER:

   

   

   

LESSOR’S BROKER:

   

      

   

   

   

   

      

Attn:

   

   

   

   

   

Attn:

   

   

      

Address:

   

   

      

   

   

   

Address:

   

   

      

      

   

   

   

   

   

      

   

      

   

   

   

   

      

Telephone: (            )

   

   

      

   

   

   

Telephone:(            )

   

   

      

Facsimile: (            )

   

   

      

   

   

   

Facsimile: (            )

   

   

      

NOTICE: These forms are often modified to meet changing requirements of law and industry needs. Always write or call to make sure you are utilizing the most current form: AIR Commercial Real Estate Association, 800 W 6th Street, Suite 800, Los Angeles, CA 90017. Telephone No. (213) 687-8777. Fax No.: (213) 687-8616.

   

©Copyright 1999-By AIR Commercial Real Estate Association.

All rights reserved.

No part of these works may be reproduced in any form without permission in writing.

 

 28 

   


ADDENDUM I for STANDARD OFFICE LEASE

THIS ADDENDUM is attached to and integrated as a part of that certain Lease dated May 13, 2013 , by and between CALABASAS/SORRENTO SQUARE, LLC, a Delaware limited liability company, “Lessor” , and Immunocellular Thereapeutics, LTD., a Delaware corporation, “Lessee”, and constitutes additional Covenants, Conditions and Agreements contained herein, which Addendum shall prevail in the event of any conflict between the Covenants, Conditions and Agreements contained herein and those in said Lease.

CONDITION OF PREMISES and COMPLIANCE WITH LAWS SEE ITEMS 2.2 AND 2.3 OF LEASE AGREEMENT

1. Lessee shall complete and return the “Unit Inspection Checklist” within 30 days of the lease commencement. A blank “Unit Inspection Checklist” is attached with this Lease, included with your cover letter or is available from Lessor. Unless otherwise specified in the Lease, Lessor will have no obligation to make repairs; the Unit Inspection Checklist will be a benchmark documenting the condition of the Premises when Lessee took possession. If Lessee fails to complete and return the Unit Inspection Checklist, the Unit will be deemed to be in good condition and repair at the time that Lessee took possession. To the best of Lessor’s knowledge, the Premises, in its current configuration complies with ADA and/or the City of Calabasas.

HAZARDOUS SUBSTANCES DISCLOSURE STATEMENT

2. Prior to executing this Lease, Lessee has delivered to Lessor Lessee’s executed initial Hazardous Substances Disclosure Certificate (the “Initial HazMat Certificate”). Lessee covenants, represents and warrants to Lessor that the information contained in the Initial HazMat Certificate is true and correct and accurately describes in all respects the use(s) of Hazardous Substances which will be made and/or used on the Premises by Lessee. Notwithstanding anything to the contrary contained in the Lease, Lessee shall not have the right to use any Hazardous Substances at the Premises that are not described on the Initial HazMat Certificate or to increase the quantity of any Hazardous Material used at the Premises beyond the quantity described on the Initial HazMat Certificate. Upon the prior written request of Lessor, Lessee shall deliver to Lessor a new Hazardous Substances Disclosure Certificate (the “HazMat Certificate”) executed by Lessee and describing Lessee’s then-present use of Hazardous Substances on the Premises. The HazMat Certificates required hereunder shall be in the form attached hereto as Exhibit “D”.

FIXED RENTAL INCREASES SEE ITEM 1.5 OF LEASE AGREEMENT

3. The Base Rent shall be increased annually by Three Percent (3%) to the amounts set forth on the dates below:

 

09/1/14 = $ 8305.00 Per Month

 

08/1/15 = $ 8554.00 Per Month

ADDRESS FOR RENT PAYMENTS AND NOTICES SEE ITEMS 4.3 AND 23.1 OF LEASE

4. Lessee’s payments of rent and other amounts due, shall be considered to have been received by Lessor only when received by mail.

   

 

   

   

   

   

   

Rent VIA U.S. MAIL :

CALABASAS/SORRENTO SQUARE, LLC

c/o Mid Valley Management

P.O. Box 514779

Los Angeles, CA 90051-4779

   

Rent VIA EXPRESS MAIL :

CALABASAS/SORRENTO SQUARE, LLC

c/o Mid Valley Management

23622 Calabasas Road, Suite 200

Calabasas, CA 91302

   

LESSOR ADDRESS FOR NOTICES :

CALABASAS/SORRENTO SQUARE, LLC

c/o Mid Valley Management

23603 Park Sorrento, Suite 102

Calabasas, CA 91302

Or at such address as Lessor may from time to time hereafter designate by notice to Lessee.

Rental payments will not be accepted bv any of Lessor’s Leasing Offices .

 

RENT MAY ALSO BE PAID ONLINE: SEE OUR WEBSITE FOR INFORMATION ON HOW TO PAY ONLINE, midvalleymanagement.com

EXISTING FURNISHINGS IN SUITE

5. Lessor shall transfer title of the any furnishings currently in existence in the Premises to the Lessee for $1.00 in total consideration. Lessor and Lessee shall execute a Bill of Sale concurrently with the execution of the Lease. See Exhibit “E”.

EARLY ACCESS

6. Lessee shall have access to the Premises prior to the commencement date for the purpose of installing telecom cabling, free of any cost, as long as it does not interfere or delay with Lessor’s ability to substantially complete tenant improvements.

SUITE IMPROVEMENTS

7. Lessor, at Lessor’s sole cost and expense agrees to the following:

Lessor shall have Lessor’s General Contractor, Mike Smith Construction, prepare a scope of work and pricing plan for review based on Lessee’s proposed Renovation Plan ( Exhibit “C” ) dated May 7, 2013. Plan to be approved by Lessor and Lessee prior to the commencement of any work. Renovation Plan includes, but is not limited to:

 

Install new door/frame hardware to match existing and clear glass to sit on existing low wall;

 

Remove and patch existing wall plate;

 

Flush-mount 4- plex and data/telephone outlet

 

Remove light fixture

 

Provide new outlets as indicated on preliminary suite plan by Lessee

 

Replace PL center and cap with new PL with wood trim

 

Alter buzzer at entry door

 

New carpet, base and paint throughout to building standard. Lessee to make selections from Lessor’s samples.

Signatures on following page

 

 29 

   


   

Document Reference Date: Dated this 13th Day of May, 2013

   

 

   

   

   

   

   

   

   

   

   

AGREED AND ACCEPTED: “LESSOR”

CALABASAS/SORRENTO SQUARE, LLC,

A Delaware limited liability company, By The Ezralow Company, LLC, a Delaware limited liability company, dba Mid Valley Management, Its Managing Agent

   

   

   

AGREED AND ACCEPTED: “LESSEE”

Immunocellular Therapeutics, LTD., a Delaware corporation

   

   

   

   

   

   

By:

   

/s/ Andrew Gengos

      

By:

   

/s/ Candace McCusker

      

   

   

   

Title:

   

PRESIDENT & CEO

      

   

   

Candace McCusker

   

   

   

   

   

   

Its:

   

Authorized Agent

   

   

   

Date:

   

5/24/2013

      

   

   

   

   

   

Date:

   

5/24/13

      

   

   

   

By:

   

/s/ David Fractor

      

   

   

   

   

   

   

Title:

   

VP OF FINANCE

      

   

   

   

   

   

   

Date:

   

5-24-13

      

   

 

 30 

   


GENERAL RULES & REGULATIONS FOR COMMERCIAL OFFICE LEASE

KEYS

1. Lessor has the right to retain keys to the locks on the entry doors to the Premises and all interior doors at the Premises. Lessor requires Tenant to obtain all keys to door locks at the Premises from Lessor’s engineering staff or Lessor’s locksmith and to only use Lessor’s engineering staff or Lessor’s locksmith to change locks at the Premises. Lessee shall pay Lessor or its locksmith’s standard charge for all keys and other services obtained from Lessor’s engineering staff or locksmith.

Lessee shall return all keys, including mailbox keys, at the termination of its tenancy and shall be responsible for the cost of replacing any keys that are lost, and the cost to replace and re-key any locks that have been altered.

TENANT ALTERATIONS AND LESSEE’S CONTRACTORS SEE ITEM 7.3 (B) OF THE LEASE AGREEMENT

2 . Lessee shall not employ any service or contractor for services or work to be performed in the Premises except as approved by Lessor. Prior to the commencement of any work, Lessee’s contractor must provide Lessor with a copy of their valid contractor’s license and a *Certificate of Insurance which, at Lessor’s election, may require an additional insured endorsement naming Lessor and Mid Valley Management as Additional Insureds. The Limits of Liability on both General Liability and Worker’s Compensation must be a minimum of $1,000,000.00 each. FOR INSURANCE COMPANY REQUIREMENTS SEE ITEM 8.5 OF THE LEASE AGREEMENT.

HEATING AND AIR-CONDITIONING

3. Lessee shall not use any method of heating or air-conditioning other than that supplied or approved by Lessor.

HEAVY OBJECTS AND NOISE

4. Lessee shall not place anything in or around the Premises, Building or Business Complex that causes excessive vibration or floor loading. Business machines and/or mechanical equipment belonging to Lessee which cause noise or vibration that may be transmitted to the structure of the Building in which the Premises are located, or to any space therein, to such a degree as to be objectionable to Lessor or to any Tenants in the Building, shall be placed and maintained by Lessee, at Lessee’s expense, on vibration eliminators or other devices sufficient to eliminate noise or vibration. Arrangements must be made to move equipment during non-business hours. The persons employed to move such equipment in or out of the Building in which the Premises are located must be acceptable to Lessor, and carry satisfactory liability insurance to protect Lessor’s Property. Lessor will not be responsible for loss of or damage to any such equipment or other Property from any cause, and all damage caused to the Building in which the Premises are located by maintaining or moving such equipment or other Property shall be promptly repaired at the expense of the Lessee.

ROOF ACCESS

5. Neither Lessee, Lessee’s Agent, Contractors, Employees or invitees shall enter upon the roof of the Premises (except in the case of an emergency) for any purpose whatsoever without first receiving Lessor’s consent which shall not be unreasonably withheld.

5.1 If the Lessee, Lessee’s Agents, Contractors, Employees or invitees shall enter upon the roof of said Premises, whether with or without the consent of Lessor, then the Lessee specifically indemnifies and agrees to hold Lessor harmless from any and all claims, actions or causes of action resulting from injuries incurred to any of said individuals or any other Person or Property, caused by or as a result of their entering upon the roof of said Premises.

5.2 In the event that Lessor grants written permission to the Lessee or any of the persons set-forth above to have roof access, said consent shall be expressly on the condition that each time said Lessee or those persons designated by Lessee to enter upon the roof that they first execute a written Letter of Agreement provided by Lessor (a) expressly indemnifying and holding Lessor free and harmless from any and all damages caused by said individuals to the Leasehold Premises, (b) indemnifying Lessors from any personal injury damages caused in connection therewith,

5.3 Lessee’s Contractor shall provide Lessor with Certificates of Insurance with an additional insured endorsement and in accordance with Paragraph 2., above.

RIGHT TO CONTROL AND PREVENT ACCESS

6. Neither the Lessee, its Agents, employees, invitees or guests shall obstruct any sidewalks, passages, exits, entrances or stairways of the Premises. The passages, exits, entrances and stairways are not for the benefit of the general public other than for access and egress; and Lessor shall in all cases retain the right to control and prevent access thereto of all persons whose presence in the judgment of Lessor would be prejudicial to or interfere with the general welfare safety, character, reputation and interest of the Project and its Tenants, provided that nothing contained herein shall be construed to prevent such access to persons with whom any Tenant normally deals in the ordinary course of its business (unless such persons are engaged in acts adverse to the Project and its Tenants, and/or illegal activities).

DELIVERIES

7. Furniture, significant freight and equipment shall be moved into or out of the building only with Lessor’s knowledge and consent and subject to such reasonable limitations, techniques and timing, as may be designated by Lessor. Lessee shall be responsible for any damage to the Office Building Project arising from any such activity.

WORK AREAS

8. All work must be confined within the Leased Premises.

PROTECTION OF PREMISES

9. Lessee assumes any and all responsibility for protecting its Premises from theft, robbery, vandalism and pilferage, which includes keeping doors locked and other means of entry to the Premises closed. Lessor strongly suggests that Lessee re-key the suite upon taking possession, which cost is at Lessee’s sole cost and expense. If Lessee elects to re-key, the suite must be keyed to Lessor’s master key system (if applicable) using Lessor’s vendor. All doors opening to public corridors shall be kept closed at all times except for normal ingress and egress to the Premises.

 

 31 

   


LESSEE’S ALARM SYSTEM

10. If Lessee desires to install an alarm system, all equipment must be installed inside Lessee’s unit so as not to be visible and shall otherwise comply to the standards set by Lessor for all alarm systems contained in the Business Complex. Lessor must approve all alarm systems. When equipment is removed, Lessee must restore the Premises to its original condition. Only one alarm sticker per unit placed on Lessee’s door is permitted.

RUBBISH REMOVAL

11. No rubbish, containers or debris are to be left outside of Lessee’s unit. Lessee shall store all its trash and garbage within the interior of the Premises. No material shall be placed in the trash receptacles if such material is of such nature that it may not be disposed of in the ordinary and customary manner of removing and disposing of trash in the vicinity of the Project without violation of any law or ordinance governing such disposal. If Lessor shall determine that the trash generated by or at the Premises, in Lessor’s reasonable estimation, shall be excessive, Lessee shall pay to Lessor, upon demand, such additional charges as Lessor shall equitably impose for such excess trash removal.

EXTERIOR DAMAGE BY LESSEE

12. During the Lease Term, and at expiration (or early termination) of this Lease, if Lessee dirties, soils or damages the exterior of Lessor’s Business Complex, Lessee will be responsible for the repair of this damage.

 

 32 

   


   

SIGNAGE

13. Lessee shall not place or permit to be placed any projecting sign, marquee, decoration or awning on said Premises without the written consent of Lessor; which consent shall not be unreasonably withheld. All signs which are permitted shall be conforming to the signage criteria established from time to time by Lessor for the Premises, Building and the Business Complex, as applicable, and shall be maintained by Lessee at its sole expense, including, but not limited to sign fabrication, maintenance, operation (including any required utilities), repair and removal. Lessee, upon the request of Lessor, shall immediately remove any sign or decoration which Lessee has placed, or permitted to be placed in, on or about the Premises of which, in the sole option and discretion of Lessor, is objectionable or offensive; and if Lessee fails to do so, Lessor may enter upon said Premises and remove said item and charge the cost thereof to Lessee. Lessee shall not place or permit to be placed upon any side wall, rear wall, window or roof; any sign, advertisement or notice without the written consent of Lessor, which consent shall only be given where the proposed sign, advertisement or notice complies with the specifications of size, shape, design, color or material established by Lessor and which are applicable to all Tenants of Lessor’s Business Complex. See Addenendum I, Item 4., for additional information.

DIRECTORY

14. Directory signage, which is the sole cost and expense of Lessee, is exclusively for the display of the names and locations of Tenants only. Lessor reserves the right to exclude any other names on said directory.

WINDOWS AND WINDOW COVERINGS

15. Lessee shall not tint windows, nor place any non-standard window coverings upon the Leased Premises (e.g. curtains, draperies, blinds, etc.) without Lessor’s written consent.

CANVASSING AND SOLICITATION

16. Canvassing, soliciting and distribution of handbills or other written material and peddling in the Project is prohibited; each Tenant shall cooperate to prevent same.

FOUL, NOXIOUS GAS OR SUBSTANCE

17. Lessee shall not use, keep, or permit to be used or kept, any foul or noxious gas or substance in or on the Premises; or permit or allow the Premises to be occupied or used in a manner which by reason of any odor is offensive or objectionable to Lessor, in its sole and exclusive judgment, or to other tenants or occupants of the Building.

ANIMALS

18. Lessee shall not bring into or keep in or about the Premises any birds or animals (except service animals for the disabled.)

UNDER THE INFLUENCE

19. Lessor reserves the right to exclude or expel from the Premises any person who, in Lessor’s judgment, is intoxicated or under the influence of liquor, drugs or other abusive substances, or who is otherwise in violation of any Rules and Regulations of the Project.

CHANGES IN RULES AND REGULATIONS

20. Lessor reserves the right by written notice to Lessee to rescind, alter or waive any Rule or Regulation prescribed for Lessor’s Business Complex at any time when, in Lessor’s judgment, it is necessary, desirable, proper and in the best interest of Lessor’s Business Complex and its Tenants. Lessee agrees to be bound by any changes, revisions or modifications.

WAIVER OF RULES AND REGULATIONS

21. Lessor, in its sole discretion reserves the right to waive any one of these rules or regulations, and/or as to any particular Lessee, and any such waiver shall not constitute a waiver of any other rule or regulation or any subsequent application thereof to such Lessee. Lessor will have no liability if other Complex tenants or guests fail to comply with rules or regulations, applicable law, or that party’s lease.

ALTERNATIVE TELEPHONE OR TELECOMMUNICATIONS PROVIDER:

22. A. Lessor Consent Required. In the event that Lessee wishes to utilize the services of a telephone or telecommunications provider whose equipment is not servicing the Building as of the date of Lessee’s execution of this Lease (“Provider”), no such Provider shall be permitted to install its lines or other equipment within the Building without first securing the prior written consent of Lessor, which consent shall not be unreasonably withheld. At Lessor’s discretion, Lessee may be presented with a Letter of Agreement outlining the Conditions of Consent prior to work being done, and any additional requirements by Lessor

         B. Defacement of Premises: Lessor shall have the right to approve where and how telephone wires are to be introduced to the Premises. No boring or cutting for wires shall be allowed without the consent of Lessor. The location of telephone call boxes and other office equipment affixed to the Premises shall be subject to the approval of Lessor. Lessee shall not mark, drive nails or screws, or drill into the partitions, woodwork or plaster contained in the Premises or in any way deface the Premises or any part thereof without Lessor’s prior written consent. Lessee shall not install any radio or television antenna, satellite dish, loudspeaker or other device on the roof or exterior walls of the Project. Lessee shall not interfere with broadcasting or reception from or in the Project or elsewhere.

C. The replacement or repair of any ceiling tiles, damaged T-bar or existing wiring during Lessee’s installation of phone or computer cabling, shall be borne by Lessee, in addition to any damage to Lessor’s common areas.

UTILITIES AND SERVICES

23. Janitor service shall include ordinary dusting and cleaning by the janitor assigned to such work and shall not include cleaning of carpets or rugs, or moving of furniture and other special services, except normal vacuuming. Window cleaning shall be done only by Lessor at reasonable intervals and as Lessor deems necessary. Janitorial services are currently scheduled Monday through Thursday and Saturdays.

 

 33 

   


No cooking shall be done or permitted on the Premises. Notwithstanding the foregoing, Underwriter’s Laboratory approved equipment and microwave ovens may be used in the Premises for heating food and brewing coffee, tea and similar beverages for employees and visitors of Lessee, provided that such use is in accordance with all applicable federal, state and city laws, codes, ordinances, rules and regulations; and provided further that such cooking does not result in odors escaping from the Premises.

If use of the aforementioned appliances places an excessive load on the electrical circuitry of the Premises causing the breaker(s) to trip, it will be Lessee’s responsibility to contact Lessor or Lessor’s vendor to re-set breaker and all costs related thereto will be charged back to Lessee. If Lessor’s vendor determines that additional electrical is necessary to effectively operate this equipment, that cost will be borne by Lessee.

HOURS OF SERVICE (HVAC and Utilities)

24. The hours of operation are referenced in Paragraph 1.12 of the Lease Agreement. Lessee acknowledges that there will be no air circulation or temperature control within the Premises when the HVAC i s not operating and, consequently, during such times the Premises may not be suitable for human occupation or for the operation of computers and other heat sensitive equipment. If Lessee requires after hours utilities and services, Lessee shall be subject to (a) payment by Lessee of Lessor’s vendor service charge to adjust the time clock, if necessary, and (b) the payment by Lessee of Lessor’s standard charge, as determined by Lessor from time to time, in Lessor’s sole discretion, for after hours HVAC and (c) Lessee providing to Lessor at least one (1) business day’s advance written notice of Lessee’s need for after hours HVAC. As of the date of this Lease, and subject to future increases, the standard charge for after hours HVAC is Twenty- Five Dollars ($25.00) per hour, per zone. The charges for all after hours HVAC are payable on demand. Notwithstanding, Lessee shall have access and use of the Premises 24/7.

SMOKING

25. Lessee shall not suffer or permit smoking or carrying of lighted cigars or cigarettes in accordance with City of Calabasas Ordinance 2006-217. Smoking is permitted only in area designated by City of Calabasas as shown on Exhibit “A”.

 

 34 

   


VENDING MACHINES

26. Lessee shall not install, maintain or operate any vending machines upon the Premises without Lessor’s written consent.

SAFETY and COMPLIANCE

27. Lessee shall comply with all safety, fire protection and evacuation regulations established by Lessor or any applicable governmental agency.

PARKING RULES AND REGULATIONS

PERMITTED AND PROHIBITED PARKING

1. Parking is permitted in designated striped areas only. All other Vehicles not parked in such areas are subject to being towed away at Lessee’s expense (22658 CVC). Parking is prohibited:

 

(a)

in areas not striped for parking;

 

(b)

in aisles;

 

(c)

where “No Parking” signs are posted;

 

(d)

where “Handicap” signs are posted, unless Handicap I.D. is posted in or on vehicle;

 

(e)

on ramps;

 

(f)

in fire lanes, which must not be blocked;

 

(g)

in specifically assigned and reserved spaces to others than Lessee; and

 

(h)

in such other areas as may be designated by Lessor, its Agents, Lessee or Licensee.

COMMON AREA PARKING

2. Lessee acknowledges that the parking spaces as specified in Paragraph 1.2(b) of the Lease will not necessarily be located in close proximity to Lessee’s Premises or each other, if more than one space is involved. Lessee agrees not to overburden the parking facilities and agrees to cooperate with Lessor and other Tenants in the use of parking facilities. At no time may Lessee’s number of parking spaces exceed the number referenced in Paragraph 1.2(b) of the Lease Agreement without express written permission from Lessor. Lessee hereby agrees not to occupy or permit its FulI-Time or Part-Time Employees to occupy more than the number of spaces specified in 1.2(b) of the Lease Agreement.

OVERNIGHT STORAGE OF VEHICLES OR TRAILERS

3. There will be no overnight storage of vehicles or trailers in the parking lot. Vehicles used and moved on a daily basis are exempt. There will be no storage of wrecked or damaged vehicles at any time.

DIRECTIONAL SIGNS AND ARROWS

4. All directional signs and arrows must be observed.

SPEED LIMIT

5. The speed limit will be a reasonable speed.

RESPONSIBILITY FOR LOCKED VEHICLES AND DAMAGES

6. Unless otherwise instructed, every person is requested to park and lock his/her own vehicle. All responsibility for damage to vehicles to be repaired is assumed by authorized users. Lessee shall repair or cause to be repaired at its sole cost and expense any and all damage to the Project Parking Facility or any part thereof caused by Lessee, its authorized users, invitees or guests, or resulting from vehicles of each of them. Lessee specifically waives any claims against Lessor arising out of damage to said vehicles, injury to persons or loss of property, all of which are risks assumed by the party using the parking area and facilities.

PROHIBITED USE

7. The maintenance, washing, waxing or cleaning of vehicles in the Common Areas or the subterranean parking structure is prohibited. Lessor reserves the right to contract with an auto detailing service.

Lessee may not park any vehicle in any of Lessor’s parking areas that creates safety or health issues or can cause property damage. Any vehicle found to be leaking any fluids (i.e., motor oil; transmission fluid), must park their vehicle off the Premises. Lessee shall be responsible for the cost to repair any damages to Lessor’s parking lot caused by said vehicle.

LESSEE/EMPLOYEE IDENTIFICATION

8. Upon move in, Lessee shall provide Lessor with a list which includes the name of each person using the parking facilities based on Lessee’s parking rights under this Lease and the license plate number of the vehicle being used by that person. Lessee shall provide Lessor with an updated list within five (5) days after any part of the list becomes inaccurate so that those persons authorized to use Lessor’s parking facilities will remain on the list of authorized users.

PARKING STICKERS/IDENTIFICATION DEVICES

9. Parking stickers or identification devices shall be the property of Lessor and be returned to Lessor by the holder upon termination of the holder’s parking privileges. Lessee will pay such replacement charge as is reasonably established by Lessor for the loss of such devices. Loss or theft of parking identification stickers or devices from automobiles must be reported to the parking operator immediately. Lessee, it’s employees and authorized users are required to display identification devices in their vehicles.

KEY CARDS

10. If Lessee holds subterranean parking spaces, upon assignment of parking, Lessee will be provided with the applicable number of Key Cards for operation of the gate entry system. Lessee agrees to pay to Lessor $ 25.00 for each replacement of lost or *damaged Key Cards for the entrance to the garage. * Other than normal wear and tear.

 

 35 

   


COMPLIANCE WITH PARKING RULES & REGULATIONS

11. Lessor reserves the right to refuse the use of Lessor’s parking facilities and/or the sale of monthly identification devices to any person or entity that willfully refuses to comply with the applicable rules, regulations, laws and/or agreements, which shall include Lessee, Lessee’s employees, visitors and/or invitees. It is Lessee’s responsibility to see that all of its employees, agents and invitees comply with the rules and regulations.

LESSOR MAY CHARGE LESSEE

12. In addition to all of Lessor’s right and remedies available under the Lease, or at law or in equity, if any vehicle owned or operated by Lessee, its employees, agents, contractors or subtenants, shall at any time be parked in any of the prohibited areas, Lessor shall have the right to charge Lessee as Additional Rent due upon demand *$10.00 for each vehicle for each day, or any part thereof, such vehicle is so parked. * SUBJECT TO INCREASE

ATTENDANT PARKING

13. Lessor in its sole discretion reserves the right to contract with a Parking Attendant Service. The parking operator, or his employees or agents, shall be authorized to move cars to facilitate parking, or direct tenants and visitors to the appropriate parking areas. Lessee, its employees, invitees may not double park or block other vehicles. Failure to leave a key with the parking attendant when no

 

 36 

   


space is available shall be cause for termination of the right to use Lessor’s parking facilities. Lessee agrees that all responsibility for damage to cars or the theft of or from cars is assumed by the driver, and further agrees that Lessee will hold Lessor harmless for any such damages or theft.

SUBTERRANEAN PARKING STRUCTURE

USE OF SUBTERRANEAN FACILITY

14. During the term of the Lease and subject to the availability and the rules and regulations as modified by Lessor from time to time, Lessee may lease, non-reserved or assigned parking spaces in Lessor’s subterranean parking structure located at 23622 Calabasas Road, at the monthly rate applicable for parking as set by Lessor, and referenced below in Item 19. Lessor may, in its sole discretion, and upon availability, assign parking spaces to Lessee and designate the location of any assigned spaces. For the purposes of this Lease, a “parking space” refers to the space in which one (1) motor vehicle is intended to park (e.g., a tandem parking stall includes two single parking spaces front to back). If Lessee commits or allows in the parking facility any of the activities prohibited by the Lease or Rules, then Lessor shall have the right, without notice, in addition to such other rights and remedies it may have, to revoke any assigned parking space, remove or tow away the vehicle involved and charge the cost to Lessee, which cost shall be immediately payable by Lessee upon demand by Lessor.

GATE CLEARANCE and DAMAGES

15. Lessor’s overhead gate has a clearance of 6’6”. Lessor will not be held responsible for Lessee’s inappropriate use of gate entry nor for oversized vehicles with or without roof racks that attempt entry. Lessee shall pay for any damages to Lessor’s Gate caused by inappropriate use of gate entry.

Lessor shall not be responsible for any damage or injury to any vehicles of Lessees, Lessee’s employees, invitees, licensees, or vendors due to malfunction or non operation of the subterranean garage gate. It is further understood and agreed by Lessee that the garage gate is not for security purposes. Lessee is expected to use caution and reasonable judgment at all times with respect to the parking of all vehicles.

GATE—HOURS OF OPERATION

16. Lessor’s subterranean parking structure is accessible by Key Card. At certain times, as set by Lessor at Lessor’s discretion, the gate may be open. During these hours, no Key Card is required. When Key Cards are necessary, Lessee is to enter garage one vehicle at a time. Following another vehicle through the gate may cause damage to Lessee’s vehicle. Incoming vehicles have the right of way.

CHANGES TO PARKING RULES and REGULATIONS

17. Lessor reserves the right to modify these rules or adopt such other reasonable and non-discriminatory rules and regulations as it may deem necessary for the proper operation of the parking areas.

PARKING CHARGES (If Applicable)

18. In accordance with the Lease Agreement, a portion of Lessee’s allotted parking may be subterranean parking, which is subject to availability. The current monthly charges are listed below:

Lessee shall be entitled to a maximum of Eleven (11) Parking Spaces which shall be distributed among surface spaces in the common area and the subterranean parking structure. At no time shall Lessee’s number of parking spaces exceed eleven (11).

(a) Subterranean Garage: Going forward and subject to availability, the initial monthly parking rate per single, un-reserved parking space is $60.00 per month , and $125.00 per month for each assigned parking space (subterranean garage) for the initial term of the lease.

a.1 As Lessee’s need for unreserved subterranean parking spaces increases, Lessor shall guarantee a minimum of eight (8) and a maximum of Eleven (11) unreserved parking spaces at the rate of $60.00 per space for the initial term of this lease starting with the request for a fifth (5 th ) parking space.

a.2 Lessee agrees that as Lessee’s subterranean parking spaces increase, the number of surface parking spaces will decrease accordingly. At no time shall Lessee’s total number of parking spaces exceed eleven (11).

(b) Surface Parking: Lessor agrees that unassigned and visitor surface parking is $0.00 through the initial lease term.

(c) Calabasas Inn: Subject to availability, the cost for permitted, unassigned parking at the Calabasas Inn shall be $40.00/Mo.

(d) Visitor Parking: Validation, if established, will be permissible only by such method as Lessor and/or Lessor’s representatives may establish at rates generally applicable to visitor parking.

   

 

*

Monthly parking fees, if any, shall be payable in advance prior to the first day of each calendar month.

19. PARKING ASSOCIATED WITH THIS LEASE

Total Number of Parking Spaces Allowed Per Lease: 11

   

 

   

   

   

   

   

   

   

   

   

   

   

      

7

   

   

      

Surface Spaces, Unassigned (Calabasas Square) $0.00 Per Month for initial lease term

   

   

      

4

   

   

      

Subterranean, Unassigned @* $0.00 Per Month *See 18 a.1 above

 

 37 

   


LOGO

 

 38 

   


LOGO

 

 39 

   


LOGO

 

 40 

   


LOGO    

 

 41 

   


   

B. Is your industrial wastewater treated before discharge? Yes              No             

     If yes, what type of treatment is being conducted?

¨    Neutralization

¨    Metal hydroxide formation

¨    Closed-loop treatment

¨    Cyanide destruct

¨    HF treatment

¨    other

SUBSURFACE CONTAINMENT OF HAZARDOUS MATERIALS/WASTES

A. Are buried tanks/sumps being used for any of the following:

¨    hazardous waste storage

¨    chemical storage

¨    gasoline/diesel fuel storage

¨    waste treatment

¨    wastewater neutralization

¨    industrial wastewater treatment

¨    none of the above

B. If buried tanks are located onsite, indicate their construction

¨    steel     ¨    fiberglass      ¨    concrete      ¨    inside open vault      ¨    double walled

C. Are hazardous materials or untreated industrial wastewater transported via buried piping to tanks, process areas or treatment areas? Yes              No             

D. Do you have wet floors in your process areas? Yes              No             

If yes, name processes:                                                                                                                             

E. Are abandoned underground tanks or sumps located on the property? Yes              No             

HAZARDOUS MATERIALS SPILLS

A. Have hazardous materials ever spilled to:

¨    the sewer

¨    the storm drain

¨    onto the property

¨    no spills have occurred

B. Have you experienced any leaking underground tanks or sumps? Yes              No             

C. If spills have occurred, were they reported? Yes              No             

Check which of the government agencies that you contacted regarding the spill(s):

¨    Department of Health Services

¨    Department of Fish and Game

¨    Environmental Protection Agency

¨    Regional Water Quality Control Board

¨    Fire Department

D. Have you been contacted by a government agency regarding soil or groundwater contamination on your site? Yes              No             

     Do you have any exploratory wells onsite? Yes              No             

     If yes, indicate the following:

Number of wells                 Approximate depth of wells:                 Well diameters:                     

PLEASE ATTACH ENVIRONMENTAL REGULATORY PERMITS, AGENCY REPORTS THAT APPLY TO YOUR OPERATION AND HAZARDOUS WASTE MANIFESTS.

Check off those enclosed:

¨    Hazardous Materials Inventory Statement, HMIS

¨    Hazardous Materials Management Plan, HMMP

¨    Department of Health Services, Generatory Inspection Report

¨    Underground Tank Registrations

¨    Industrial Wastewater Discharge Permit

¨    Hazardous Waste Manifest

   

 

   

   

   

   

   

Signature:                                                                                                                                            

      

   

 

 42 

   


   

 

 

      

Name Written:

      

   

   

   

   

Title:

      

                                                  Phone:                                      

      

   

   

   

Date:                                                                  

      

   

Exhibit “D” – HazMat

Updated: 2012

 

 43 

   


   

BILL of SALE for EXISTING FURNISHINGS

   

 

   

   

   

Lessee:

      

Immunocellular Therapeutics, LTD., a Delaware corporation

   

   

Premises:

      

23622 Calabasas Road, Suite 300, Calabasas, CA 91302

Lessor shall transfer title of all of the furnishing currently in existence in the Premises at the time of lease execution for $1.00 in total consideration.

It shall be the responsibility of Lessee, at Lesse’s cost, to dispose of any furnishings not required by Lessee.

Document Reference Date: May 13, 2013

   

 

   

   

   

AGREED and ACCEPTED: “LESSEE”

   

Immunocellular Therapeutics, LTD.,

a Delaware corporation

   

By:

   

/s/ Andrew Gengos

      

   

   

Its:

   

President & CEO

      

Date of Signing:

   

5/24/2013

      

   

 

LOGO

BILL of SALE for EXISTING FURNISHINGS

EXHIBIT “E”

   

 

 44 

   


   

RENT CONCESSION AGREEMENT

THIS DOCUMENT shall set forth the agreement of Calabasas/Sorrento Square, a Delaware limited liability company “Lessor”, and Immunocellular Therapeutics, LTD. , a Delaware corporation , “Lessee”, concerning the Rent Abatement offered to Lessee in connection with that certain Lease dated May 13, 2013, by and between Lessor and Lessee for the Premises located at: 23622 Calabasas, Suite 200, Calabasas, CA 91302 .

AS MATERIAL CONSIDERATION for the Rent Concession set forth herein is Lessee’s agreement to lease the Premises on all terms and provisions of the Lease for the entire Lease term. Lessee acknowledges that the Free Rent as set forth below (herein called “Rent Concession”) is a concession given to Lessee for leasing the Premises for a term stated in the Lease Agreement.

A. ABATEMENT MONTHS: A portion of the Base Rent shall be abated in accordance with the following:

 

August, 2013     = equal to One (1) Month’s rent

 

September, 2013 = equal to One (1) Month’s rent

B. ADDITIONAL RENT: Notwithstanding the foregoing, Lessee shall pay all Additional Rent and other costs and expenses due by Lessee under the Lease accruing during the Abatement Months.

c. CONDITIONAL RENT ABATEMENT: The Rent Abatement is conditioned upon Lessee’s not having committed an Event of Default under this Lease.

D. EVENT OF DEFAULT: If Lessee commits an Event of Default, that is not cured within the time period indicated, then

I. Lessee shall immediately pay to Lessor upon demand a sum equal to the total amount of Rent Abatement which has been used by Lessee as of the date of the occurrence of such Event of Default. i

II. All of the Rent Abatement which has not been used by Lessee as of the date of the occurrence of such Event of Default shall thereby automatically terminate and become null and void, and Lessee shall thereafter pay all Rent when due under this Lease, without regard to the rental abatement provisions of this Lease.

THIS DOCUMENT shall not be deemed binding upon Lessor unless and until it is executed by Lessor and a copy is delivered to Lessee.

Dated this 13th day of May, 2013

   

 

   

   

   

   

   

   

   

“LESSOR”

   

“LESSEE”

   

   

Calabasas/Sorrento Square,

A DELAWARE LIMITED LIABILITY COMPANY, BY THE EZRALOW COMPANY, LLC A DELAWARE LIMITED LIABILITY

   

Immunocellular Therapeutics, LTD.,

A DELAWARE CORPORATION

COMPANY, DBA MID VALLEY MANAGEMENT,

   

By:

   

/s/ Andrew Gengos

      

ITS MANAGING AGENT

   

   

   

   

   

   

   

   

By:

   

/s/ Candace McCusker

      

   

Title:

   

PRESIDENT & CEO

      

   

   

Candace McCusker

   

   

   

   

   

   

Authorized Agent

   

Date:

   

5/24/2013

      

   

   

   

   

Date:

   

5/24/13

      

   

By:

   

/s/ David Fractor

      

   

   

   

   

   

   

   

   

Title:

   

VP OF FINANCE

      

   

   

   

   

   

   

   

   

Date:

   

5-24-13

      

Rent Concession Agreement

      

 

EXAMPLE : IF LESSEE HAS A TWO YEAR TERM AND IF LESSEE DEFAULTS IN THE 12 TH MONTH OF THE LEASE TERM. 12 MONTHS REMAINING ON LEASE TERM. LESSEE TO REPAY FOR MONTHS 13 THROUGH 24@$83.33 PER MONTH, OR $1,000.

5300 Rent Concession

Updated: 5/13/13

 

 45 

   


OPTION TO RENEW

Lessor grants to Lessee the option to extend the term of this Lease for One (1) Three (3) Year term commencing when the prior term expires (herein called “option term”) provided written notice is delivered to Lessor no less than Six (6) Months and no more than Nine (9) Months prior to the date that the option period would commence, time being of the essence. If proper notification of the exercise of the option is not given and/or received, such option shall automatically expire. The terms and conditions of this Lease shall remain in full force and effect during the option term, except that:

1. The monthly base rent for the option term shall be equal to the then fair-market rent and concessions for the building (“market rate”) . However, in no event will the monthly rent during the option term be less than the monthly rent for the last month of the initial Lease term or any extensions thereto.

2. If the option term is greater than one (1) year, the rent for the first year of the option term shall be at market rate; thereafter, on each yearly anniversary of the option term, the rent shall be increased by Three ( 3 %).

3. Other than as provided in the Lease, Lessee shall accept the Premises “as is” and “with all faults” and Lessor has no obligation to improve same in any way.

4. In the event that Lessee has more than one option, it may only be exercised consecutively. This option to extend is personal to the original Lessee and is not transferable or assignable in any manner whatsoever.

5. Lessee shall have no other right to extend the term beyond the option term.

6. That in the event Lessor has prepared a new or revised Lease Agreement covering the subject business or industrial complex, then, in that event, Lessee shall review and negotiate in good faith, execute a new Lease Agreement for the extended term and said new Lease Agreement shall be applicable and operative during the option term.

7. If Lessee is in default on the date of giving the option notice or at any time prior to the commencement of the renewal term, beyond any applicable cure period, the option notice shall be totally ineffective and this Lease shall expire at the end of the initial term.

The parties hereto have executed this Option to Renew on the date of signing set forth below:

DOCUMENT REFERENCE DATE: MAY 13, 2013 (FOR REFERENCE PURPOSES ONLY)

   

 

   

   

   

   

   

   

   

   

   

LESSOR:

   

   

   

LESSEE:

Calabasas/Sorrento Square, LLC

a Delaware limited liability company

   

   

   

Immunocellular Therapeutics, LTD.,

a Delaware corporation

      

By The Ezralow Company, LLC,

a Delaware limited liability company,

   

   

   

BY:

   

/s/ Andrew Gengos

      

dba Mid Valley Management, Its Managing Agent

   

   

   

DATE OF SIGNING:

   

5/24/2013

      

   

   

   

   

   

BY:

   

/s/ Candace McCusker

      

   

   

   

   

   

   

   

   

Candace McCusker, Authorized Agent

   

   

   

BY:

   

/s/ David Fractor

      

DATE:

   

5/24/13

      

   

   

   

DATE OF SIGNING:

   

5-24-13

      

OPTION TO RENEW

       

 

 46 

   


   

Exhibit 10.2

 

LOGO

MASTER SERVICES AGREEMENT

MASTER SERVICES AGREEMENT

This Master Services Agreement (“MSA”) is made by and between Averion International Corp. (“Averion”), with an address at 225 Turnpike Road, Southborough, MA 01772 and ImmunoCellular Therapeutics, Ltd. (“Client”), with an address at 21900 Burbank Blvd, 3rd Floor, Woodland Hills, CA 91367. The parties agree that this MSA shall govern any and all work to be completed by Averion for the Client.

Governance

As a “master” form of contract, this MSA allows Averion to work on one or more projects without having to re-negotiate the basic terms and conditions contained herein. This MSA will cover work assignments as well as consulting activities without formal work assignments.

Client shall engage Averion to provide and Averion shall provide consulting services as directed by the Client or as specified in mutually agreed upon written Work Assignments as well as any mutually agreed upon written modifications (Amendment) to a Work Assignment. Each such Work Assignment and Amendment are governed by the terms and conditions of this MSA; provided, however, that in the event of a conflict between this MSA and a specific Work Assignment/amendment, the Work Assignment/Amendment shall control.

If Client wants to change a specific Work Assignment/amendment or to obtain additional services not identified in a Work Assignment, the Client must advise Averion and submit written specifications to Averion. Averion will then supply the Client with a written Change Order for the additional services. Upon written acceptance of the Change Order by the Client, these services will be performed subject to the terms of this MSA.

In the event the Food, Drug and Cosmetic Act, or any rule or regulation governing any Work Assignment, including without limitation any Good Clinical Practice regulation, is amended, revised or revoked during the term of any Work Assignment, the parties shall discuss the effect of such change on the Work Assignment. Any changes that Client determines to implement shall be handled as a Change Order, as above.

Client remains the sponsor of all studies and has not transferred any obligations to Averion pursuant to 21 CFR 312.52 unless specified in the Work Assignment. In any such instances, the obligations of Averion will be mutually agreed upon by Client and Averion in writing. Client will retain control of the relationship with the FDA unless specified in the Work Assignment.

Understanding

Both parties agree that this MSA supersedes all prior proposals, letters, discussions, negotiations, and agreements of any nature, excluding any prior Confidentiality Agreement between the parties, which shall be replaced by this MSA on the effective date of this MSA. This MSA may be amended only in a writing signed by both the Client and Averion.

Notice and Opportunity to Cure

If one party believes the other has materially failed to perform as provided in this MSA or under any Work Assignment, it shall so notify the other in writing, stating in reasonable detail the nature of the deficiency. Within fifteen (15) business days, the breaching party shall respond in writing with a plan to cure which will specify the agreed upon time to effect a cure, which shall be approved by the non-breaching party, approval shall not be unreasonably withheld. No action arising hereunder may be instituted after one year from when the non-breaching party learns of, or should reasonably be expected to have learned of, the full facts upon which action would be based.

   

               

 

   

Page  1 

   


 

LOGO

MASTER SERVICES AGREEMENT

Proposals

(a) Averion may submit to Client a written Work Assignment/Change Order proposal specifying objectives, tasks, assumptions, delivery, and estimated costs, as a proposed Work Assignment/Change Order. Subject to the overall limit that has been agreed to by Averion and Client on the amount of fees that may be charged by Averion, all work done by Averion and proposed to Client will be calculated on a fee for service basis with the base rates and estimated completion times specified in each Work Assignment/Change Order. If Client is not satisfied with the written Work Assignment/Change Order proposal, the parties shall use best efforts to resolve any such issues within sixty (60) days of receipt thereof. In any event, Client shall accept any proposed Work Assignment/Change Order by written notice to Averion within sixty (60) days of receipt of Averion’s written proposal; otherwise the proposed Work Assignment/Change Order shall be deemed void. All labor rates and other direct costs to be used in Work Assignments and Change Orders are subject to change every January. In the event, Averion is authorized by the Client to begin working on any Work Assignment/Change Order, while the Work Assignment/Change Order is under Client review, Averion will invoice Client on a Fee-for-service basis.

(b) Client will designate one or more individuals to represent the Client with authority to make decisions with respect to this MSA and each Work Assignment proposal or Change Order. Each Work Assignment and Change Order must be signed by Client’s authorized individual and Averion prior to going into effect.

Invoices

(a) Averion will invoice Client monthly for services provided during the preceding monthly period. Services performed under a Work Assignment/Change Order will be billed according to the terms of the Work Assignment/Change Order, while consulting without a signed work assignment will be invoiced on a fee for service basis according to the rate schedule provided with Work Assignment/Change Order. Client agrees to pay Averion all charges related to services described in the invoices within 30 days of receipt of invoice. Thereafter, interest shall accrue and be payable at the rate of 12% per annum, calculated at the rate of 1% per month. In the event that Client disputes any portion of the invoice, Client shall notify Averion of such dispute within ten (10) business days of receipt and Client and Averion shall mutually agree upon a resolution of such dispute within ten (10) business days of receipt of the notice of dispute. Client will be responsible for payment for any amounts not in dispute, as stated herein. Client shall make all payments to Averion in United States Dollars (“US Currency. Averion may suspend work on any assignment with thirty days advance notice if payment is in arrears and undisputed. All pass through costs invoiced to Client will be at actual cost with no mark-up for administration or overhead. In the event Averion incurs a pass through cost in a currency other than U.S. Dollars, the parties shall determine the amount payable based on the relevant conversion rate as reported in The Wall Street Journal on the invoice date. If at any time during the term of this Agreement the Base Exchange Rate for Services specified in a foreign currency has fluctuated more than 3%, plus or minus, Averion will calculate a foreign currency exchange adjustment for those Services. The adjustment will be calculated by comparing the Base Exchange Rate with the Wall Street Journal foreign currency exchange spot rate on the last business Friday before each invoice is issued. Any resulting decrease in costs will be credited to Client and any resulting increase in costs will be invoiced to Client.

(b) A normal business day is an eight-hour day. Partial days or additional hours worked during a 24-hour period will be billed by Averion as actual hours worked. Upon written approval in advance by Client, Client will reimburse Averion for travel and other direct costs incurred by Averion personnel, contractors, or consultants. Averion personnel, contractors or consultants required to travel out of state will bill Client for an 8-hour day for any partial days worked.

Labor

Averion personnel, contractors, and consultants are independent contractors and shall not be considered to be Client employees during the term of this MSA. Averion has the right to designate who will work on this project, provided that no contractors or consultants (collectively, “Third Party Contractors”) will be designated without the prior written approval of the Client, which shall not be unreasonably withheld. Client can request reassignment of Averion staff or Third Party Contractors for any unsatisfactory performance that is unresolved to Client’s satisfaction after written notice to Averion and after Averion has a reasonable opportunity to cure. In the event either party directly or indirectly solicits staff or contractors from each other, the soliciting party agrees to give immediate notice to the non-soliciting party. If either party hires staff or consultants during the term of this MSA, then the soliciting party agrees to pay 40% of the annual salary of that staff or contractors within three (3) months of the date of the hire to the other.

Averion Warranty

(a) Averion warrants that its services shall be of professional quality. Any services provided by Averion under the technical direction of the Client, which the Client claims are less than professional quality or do not substantially meet the stated performance standards, shall be corrected by Averion without charge to Client provided that the Client provides Averion with a written notice of alleged poor

 

   

Page  2 


LOGO

MASTER SERVICES AGREEMENT

quality at the earliest known opportunity; but in no event later than ninety (90) days after receipt of the final deliverable. Absent such notice, all services and deliverables are deemed accepted and conforming within one hundred eighty (180) days of such delivery. As Client’s exclusive remedy and Averion’s sole liability for any such defects, Averion shall cure such defects, at Averion’s expense, such that performance and deliverables conform to the applicable specifications in effect at the time performance was due and without modification of said specifications.

(b) During the term of any Work Assignment/Change Order governed by this MSA, Averion, at its sole cost and expense, shall carry and maintain insurance in the amount of Three Million ($3,000,000) Dollars. Upon written request of Client, Averion shall provide Client with a Certificate of Insurance stating that such insurance policy is in full force and effect. In the event of any breach or default by Averion under this MSA or any applicable Work Assignment/Change Order that is not cured in accordance with the preceding paragraph, Client’s monetary remedy shall be limited to the lesser of the total fees associated with any Work Assignment/Change Order or $3,000,000 across all Work Assignments/Change Orders and Client agrees that this monetary remedy shall represent the total liability of Averion under this MSA and all Work Assignments/Change Orders governed by this MSA.

(c) EXCEPT AS EXPRESSLY STATED IN THIS SERVICESWARRANTY, AVERION MAKES NO OTHER WARRANTIES WITH RESPECT TO ITS PERFORMANCE HEREUNDER, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES WITH RESPECT TO THE OUTCOME OF ITS PERFORMANCE OR ANY ANALYSIS, THE VIABILITY OF PRODUCTS WHICH ARE THE SUBJECT OF ANY STUDY, WHETHER OR NOT THE PRODUCTS SHALL BE CLEARED BY THE FDA OR ANY OTHER REGULATORY AGENCY FOR THE STATED INDICATIONS OR IN ANY PARTICULAR TIME, WHETHER OR NOT ANY APPLICATION SHALL BE FILED, THAT THE PRODUCTS SHALL BE A COMMERCIAL SUCCESS, OR THAT THE CLIENT WILL OBTAIN ANY REVENUES OF ANY SIZE FROM ANY PRODUCT IN ANY STUDY.

(d) The Client acknowledges that the services to be provided by Averion are based on information supplied by the Client and other information in the public domain. Averion does not guarantee or warrant such services to any specifications, functions or other standards other than those supplied by Client. The sole remedy of the Client for any breach or default by Averion is the remedy specified herein or termination of this MSA as herein provided.

Client Warranties

Client warrants that it has obtained all necessary governmental and regulatory approvals to conduct any study or clinical trial described any Work Assignment, including without limitation, all applicable FDA and IRB approvals; and that all approvals shall be in full force and effect during the relevant term of any Work Assignment. Unless expressly agreed in a Work Assignment, Client is solely responsible for interaction with regulatory agencies, including without limitation, the FDA. Client further warrants that the conduct of any studies or clinical trials under this MSA will not infringe any patents, trademarks or copyrights held by third parties.

Indemnification

(a) Client agrees to indemnify, defend and hold harmless Averion, its subsidiaries, and their respective directors, officers, agents, employees and permitted subcontractors (collectively “Averion Indemnitees”) from and against any and all costs (including reasonable attorneys’ fees and expenses of litigation), expenses, damages, loss and liabilities incurred or imposed as a result of any third party claim, suit, action, demand or judgment (“Losses”) arising from or attributable to the negligence, gross negligence, intentional misconduct or inaction of Client in the performance of any of its obligations under this MSA, including without limitation:

(1) personal injury and property damage suffered by a participant due to any drug, device, biologic, consent, procedure, or protocol arising out of or in connection with, any Work Assignment/Change Order under this MSA, including without limitation, injury and damage received as result of receiving medical care or as a result of medical malpractice;

(2) any harmful or otherwise unsafe effect, including without limitation, a claim based upon a person’s use, consumption, sale, distribution, or marketing of any drug, device, biologic or procedure used in or resulting from any Work Assignment/Change Order under this MSA;

(3) Client’s performance of or involvement with any drug, device, biologic or procedure used in or resulting from any Work Assignment/Change Order under this MSA or Client’s negligent use of any data or information provided by Averion pursuant to this MSA;

(4) any violation of applicable law, rule or regulation for which Client bears responsibility for compliance; or

(5) otherwise resulting from Averion’s proper performance of the services under this MSA and any Work Assignment/Change Order hereunder;

 

   

Page  3 


LOGO

MASTER SERVICES AGREEMENT

provided, however, that if any such Loss arises in whole or in part from the negligence, or intentional misconduct of any Averion Indemnitee(s), then the amount of such Loss for which Client shall indemnify the Averion Indemnitee(s) pursuant to this provision shall be reduced by an amount proportionate to the percentage of the responsibility of the Averion Indemnitees for such Loss.

(b) Averion agrees to indemnify, defend and hold Client and its directors, officers, agents, employees and subcontractors (collectively “Client Indemnitees”) harmless from and against any and all Losses to the extent such Losses arise from or are attributable to, the negligence, gross negligence, or intentional misconduct of Averion or its directors, officers, agents or employees, permitted contractors, or consultants provided however, Averion shall have no liability or responsibility to indemnify Client Indemnitees to the extent any Loss is attributable to the negligence, gross negligence, intentional misconduct or inaction of Client as defined above.

(c) As a condition of the indemnification provided herein, the indemnified parties shall promptly notify the indemnifying party in writing of any claim, action or proceeding potentially giving rise to indemnification hereunder. The indemnifying party shall have sole and absolute control of, and discretion in, the handling of any such claim, action or proceeding, including the selection of legal counsel. The indemnified parties shall fully cooperate with the indemnifying party in the defense and settlement of all such claims, actions and proceedings. The indemnifying party shall keep the indemnified entity reasonably informed concerning all said claims, actions or proceedings and shall not admit liability without the prior written consent of the indemnified entity.

This provision on indemnity shall survive termination or expiration of this MSA.

Limitation of Liability

(a) Notwithstanding anything to the contrary in this MSA or in any Work Assignment, the parties agree Averion shall not be liable for: (1) the lack of efficacy or complications associated with any product under study outside of Averion control, or (2) the act of any principal investigator, sub-investigator, clinical research associate, nurse, nurse-practitioner, pharmacist, or any other employee or consultant licensed to practice medicine or employed by or under agreement with any hospital, clinic, nursing service, site management organization, or other entity which is contracted to be a site for any study conducted pursuant to this MSA, even if Averion shall pay, compensate, select, train, contract with or otherwise interact with any of the foregoing.

(b) NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY THIRD PARTY FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OF ANY KIND (INCLUDING BUT NOT LIMITED TO LOST PROFITS) IN CONNECTION WITH THIS AGREEMENT, EVEN IF THE PARTY HAS BEEN ADVISED OF SUCH DAMAGES.

This limitation of liability shall survive termination or expiration of this MSA.

Confidentiality

In order for Averion to provide services to the Client, confidential and proprietary information may be disclosed to Averion relating to Client’s past, present, and future activities (collectively, “Confidential Information”). Averion will instruct its employees, contractors, and consultants not to disclose any Client Confidential Information to third parties. Confidential Information does not include 1) information in the public domain; 2) information previously known by Averion employees or consultants prior to the commencement of this MSA or any Work Assignment; 3) information given to Averion by a third party, not known to be violating Client confidentiality; or 4) information independently developed by Averion outside the scope of the project or this MSA, or without use of Client Confidential Information. Averion agrees to keep all Client Confidential Information confidential during the term of this MSA and for a period of five (5) years from the date of termination or expiration of this MSA. Nothing in this section will prohibit Averion from disclosing Confidential Information pursuant to regulation or court order, provided Averion gives the Client as much advance notice as practical prior to disclosure and Averion protects the Client Confidential Information to the same degree as Averion protects its own Confidential Information. The Client shall bear all costs if Client wishes to dispute the disclosure of its Confidential Information.

Work Product

(a) All tangible reports, tables, data analyses, figures, listings, and correspondence created by Averion pursuant to this MSA specifically for the Client (collectively “Work Product”) other than the Averion Intellectual Property (defined below) belong to the Client and will not be disclosed by Averion to any third party except as required by any applicable federal or state law or regulation (and provided, in such event, that Averion shall notify the Client as soon as possible of such required disclosure). Averion hereby assigns, sells and transfers to client all of Averion’s right, title and interest in and to all such Work Product and all intellectual property rights therein and Client shall provide Averion with a royalty-free non-exclusive license to use the Work Product worldwide throughout the term of this MSA solely for the purposes of this Agreement.

 

   

Page  4 


LOGO

MASTER SERVICES AGREEMENT

(b) Averion owns all rights in and to its general use intellectual property related to its business, including without limitation, all software, algorithms, processes, systems, know-how, and all data collection, report generation, metrics, data checking, data quality checking, data analysis, data displaying and modeling based procedures that it uses in its general business (collectively, “Averion IP”).

(c) Averion agrees not to disclose that the Client has specifically retained Averion for professional services unless the Client has specifically authorized that such disclosure can be made.

Property

All data and materials furnished by Client to Averion for use by Averion in connection with the services performed under this MSA or any Work Assignment or Change Order shall remain the sole property of the Client. Client may request the return of all data and confidential materials given to Averion. Averion will ship all materials back to Client upon satisfactory negotiation of all invoices.

Averion Audits

Client shall be entitled to one audit at no charge to Client per Work Assignment and subsequent Change Orders at the Client’s discretion and upon reasonable advance notice to Averion. Audits are intended to monitor the operations of Averion hereunder, to examine standard operating procedures, facilities, books, records, papers, files and documentation, including computer files, data bases and records, at Averion’s facilities, and, generally, to understand the manner in which tasks are being performed hereunder, determine the adequacy of records, ensure the tasks are being performed in accordance with this Agreement and applicable regulations. This audit shall be conducted during normal business hours and will be at no expense to the Client. Subsequent audits win be billed on a fee for service basis.

Exemption

Client acknowledges that Averion will require from Client information, materials, and data in order to perform services properly. Averion is not responsible for errors, delays, or other consequences arising from the failure of Client to provide such data, records, or necessary background to permit Averion to perform services. Neither party will be liable for any delay or failure to perform as required under this MSA to the extent that such delay or failure to perform is caused by circumstances reasonably beyond either party’s control, including, without limitation, labor disputes, accidents, any law, order or requirement of any governmental agency or authority, civil disorders or commotions, acts of aggression or terror, fire or other casualty, strikes, acts of God, explosions, material shortages, act required to comply with any laws of the United States or Massachusetts. Performance time will be considered extended for a period of time equivalent to the time lost because of any such delay or failure to perform.

Generic Drug Enforcement Act of 1992

Averion represents that it and its employees, affiliates and agents have never been (i) debarred or (ii) convicted of a crime for which a person can he debarred under Section 306(a) or 306(b) of the Generic Drug Enforcement Action of 1992. Averion represents that it has never been and, to the best of its knowledge after due inquiry, none of its employees, affiliates, or agents has ever been (1) threatened to be debarred or (2) indicted for a crime or otherwise engaged in conduct for which a person can be debarred, under Section 306(a) or (b). Averion agrees that it will promptly notify Client in the event of any such debarment, conviction, threat or indictment.

Assignment

Neither party shall assign this MSA or any Work Assignment/Change Order without the prior written consent of the other party; provided, however a party may assign this MSA or any Work Assignment/Change Order without prior consent in the event of the sale of its business.

Non-Waiver

The waiver, forbearance or failure by either party to claim a breach of any provision of this MSA or any Work Assignment or Change Order pursuant hereto, or to exercise any right or remedy provided by this MSA, shall not be deemed to constitute a modification of any provision of this MSA, or a waiver or estoppel with respect to any subsequent breach or with respect to any provision thereof.

Changes and Modifications

No changes or modifications of this MSA or any Work Assignment or Change Order shall be deemed effective unless in writing and executed by the parties hereto.

 

   

Page  5 


LOGO

MASTER SERVICES AGREEMENT

Severability

If any provision of this MSA or any Work Assignment/Change Order pursuant hereto shall be determined to be invalid or unenforceable, the validity and effect of the remaining provisions of this MSA or such Work Assignment/Change Order shall not be affected thereby.

Term, Termination and Effects of Termination

(a) This MSA will be effective from the date of signature of the latter party to sign and will remain in effect for a period of five years or until the last Work Assignment/Change Order is completed, whichever is longer. Notwithstanding the foregoing, Averion may terminate this MSA and all open Work Assignments/Change Orders upon written notice in the event that Client files for bankruptcy protection or seeks any similar relief from creditors, or fails to pay for work done as required. Upon termination of this MSA and payment in full for all work done through termination of any Work Assignment/Change Order, in addition to payments specified by any early termination clauses in a Work Assignment/Change Order, if so requested by the other party, each party will promptly return to the other all documents or data which are specified to contain Confidential Information, provided, however, that each party may retain one copy of such Confidential Information for documentation.

(b) If a study is stopped for efficacy, safety, or compliance in accordance with the applicable protocol, the Work Assignment/Change Order will be immediately terminated and Averion will have thirty (30) days to wind-down the Work Assignment/Change Order. Alternatively, Client may terminate a Work Assignment/Change Order for any reason with thirty (30) days written notice. Upon receipt of notice of such early termination of any Work Assignment/Change Order, Averion shall use commercially reasonable efforts to avoid incurring any additional costs and to fully cooperate in disengaging from any Work Assignment/Change Order and eliminating or minimizing all externally cancelable costs, damages, penalties and expenses connected with the termination of the Work Assignment/Change Order or this MSA. Averion shall comply with all applicable warranties during the wind-down period, provided however, that if the Client does not permit Averion to perform applicable compliance-related activities (e.g., GCP, SOP or other applicable standard) during such period, Client agrees to accept the materials without a warranty for such compliance-related activities; or permit such compliance related activities in accordance with a budget estimate to be provided by Averion. However, nothing in the foregoing is intended to compromise patient safety in the event a study is suspended or terminated. Further, the parties shall cooperate with each other during such trial or project termination to safeguard patient safety and otherwise to comply with applicable laws and regulations.

Headings

Any heading used in this MSA or any Work Assignment/Change Order is inserted for convenience of reference only and shall not be construed to affect the construction or interpretation of any provision hereof.

Governing Law

This MSA and the rights and obligations of the parties hereunder shall be governed by and consumed in accordance with the laws of the Commonwealth of Massachusetts, without regard to its conflicts of law rules. Any legal proceeding arising out of or relating to this MSA shall be brought in a court located in the Commonwealth of Massachusetts. Each party consents and submits to the exclusive jurisdiction and venue of such courts for the purpose of all legal actions and proceedings arising out of or relating to this MSA, including the federal district courts located in the Commonwealth of Massachusetts.

 

   

Page  6 


LOGO

MASTER SERVICES AGREEMENT

Notice

Any notice to be given hereunder or under any Work Assignment/Change Order, unless otherwise specified in the relevant Work Assignment/Change Order, shall be in writing and shall be deemed given 3 days after being deposited in the United States certified mail (postage prepaid, return receipt requested), 1 day after being deposited with a nationally recognized overnight courier (shipping prepaid), or immediately upon acknowledged hand delivery or electronic confirmation of being sent by facsimile as follows (or to such other addressee as a party specifies from time to time via written notice as below):

   

 

If to Averion:

   

If to Client:

   

   

   

Averion International Corp.

225 Turnpike Road

Southborough, MA 01772

Attention: Chief Executive Officer

Fax: 508-597-5836

   

ImmunoCellular Therapeutics, Ltd.

21900 Burbank Blvd, 3rd Floor

Woodland Hills, CA 91367

   

   

   

In witness whereof, the parties intending to be legally bound, do hereby execute this MSA by their duly authorized representatives:

   

   

   

AVERION INTERNATIONAL CORP.

   

IMMUNOCELLULAR THERAPEUTICS, LTD.

   

   

   

Accepted by:

   

Accepted by:

   

   

   

/s/ Lawrence R Hoffman

   

/s/ Manish Singh

Authorized Signature

   

Authorized Signature

   

   

   

CFO

   

President & CEO

Title

   

Title

   

   

   

9/1/10

   

Aug, 31, 2010

Date

   

Date

   

   

 

   

Page  7 


Exhibit 31.1

Certification of the Principal Executive Officer Under Section 302 of the Sarbanes-Oxley Act

I, Andrew Gengos, certify that:

 

1.

I have r eviewed this Form 10-Q of ImmunoCellular Therapeutics, Ltd.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant ’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant ’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant ’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant ’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant ’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant ’s internal control over financial reporting.

   

   

 

   

   

   

   

Date: August 7, 2013

By:

/s/ Andrew Gengos

      

   

   

Name:

Andrew Gengos

   

   

Title:

President and Chief Executive Officer

   


Exhibit 31.2

Certification of the Principal Financial Officer Under Section 302 of the Sarbanes-Oxley Act

I, David Fractor, certify that:

 

1.

I have r eviewed this Form 10-Q of ImmunoCellular Therapeutics, Ltd.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant ’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant ’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant ’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant ’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant ’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant ’s internal control over financial reporting.

   

   

 

   

   

   

   

Date: August 7, 2013

By:

/s/ David Fractor

      

   

   

Name:

David Fractor

   

   

Title:

Principal Financial and Accounting Officer

   


Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the “Company”) hereby certifies that, to the best of his knowledge:

 

1.

The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2013 (“Periodic Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

 

2.

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

   

   

 

   

   

   

   

Date: August 7, 2013

By:

/s/ Andrew Gengos

      

   

   

Name:

Andrew Gengos

   

   

Title:

President and Chief Executive Officer

   


Exhibit 32.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the “Company”) hereby certifies that, to the best of his knowledge:

 

1.

The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2013 (“Periodic Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

 

2.

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

   

   

 

   

   

   

   

Date: August 7, 2013

By:

/s/ David Fractor

      

   

   

Name:

David Fractor

   

   

Title:

Principal Financial and Accounting Officer